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In recent years, 3D printing technologies have been adopted into the medical and 
pharmaceutical industry for the fabrication of personalised medicines, oral dosage forms, 
medical implants, medical devices, tissue engineering applications, and many more. 
However, the use of 3D printing, in particular the low-cost Fused Deposition Modelling 
(FDM) 3D printing technique, has been limited due to the limited number of 
biocompatible materials suitable for pharmaceutical and biomedical applications. In this 
study, the FDM 3D printing technique was being explored for the fabrication of 
pharmaceutical products as it is the most widely available and easily accessible 3D 
printing technology.  
In order to improve the usability of FDM 3D printing for pharmaceutical and biomedical 
applications, the studies to fabricate several different biocompatible filaments 
composition that can be used for drug loading were carried out. Firstly, filaments made 
of several pharmaceutical grade polymers were being developed using hot-melt extrusion 
(HME). Three types of biocompatible polymeric filaments have been developed. They 
are (Polylactic Acid) PLA-based, (Hydroxypropyl Cellulose) HPC-based and 
(Polycaprolactone) PCL-based. These filaments were added with a plasticiser, 
polyethylene glycol (PEG), to improve their processability and physicochemical 
properties of the produced filaments so that they can used in an FDM 3D printer. The 
HPC-based filaments were loaded with a model drug, theophylline, that exhibits poor 
aqueous solubility, whereas the PCL-based filaments were loaded with a readily soluble 
model drug, metformin. The studies showed that the filaments were effective in sustaining 
the release of both drug, and the sustain release properties of the filaments can be adjusted 
by altering the composition of the polymers.  
The studies showed that the HME technology is very compatible with FDM 3D printing 
as it is able to produce 3D printable filaments by mixing different polymeric materials. 
The filaments can also be loaded with a desired drug at a required dose to allow the 3D 
printing of drug delivery systems. This technique allows the fabrication of personalised 
drug delivery systems in-house. It can be beneficial for clinics and hospitals in remote 
areas as the lead times can be reduced when in-house fabrication is possible. The ability 
to fabricate personalised medicines at hand also means that the dose can drug release 




that, this technique can change way medicines are transported and stored, which could 
potentially help save cost on transportation and inventory. In addition to medicines, the 
FDM 3D printing technique can also be used to produce other personalised drug delivery 
systems such as microneedles, braces and implants of various shapes due to the flexibility 
of the 3D printing process.  
The other aspect of this research was on the fabrication of biomedical sensors that can 
potentially be integrated with the 3D printed drug delivery systems to form a smart drug 
delivery device. The idea of smart drug delivery device is that it is capable of continuous 
monitoring the health of a patient and then administer drug to the patient whenever it is 
required. The development of such smart medical devices has been one of the hottest 
interests in the biomedical sector. One of the main issues with such technologies is the 
high cost which has caused the technologies to be not so affordable for many people. 
Therefore, the studies to fabricate some simple biomedical sensors such as a temperature 
sensor and a glucose sensor using simple and cost-effective manufacturing technique 
were being explored. The fabrication techniques used are FDM 3D printing and a thin-
film fabrication technique that involves deposition of material using a thermal evaporator. 
Low-cost manufacturing techniques were being explored in order to help reduce 
manufacturing cost which could help improve the affordability of such technologies. The 
fabricated temperature and glucose sensors exhibit great stability in performance and 
mechanical flexibility. The flexibility allows the sensors to be conformable to curved 
surfaces such as the skin. Hence, the sensors are suitable to be used as a wearable device 
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Chapter 1 : Introduction 
3D printing has received much interest across many industries due to its 
manufacturing flexibility as it is able to produce objects of any shapes and designs without 
the need of a mould. The biomedical industry has also benefited from this manufacturing 
flexibility, in particular for the manufacturing of personalised medicines and various 
customised medical devices [1,2]. Hence, the study here investigates the versatility of a 
low-cost 3D printing technology in producing personalised drug delivery systems when 
coupled with the hot-melt extrusion (HME) technology.  
In recent years, there has also been increasing interest in integrating sensors with medical 
devices to make them smart medical devices. The purpose of the smart medical devices 
is to be able to detect and monitor the response of the human body at every single moment. 
These can often be in the form of wearable devices or implants. These devices can play a 
crucial role in the detection of any life-threatening conditions. Any medical implants 
integrated with sensors can be termed smart medical implants. Smart medical implants 
are able to improve the functionality and longevity of implantable devices. The function 
of the smart medical implants is to provide real-time information of any part the human 
body that is of interest. This information is very useful as it can help further improve the 
quality of life [3]. This is because patients can monitor their own health at any moment 
and they do not need to consult a healthcare professional all the time which would give 
them a peace of mind. The data collected on the smart medical device can be uploaded to 
a database which could also be accessed by the doctors in charge. The system can alert 
the doctor and patient when the condition of the patient needs attention. Smart medical 
implants being used as a sensing system also improves patient compliance. As the implant 
can be used to measure vital health information such as blood pressure, heart rate, body 
temperature or glucose level, the need for patient to attend appointments just to take some 
measurement can be avoided. This can also relieve the work pressure of healthcare 
professionals. Apart from that, even healthy people nowadays would like to monitor how 
their lifestyle affects their body which has resulted in the increased demand for health 
monitoring systems. Hence, the field of smart medical devices has been a hot research 
topic not just for academics, but also for healthcare and technology companies.  
The core of these smart healthcare technologies relies on the sensors in the devices for 
them to function as purposed. Therefore, the reliability and affordability of the sensors 




are vital for the function of these devices. The study here also investigates the feasibility 
of using 3D printing and a thin-film fabrication technique to produce simple biomedical 
sensors. The use of simple and low-cost fabrication techniques to produce reliable sensors 
can potentially improve of affordability of the sensors and healthcare technologies.   
This chapter presents a literature review on several topics including the different 3D 
printing techniques used for biomedical applications, the latest developments on 
integrating HME with fused deposition modelling (FDM) 3D printing as a continuous 
process to produce various pharmaceutical dosage forms and implants, the use of sensors 
in biomedical application with a focus on temperature and glucose biosensors, the use of 
2D materials for biosensors fabrication, with a focus on the use of Molybdenum (IV) 
Sulphide (MoS2), and finally the 3D printing of biosensors. The general outline of the 
thesis is presented at the end of this chapter.  
1.1 Introduction to 3D printing 
3D printing, also commonly known as additive manufacturing, is a process that creates a 
three-dimensional object layer-by-layer from a digital model. The digital 3D models can 
be generated using computer-aided design (CAD) software or from 3D scanners that 
capture images of a real-life object and the image being converted into a printable file 
from a computer [4]. The first 3D printing technology, which is a stereolithography (SLA) 
method that uses a vat photopolymerisation process, was invented by Charles Hull in the 
early 1980s  [5]. However, 3D printers were only widely available commercially in the 
early 2010s [6]. 3D printing is also known as rapid prototyping as it was primarily used 
for making prototypes during the early stages of this technology [7]. This is because 3D 
printing technology is very cost-effectiveness and has short a production time, where 3D 
objects can be made very quickly without needing any moulds. Therefore, it played an 
important role in product design and manufacturing across various disciplines as it is very 
useful for the design and testing phase in the development of a new product [8]. 3D 
printing has major advantages over traditional rapid prototyping processes, as the 
materials used in 3D printers are less expensive and it is able to provide a faster mode of 
iteration [6]. The rapid growth and improvement in the 3D printing technology have made 
it not just a rapid prototyping technique, but also a preferred production method in major 
industries [9–11]. Therefore, 3D printing is considered a very cost-effective 
manufacturing process, especially in producing objects with high complexity. It is now a 
preferred method to produce custom-designed objects, which could be very expensive 




and time-consuming using conventional manufacturing techniques such as injection 
moulding, machining and casting [11–14]. Nowadays, 3D printing technology is being 
used across various industries including architecture [15], construction [16], automotive 
[17], food [18], fashion industry [19], medical sector [5] and many others. The 3D 
printing technology has gained much popularity in the healthcare and medical field not 
just for its cost-effectiveness but also for manufacturing flexibility. It is very useful in 
creating devices or medicine that are tailor-made for specific patients. The healthcare 
market in using 3D printing is expected to show significant growth due to the increasing 
demand for custom-tailored and patient-specific medical products. The ability of 3D 
printing to produce rapidly only with a CAD model, allows for on demand-fabrication, 
creating the possibility for medical devices to be produced in-house. Custom made 
prostheses, hearing aids and some implants have been successfully made using 3D 
printing technology. It can also fabricate the 3D constructs from a patient’s own medical 
images, such as computed axial tomography (CAT) and magnetic resonance imaging 
(MRI) [20]. These parts could be very useful for surgeons to practice on before 
performing a surgery on the real patient, and can also be used as a guidance and 
explanation of the operation procedure to the patient [21]. 
1.1.1 Types of 3D printing 
As the interest in using 3D printing across different industries is rapidly increasing, 
different 3D printing technologies have been invented to meet the demand of a wide range 
of industries. As the technology evolves, it is now possible to create 3D objects of any 
complex geometries that were previously difficult to make. There is now also a wide 
range of 3D printable materials, including some advanced materials such as high strength 
polymers, ceramics, metals, and composites. It is now possible to even 3D print a human 
organ by using cells as a printing material [22]. All the 3D printing technologies are 
different in terms of speed, resolution, and printing materials. The working principles will 
also differ according to the materials being used. The most commonly available 3D 
printing technologies are as shown in Table 1.1. However, not all 3D printing 
technologies are suitable for biomedical applications. For example, the direct energy 
deposition which involve the use of a high energy laser beam may be the main concern 
for pharmaceutical applications as the laser beam could potentially degrade the drug and 
pharmaceutical excipients [23]. On the other hand, inkjet-based, extrusion-based and 




light-assisted 3D printing systems have successfully been used for bio 3D printing using 




Table 1.1: The most commonly available 3D printing technologies 





Uses ultraviolet or digital light for 
photopolymerisation process to cure 
light sensitive polymers 
(photopolymers). The molecules of the 
polymers will be crosslinked during 
the photopolymerisation process, 
forming a solid 3D object that does not 
dissolve in its liquid monomer 
Photocurable resins SLA, DLP [32–36] 
Powder Bed Fusion 
Uses laser as a thermal source to 
induce partial or full fusion between 
the powder particles then a roller or 
blade is used to add and smoothen 
another layer of powder. The two main 
processes involve are sintering and 
melting 
Polymer, metal, glass SLS, SLM [37–42]  
Material Jetting 
Deposits liquid droplets onto the 
printing bed to partially soften a layer 




Polyjet, Inkjet [43–47]  
Material Extrusion 
Polymers being melted and pushed out 
through a heated nozzle, depositing the 
melted materials on top of each other, 
allowing each layer to bind with one 




another, eventually forming a solid 3D 
object 
Direct Energy Deposition 
High power-density laser is focussed 
onto a continuous stream of metal 
powders to melt the metal powders, 
fusing the melted powders together to 
form a 3D object 
Metals including stainless 
steels, copper, aluminium, 
titanium, nickel, cobalt and 
tin 
LENS [52–54]  
Binder Jetting 
Liquid bonding agent deposited onto a 
powder bed to bind the powder particle 
together, forming a 3D object. Does 
not require support materials during 
3D printing. 
Ceramic, metal, glass, 
polymer 
CJP [55–58]  
 
CJP  = Colour Jet Printing 
DLP = Digital Light Processing 
FDM = Fused Deposition Modelling 
LENS = Laser Engineered Net Shaping  
PAM = Pressure Assisted Microsyringe 
SLA = Stereolithography 
SLM = Selective Laser Melting 





Most 3D printing technologies are still quite expensive and not easily accessible, 
particularly for technologies that can 3D print object with very high accuracy and 
resolution. The most easily accessible and affordable 3D printing technology is the 
material extrusion-based 3D printing. One of the most commonly available systems is 
Fused Deposition Modelling (FDM). FDM based 3D printers are so common that they 
are even found in homes for personal use. FDM is one of the 3D printing techniques that 
is available in open-source, which makes this technology the most affordable, as 
compared to others such as selective laser sintering (SLS), powder-based 3D printing, 
and stereolithography (SLA). Open-source means that all information related to the 
printer can be shared freely with the public and can be easily built by anyone, making it 
possible for anyone to have an FDM 3D printer as a common household object. RepRap 
is a 3D printing community that started the open source 3D printer revolution [59]. In 
FDM 3D printers, thermoplastic materials are typically used as the starting material. 
These thermoplastics materials that are fed into an FDM printer are usually in the form 
of a filament. The thermoplastic filaments are melted or softened, and then extruded from 
a printer head that is able to move in the x- and y-direction. The object is formed by many 
layers of melted thermoplastic. Each layer fuses and bonds to the layers below [60]. The 
layers of melted thermoplastic solidify almost immediately after being extruded from the 
print head. As one layer cools down and solidifies, another layer of the melted filament 
will be deposited on top of it until the printing of the object is finished (Figure 1.1). Due 
to the working principle of FDM, the resolution of the 3D printed object is often a 
limitation. This is because there is always a limitation on how thin the molten filaments 
can be extruded through the printing head. Currently, the highest resolution that an FDM 
3D printer can achieve is 20 µm with a nozzle size of 0.4 mm by Robo 3D R2 (Robo 3D, 






Figure 1.1: Mechanism of a Fused Deposition Modelling (FDM) 3D printer 
(Reproduced with permission from reference [23]). 
Acrylonitrile Butadiene Styrene (ABS) and Polylactic Acid (PLA) are the two most 
common thermoplastics used in FDM machines [62]. One other commonly used 
biodegradable polymer in FDM 3D printing is polycaprolactone (PCL). Unlike ABS and 
PLA, PCL has much lower printing temperature (~60 °C) due to its low melting 
temperature and low glass transition temperature [63]. As a result, the printing of PCL 
often does not need a heated printing bed as the material can be easily softened in the 
presence of heat. PCL can sometimes be soft and flexible even at room temperature, 
making it a challenge to be 3D printed [64]. High performance thermoplastics such as 
Polyether Ether Ketone (PEEK) and Polyether Imide (PEI) are some of the newer 
thermoplastics that are currently used in FDM printers [65]. These materials usually have 
a very high melting temperature and excellent mechanical properties. They have been 
considered to be a cost-effective alternative to metal in some applications, as they are 
strong and also light [66]. PEI is a durable thermoplastic that exhibits physical properties 
such as high heat, solvent and flame resistance, high dielectric strength, thermal 
conductivity and overall strength. It has a lower impact strength and working temperature 
than PEEK [67]. Some of the PEI materials that are compatible with 3D printing have 
been used to produce plastic parts for aircraft [67]. Table 1.2 shows the comparison of 
different types of thermoplastics that are currently being used in FDM 3D printing. There 
are many challenges in using high-performance thermoplastics for FDM 3D printing due 
to their chemical and physical properties. As these materials possess very high melting 
temperature, the printing environment needs to be in a high temperature as well. This 





that the printing chamber needs to be kept at an evenly distributed high temperature as 
well during the printing process. This is because any cool areas will cause the material to 
shrink unevenly, resulting in warping or even a lack of bonding in between the layers of 
the materials [67]. One of the 3D printers that has been successfully developed by a 3D 
printing company called INTAMSYS is the FUNMAT HT (Shanghai, China) is capable 
of printing various 3D printing materials including ABS, PLA, PEI, etc.[68].
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Some post-processing might be needed for a 3D printed object using the FDM method as 
the surface finish of the object is often quite rough due to the layering of the melted 
thermoplastics. Acetone is often used to smoothen ABS so that it has a glossy finish. The 
3D printed objects can also be machined or easily sanded after printing to smooth the 
surface [65]. It has been proven that some FDM 3D printed objects have similar 
mechanical properties as the objects that are manufactured using traditional injection 
moulding and machining when the same materials are being used. Therefore, FDM 3D 
printing can provide a cost-effective alternative for producing these parts. Some high-
performance thermoplastics can also provide strength that is similar to metal parts. The 
advantage of using 3D printer thermoplastics over metal is that the thermoplastics 
products are much lighter than the metals. Some FDM printers have enhanced features 
such as having multiple printheads which allow for the printing of several different 
materials within an object. 
1.1.2 FDM 3D printing for biomedical applications 
In recent years, FDM 3D printing has been able to attract much attention for use in 
biomedical and pharmaceutical applications. It has been adopted by the biomedical and 
pharmaceutical industry as a manufacturing method due to its customisability, flexibility 
in design and the ability to create complex shapes with precision. FDM 3D printing has 
successfully been used to produce oral dosage forms [69,70], medical implants [71,72], 
scaffolds [73,74] and many other biomedical applications. The trend of using 3D printing 
to produce medicines started to gain much interest since the approval of the first 3D 
printed drug, Spritam® (levetiracetam), by the U.S. Food and Drug Administration 
(FDA) in 2015 [75]. However, this medicine is manufactured using the Zipdose 
technology based on a powder bed-liquid 3D printing technology [76]. In a powder-based 
3D printer, a binder solution is required to bind the loose powder together. The binder 
solution is sprayed onto the successive layers of powder that is being deposited onto the 
print bed [23]. The traditional methods for producing medicines have very limited process 
capability and manufacturing flexibility when compared to 3D printing. By using 3D 
printing, there is much flexibility in designing the products, which can be personally 
tailored according to the patient’s needs. For instance, tablets can be designed to have 
interesting and complex shapes which can be useful for the fabrication of paediatric 
medicines or modified-release systems [76,77]. Furthermore, tablets can be designed to 
contain several drugs that can have different drug release rates.  
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The research work done by Sadia et al. has been able to produce a novel design of a tablet 
that could accelerate drug release of 3D printed tablets. The 3D printed tablets are made 
of polymethacrylate and are designed to have built-in channels within the tablet that could 
increase the surface area/volume ratio of the tablet and also allow media perforation 
through the structure [77]. The study carried out by Goyanes et al. has also proven that 
the FDM 3D printing technology is feasible for fabricating personalised tablets containing 
drug doses tailored to individual patients or tablets with specific drug-release profiles 
[78]. Apart from that, some research work has been carried out on the possibility of 
housing multiple medications within a dosage form. This multi-active solid dosage form 
is called ‘polypill’. The ‘polypill’ can also be designed with having different release 
profiles [70]. One way to achieve this is by changing the exposed surface area or the 
geometry of the dosage form and by using more than one kind of carrier with different 
release characteristics. The external shape and volume/mass ratio of a 3D printed tablet 
can affect the release profile and pattern. The percentage of infill that can be set during 
the 3D printing process is one of the parameters that can also affect the drug release 
patterns [77,79]. Thus, 3D printing has opened up the possibility of combining multiple 
medications in a personalised tablet. This is particularly useful for patients that are 
currently taking multiple medications through many separate tablets. Besides that, there 
is also a flexibility to tailor a specific drug combination or drug release profile according 
to the patient’s needs. Therefore, 3D printing is able to fabricate these personalised 
medicines in a very timely and cost-effective manner.  
Apart from using FDM 3D printing to produce oral dosage forms, it has also successfully 
been used in the medical field for medical modelling, surgical planning and the 
production of patient-specific implants [5]. Doctors have been using 3D printed models 
to educate patients, provide surgical training as well as planning the surgical approach 
[80]. This would help increase the surgery success rate, decreasing any surgical 
complications during real surgery and reduces the need for intervention [81]. The practice 
of using 3D printed model for training has been implemented in Spain to train general 
practitioners (GPs) to carry out minor surgeries [82]. This will reduce the cost of the 
training by eliminating the need for training on animals. The CAD models that are 
required for 3D printing can also be easily taken using CT or MRI, which would also 
provide a better representation of the patient as compared to animal models. Due to the 
cost-effectiveness of FDM, it has also successfully been used for surgical planning to 
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reconstruct patients suffering from rhinocerebral mucormycosis [83].  A facial scan of 
the patient was used to produce an anatomic model using FDM 3D printing that can help 
the surgeon to plan the free flap reconstruction. This study has shown how the low-cost 
FDM 3D printer can have a positive impact on the medical field.  
It was also reported that FDM 3D printing has been a cost-effective way to produce 
medical implants. Domínguez-Robles et al. reported a study on using an FDM 3D printer 
to fabricate thermoplastic polyurethane (TPU) vaginal mesh loaded with an antibiotic as 
an alternative to conventional polypropylene vaginal mesh for the treatment of pelvic 
organ prolapse or stress urinary incontinence [84]. This study showed the versatility of 
3D printing as an alternative when conventional treatments are showing complications. 
The group also produced PLA/Lignin mixture as an FDM 3D printing material that can 
potentially be used to 3D print meshes for wound dressing purposes owing to the 
antioxidant capability of lignin [85]. Fu et al. have used FDM 3D printing to produce 
sustained release progesterone-loaded vaginal rings as a gynaecology drug delivery 
device [71]. The drug showed release lasting up to 7 days which is more effective than 
oral administration. Different shapes of vaginal rings have been 3D printed, proving the 
flexibility and ability of 3D printing to produce custom-shaped products, which could 
also result in drug release patterns.   
A study by Huang et al. has successfully 3D printed a fistula stent which was designed 
from the 3D reconstruction of the patient’s fistula image [86]. The stent was fabricated 
using biocompatible thermoplastic urethane, which is also a material that has been widely 
used in medical devices such as catheters and vascular grafts [87]. The purpose of the 3D 
printed stent was to manage enterocutaneous fistula (ECF), which is an abnormal or 
unintentional connection between the gastrointestinal tract and the skin of a patient. Kim 
and Lee reported the possibility of fabricating shape transformable bifurcated stents using 
FDM 3D printing of shape memory polymers (SMPs) that can change its shape as a 
response to external stimulation [88]. The study reported a 3D printed kirigami structure 
stent that can travel smoothly in the blood vessel when its initial shape was folded into a 
compact shape. As the stent reaches the target location, the stent was then activated to 
expand into its original form, holding up the narrowed blood vessels. This approach is 
believed to be able to improve the success rate of stent insertion.  
FDM 3D printing has also been used extensively in the hearing aids and implants industry 
[20]. This is because ear canals and shapes are often different from one to another and 
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these devices would need to be custom made to fit the patient properly. 3D printing has 
shown to be to the most cost-effective way of producing individualised devices. The 
shape of the patient’s ear is often captured using a 3D scanner. The image will then be 
translated to an STL file for 3D printing. The advancement in 3D medical imaging 
techniques has allowed the production of more patient-specific medical implants such as 
dental implants, prosthetics, hip, knee, etc [89]. The 3D imaging technologies can be 
coupled with 3D printing technologies to produce any patient-specific devices effectively 
and locally.  
FDM 3D printing can also be used in tissue engineering applications. A study by Khodaei 
et al. produced a porous PLA scaffold that can potentially be used for bone tissue 
engineering using FDM 3D printing [90]. The study compared the mechanical strength 
of the scaffold at different porosity level, showing that increasing porosity caused a 
reduction in the strength of the scaffold. Monshi et al. have also used FDM 3D printing 
to produce electroconductive PLA scaffolds for bone cancer therapy applications [91]. 
Producing scaffolds through FDM 3D printing allows the flexibility in controlling the 
desired porosity of the scaffolds which is important particularly for bone tissue 
engineering. Rajzer et al. have successfully 3D printed antibacterial 
polycaprolactone/graphene scaffolds for growing chondrocytes using FDM 3D printing 
[74]. Studies have shown that graphene exhibit antibacterial ability and can be effectively 
incorporated into a polymer matrix [92–94].  
Even during the Covid-19 pandemic, FDM 3D printers has played a very important role 
in producing personal protective equipment (PPE) such as face mask and shields for 
medical staff dealing with infected patients [95,96]. There are also reports that some 3D 
printing enthusiasts have used 3D printer to produce parts and valves for ventilators as 
well as respirators [97]. This campaign has been initiated by the public as hospitals across 
the world are facing a shortage of PPE. Although there have been doubts on how 
medically safe and compliant these 3D printed devices are, there is no doubt on the 
flexibility and versatility on producing any desired parts cost-effectively and locally using 
FDM 3D printing.  
1.2 Hot-Melt Extrusion (HME) 
The hot-melt extrusion (HME) technology was established in the early 1930s and was 
originally used for the manufacturing of plastics and rubber products [98]. It is a 
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continuous process where heat and pressure are applied to melt or soften materials 
through an orifice to produce new products of uniform shape and density. The extrusion 
process can change the physical properties of a substance when it is being forced through 
an orifice or die on the hot-melt extruder under controlled conditions [99]. The main 
component of HME is the extruder. Some of the basic elements that are assembled to 
make an extruder include a motor, an extrusion barrel, rotating screws in the barrel and a 
die or orifice that is connected at the end of the extruder [99]. The extrusion barrel 
containing the rotating screws is often made up of several sections that are bolted 
together. The extruder contains heaters that provide heat for the melting or softening of 
the materials. The screws in the extruder can provide shear stress and intense mixing of 
the materials. The friction created by the screws in the barrel and the heat provided cause 
the polymeric material to melt. The screw then conveys the melted material down the 
barrel. The extruder is controlled through a central electrical control, which is connected 
directly to the extrusion unit. Some of the processing parameters that can be controlled 
are screw speed in revolutions per minute (RPM), feed rate, temperature along the barrel 
and the die, and the vacuum level for devolatilization. A schematic diagram of a typical 
extruder is illustrated in Figure 1.2. 
 
Figure 1.2: A schematic diagram of a typical hot melt extruder (Reproduced with 
permission from reference [99]). 
In general, there are two types of hot-melt extruders: the single-screw extruder and twin-
screw extruder (Figure 1.3). Some of the advantages and disadvantages of the single-
screw extruder and the twin-screw extruder are compared in Table 1.3. The primary 
purpose of a single-screw extruder is to melt polymers and extrude them into a continuous 
shape. In the single screw extruder, there is only one screw in the extruder, which is used 
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for feeding, melting, devolatilising and pumping [100]. Materials are fed into the extruder 
from the feeder/hopper and then transported down the barrel using the screw. Most single 
screw extruders are flood fed, which means the feeder sits over the feed throat and the 
speed of the screw determines the output rate. Occasionally, the single screw extruder can 
also be starve fed, where a feed system sets the mass flow rate and the output rate is 
independent of the screw speed [100]. When the extruder is starve fed, it is fed at a rate 
less than the forwarding efficiency of the screws [101]. When the screw rotates in the 
extruder barrel, frictional forces are created between the rotating screw and the surface of 
the barrel, forming a flow channel that is responsible for transporting the material fed 
down the barrel to the proximal end of the screw [99]. Increasing the screw speed can 
increase the frictional forces created, resulting in higher heat energy created. The shearing 
caused by the rotating screw and the heat energy produced from the heaters will melt the 
material, which will then result in a melt pool of the material. The molten material will 
then be pumped through a die, which will give a fixed shape that forms the extrudate 
[100]. However, high pressure may be created during the melting process in a single-
screw extruder. The high pressure will compress the dispersed particulates in the molten 
material, which could cause agglomeration and poor mixing due to insufficient shear 
deformation. 
 
Figure 1.3: Cross-section of a single and twin-screw extruder (Reproduced with 
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• Mechanical simplicity 
• Low maintenance 
• Low cost 
• High tendency of overheating 
• Not suitable for heat-sensitive 
materials 
• Poor mixing 
Twin-screw 
extrusion 
• Easier material feeding 
• Higher kneading and 
dispersing capacity 
• Lower tendency to overheat 
• Higher process productivity 
and flexibility 
• Better control of process 
parameters 
• Enhanced mixing 
• High input energy 
• Not suitable for shear-sensitive 
materials 
On the other hand, the twin-screw extruder uses two screws arranged side-by-side in the 
barrel. The twin-screw extruder is used mainly for the purpose of mixing two or more 
materials together to form a blend. The additional materials that could be melted and 
mixed with polymers are, for example, pigments (e.g., iron/chromium oxide [102]), fillers 
(e.g., lactose, starch [103]), APIs (e.g., acetaminophen [104]) and plasticisers (e.g., 
polyethylene glycols, Triacetin [103]) [105]. Most of the time, a twin-screw extruder will 
be starve fed with the raw materials. This means that the output rate of the extrudates will 
depend on the feeder and independent of the screw speed [106]. In a twin-screw extruder, 
the screws can either be co-rotating (screws rotate in the same direction) or counter-
rotating (screws rotate in the opposite direction) (Figure 1.4). The counter-rotating screws 
can produce very high shear forces as the materials are squeezed into the gaps between 
the two screws [100]. These two types of twin-screw extrusions can further be classified 
into fully intermeshing or non-intermeshing. The fully intermeshing twin-screw extruder 
has a special self-cleaning feature, which can help reduce the non-motion during the 
extrusion process and also prevents localised overheating of the raw materials when 
inside the extruder. This is because the raw materials do not rotate along the screw in the 
configuration of the intermeshing screws. The flight of one of the screws will be able to 
clean the root of the adjacent screw, removing all the materials away from the extruder 
assembly during the extrusion process. This can also reduce any product waste that could 
happen at the end of a production batch. The non-intermeshing extruder has a weaker 
screw interaction and lower self-cleaning capability, making it not as popular as the 
intermeshing screws for material mixing applications. The non-intermeshing screws are 
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often used to process highly viscous materials and can be used to remove large amounts 
of volatile substances. The non-intermeshing screws are positioned separately from each 
other, resulting in a lower torque generation, which is suitable for processing highly 
viscous materials [99]. 
For twin-screw extruders, the shearing of the materials occurs between the rotating screws 
and between the screws and the wall of the barrel. The torque and shear created by the 
rotating screws produce heat energy that is used to melt the materials. When the melted 
material is being squeezed between the gaps of the rotating screws, it is being 
continuously stretched like a rubber band, causing viscous heating dissipation to occur 
[106]. The heat generation in a twin-screw extruder is independent of the screw speed. 
The configurations of the twin screw can be adjusted depending on the desired level of 
shear and mixing. This means that there is better control of the melting of the materials 
in a twin-screw extruder. Hence, there is a lower tendency of overheating, which is 
particularly useful when processing heat-sensitive materials [99]. 
The main feature of a twin-screw extruder is the enhanced and homogeneous mixing of 
materials during extrusion. During twin-screw extrusion, two types of mixing can occur 
(a) distributive mixing and (b) dispersive mixing. Distributing mixing involves melt 
division and recombination. This means that the materials can be evenly blended with 
minimal degradation. Apart from that, the size of the materials is reduced in distributive 
mixing. Distributive mixing allows for the use of heat and shear sensitive materials such 
as APIs. Dispersive mixing involves shear and elongational mixing [106]. It induces 
solubilisation of one component to another component. Dispersive mixing breaks down 
the droplet or solid materials to fine particles using high energy. The enhanced mixing 
feature in the twin-screw extruder contributes to the viscous heat dissipation. These make 
the twin-screw extruder more efficient in heating the materials, and hence, it can readily 
process thermoplastic polymers [106]. Some other advantages of a twin-screw extruder 
over a single-screw extruder are easier material feeding, high kneading and dispersing 
capabilities, lower tendency of overheating and shorter transit time [99]. As twin-screw 
extrusion provides uniform and homogeneous mixing, the twin-screw extrusion process 
can be easily scaled up and optimised. The possibility of scaling up the extrusion process 
makes it a more efficient process for large volume production. Therefore, the majority of 
the food and plastics industries have been using twin-screw extrusion for their production 
[107–109]. Apart from that, twin-screw extrusion has also been adopted as a 
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manufacturing process in the pharmaceutical field [110]. However, there might be an 
issue for pharmaceutical industry when it comes to the development of a formulation 
containing some expensive drug/material. 
 
Figure 1.4: Twin-screw extruder barrel (a) Counter-rotating screws (b) Co-rotating 
screws (Reproduced with permission from reference [111]). 
The screw in the hot-melt extrusion process is very important in determining the mixing 
and extrusion process. Figure 1.5 shows the parameters of a typical screw used in a hot-
melt extruder. The dimensions of the screws are normally defined in length-to-diameter 
(L/D) ratio. Most screws are coated with stainless steel which could reduce friction and 
avoid chemical reactions with the raw materials. The screw is typically divided into three 
sections along the length of the barrel: the feed section, melting/compression and 
metering (Figure 1.6). At the feed section, the screw transfers the materials from the 
hopper to the barrel. The screw in the feed section has flights that are deeper or of a 
greater pitch, and the channel depth is also wider. This allows for the raw material to fall 
easily into the screw for conveyance along the barrel and to facilitate mass flow. The 
pitch and helix angles determine the output of the extruder at a constant screw speed. The 
solid raw materials are then conveyed to the compression zone for mixing, compressing, 
melting and plasticising. The channel depth decreases the compression zone in order to 
increase the pressure in the barrel which could remove any entrapped air. The polymers 
will then soften and melt in the compression zone. As the material enters the metering 
zone, the material should be in a molten state. The metering section is to reduce the 
pulsating flow and to ensure a uniform delivery rate through the die [99,100].  
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The last section of the extruder is the die or orifice. The function of the die is to shape the 
molten material when it is exiting the extruder. It is designed to achieve the required shape 
and dimensions of the extrudate. The cross-section of the extrudate will increase upon 
leaving the die and this phenomenon is known as “die swell” [100]. This phenomenon 
depends on the viscoelastic properties of the polymers [112]. In general, there can be four 
different shapes for products made by extrusion dies including the extrudate strands, 
films, sheets and granules [99]. 
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Figure 1.5: Parameters of a screw in a hot-melt extruder. 
 
Figure 1.6: Three different zones of a screw in an extruder: Feeding, 
compression/melting and metering zone. 
1.2.1 Hot-Melt Extrusion for Pharmaceutical Applications 
Hot-melt extrusion has now emerged as a technology that plays an important role in 
the production of novel pharmaceutical products in the pharmaceutical industry 
[113].  Due to its efficiency in mixing and the increasing demand from the regulatory 
bodies to implement continuous manufacturing processes on the production of 
pharmaceutical products for better quality control, the HME technology has received 
much attention from the medical and pharmaceutical industry for the production of 
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pharmaceutical dosage forms and medical implants [106] [114]. One of the greatest 
advantages of using HME for pharmaceutical applications is that the process does 
not require the use of any organic solvents which could then eliminate the possibility 
of chemical degradation or toxicity caused by the presence of residual solvents after 
the extrusion process [115]. This technology is also more environmentally friendly 
as it does not use any organic solvent.  Apart from that, HME is a versatile technology 
in term of its scalability and its ability to integrate with other technologies and 
process analytical tools for product quality control [116,117]. The number of HME 
patents issued for pharmaceutical applications has increased significantly since the 
1980s (Figure 1.7) [118]. This is because the HME process is able to meet the 
regulatory requirements in the manufacturing process of dosage forms and also have 
large flexibility, particularly for the increasing demand for personalised medicines. 
Regulatory bodies such as the U.S. Food and Drug Administration’s (FDA) 
encourages manufacturing processes that involves process analytical technology 
(PAT) in order to enhance product and process understanding. The initiative of PAT 
is to closely monitor some key parameters during the manufacturing process which 
could help to optimise design, analysis and control within the manufacturing process 
[101,112,119]. This can be demonstrated and fulfilled in the HME process.  
 
Figure 1.7: Number of Hot-Melt Extrusion patents issued for pharmaceutical 
applications between year 1983 to 2006 (the data for chart is extracted from reference 
[118]). 
During the hot-melt extrusion process of pharmaceutical dosage forms, APIs, 
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are heated and mixed in the extruder and then being forced through a die into shapes 
including granules, cylinder or films [120–124], In recent years, much work has proven 
that HME has the ability to improve the solubility and bioavailability of poorly soluble 
drugs [125–127]. HME can produce a formulation known as the solid dispersion, where 
the bioavailability poorly water-soluble APIs can be improved in such formulations. 
Several studies have shown that the solid dispersion technique has successfully improved 
the bioavailability of poorly soluble APIs such as Ritonavir, Troglitazone, Anacetrapib, 
Suvorexant [98,125]. A solid dispersion is a system where one or more APIs are 
molecularly distributed into a hydrophilic inert carrier matrix. The matrix can either be 
crystalline or amorphous, and the APIs will be dispersed molecularly in crystalline 
particles or amorphous particles [99,128]. In the early 1990s and 2000s, the Rezulin® and 
Kaletra® tablets have been successfully produced using the HME process, which have 
shown improved bioavailability. These two tablets were produced using twin-screw 
extrusion as it can provide homogeneous and consistent mixing of multiple ingredients 
[106]. Since then, the HME process, and in particular, the twin-screw extrusion, has 
gained much popularity in the pharmaceutical industry. 
The powerful processing technology of HME has also attracted much attention in 
developing different types of drug delivery systems, as it has opened up the opportunity 
to use some of the molecules that were previously deemed not suitable to be made into 
pharmaceutical dosage forms [118]. Its ability and efficiency in producing solid 
dispersions has also made it possible for the development of sustained, modified and 
targeted drug delivery systems. The different drug release systems can be achieved by 
controlling the formulations and the processing parameters when using HME [99]. 
As seen is some early studies, HME has been used to develop sustained release matrix 
mini-tablets manufactured from ethylcellulose, HPMC and ibuprofen [129,130]. 
Vegetable calcium stearate (CaSt) was also seen reported in the development of sustained 
release pellets using as a thermoplastic excipient [131]. A microbicide intravaginal ring 
(IVR) was also prepared and developed from polyether urethane (PU) elastomers for the 
sustained delivery of UC781 [132]. There has been also a study where HME was used to 
produce sustained-release solid lipid matrices of diclofenac sodium (Df-Na), and the 
extruded products were being compressed into tablets [133]. A lipophilic excipient, 
Glyceryl dibehenate (Compritol 888 ATO (C-888)) was used for the development of Df-
NA sustained-release lipid matrices. The purpose of the study is to investigate the effects 
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of some parameters (e.g., extrusion temperatures, formulation composition, drug-lipid 
ratio) on the drug release behavior. It is found that Df-Na can either be in the crystalline 
or amorphous state depending on the processing conditions. The dissolution rate is 
affected by the drug–lipid ratio and the extrusion temperatures. There was an excellent 
distribution of Df-Na on the surface of the compressed tablets. The study has proven that 
Df-Na sustained-release tablets can be effectively produced by processing solid lipids 
using HME [133]. 
Bruce et al. have successfully developed tablets to target deliver 5-aminosalicylic acid 
(5-ASA) to the colon [134]. The tablets, prepared using the HME technique, are able to 
homogeneously disperse the crystalline 5-ASA throughout the polymeric matrix. The 
polymeric carriers used are Methacrylic Acid—Methyl Methacrylate Copolymer (1:2) 
and Eudragit® S 100. Two types of plasticisers (Triethyl Citrate (TEC) and citric acid) 
were used in the study. TEC was able to reduce the glass transition temperature of the 
polymer, thus lowering the processing temperature. It can also affect the drug release 
rates of the tablets due to the leaching of TEC during the dissolution testing. The citric 
acid causes a slower drug release rate as it causes a decrease of the pH in the 
microenvironment of the tablet, which suppresses the polymer ionisation. The drug 
release profiles of the tablets were found to fit both the diffusion and surface erosion 
model [134]. 
Apart from developing drug delivery systems with different release patterns, HME can 
also be used to create drugs that could mask the bitterness of APIs. There are still a 
significant number of drugs on the market that have very poor organoleptic properties, 
which makes it unpalatable, especially for paediatric and geriatric medications. In order 
to improve the palatability of the drugs, taste masking has been an important 
consideration for the development of a formulation [135]. There are works that have 
shown that pharmaceutical dosage forms produced using the HME process can mask the 
bitter taste of APIs. This can be done by mixing the taste-masking polymer with the APIs 
during the production of a solid dispersion. The solid dispersion can prevent the 
interaction between the drug molecules and the taste bud by preventing the release of 
bitter drugs in the saliva [99]. Eudragit E-PO has been widely used as a taste-masking 
excipient in formulations, as it is insoluble below pH 5, thus preventing the release of the 
drug in the mouth [135].  
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In addition, HME is also suitable to be made into rod-shaped implants. Ghalanbor et al. 
used HME to produce protein-loaded poly(lactide-co-glycolide) (PLGA) implants with 
the incorporation of PEG as a hydrophilic additive, aiming to improve protein stability 
and release properties [136]. The study showed that the release of the implant can reach 
100% in 60-80 days with nearly complete enzyme activity even on the last fraction of the 
released protein, lysozyme. It has proven that the HME process can maintain protein 
stability to ensure the effective delivery of protein drugs. Bode et al. also carried out a 
study to prepare PLGA and PLA based implants using HME to achieve a controlled drug 
release pattern of the drug, dexamethasone [137]. The study was carried out to investigate 
how the swelling of the polymer can have an effect on the drug release of the implant. 
HME was chosen to prepare the implants in order to achieve a homogeneous distribution 
of the drug throughout the implants. The results from the study showed that the water 
penetration for the implant were limited initially due to the hydrophobicity of the 
polymers. However, the polymer becomes more hydrophilic over time as the water that 
penetrated through the polymer cleave the polysters, allowing more water to penetrate 
and cause swelling of the polymer. Drug release only starts when swelling happens. 
Salmoria et al. showed the possibility of producing implantable polyethylene/fluorouracil 
rods using HME which would potentially be used as targeted drug delivery in cancer 
treatment [138]. The implant showed slow and controlled drug release up to 45 days, 
which is suitable for cancer treatment at the tumour site.  
HME has also been used to produce orodispersible films (ODFs), which are sheets of 
drug-loaded materials that can form a suspension or solution when coming into contact 
with saliva in the mouth without the need of water intake [139]. This type of dosage form 
is beneficial for patients who have difficulty in swallowing, for younger patients, or for 
places where water is scarce. Pimparade et al. showed the possibility of producing 
chlorpheniramine maleate ODF using modified starch and glycerol through the HME 
process [140]. Sweeteners and saliva-simulating agents were added to the formulations 
to improve palatability and the disintegration time of the film. Speer and Breitkreutz 
managed to produce OFDs that have prolonged drug release characteristics by using HME 
and solvent casting method [141]. Hypromellose was used as a film former and 
theophylline was used as a model drug. The formulations were first processed using HME 
to produce drug-loaded matrix particles, then dissolved in distilled water for solvent 
casting to produce ODFs. Musazzi et al. carried out a study to demonstrate the feasibility 
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of producing maltodextrins ODF by using a combination of HME and 3D printing [142]. 
The excipients, plasticiser and active ingredient were mixed and made into printable 
filaments using an in-house HME. The materials were then fed to the printing head for 
the printing of ODF. The preparation of ODF using HME is still very limited due to the 
high processing temperature of HME. Most polymers used for ODF preparation are heat 
sensitive. Therefore, polymeric excipients need to be carefully selected. Apart from that, 
HME can be combined with other methods such as solvent casting or 3D printing to 
produce a wider range of ODFs.  
As the interest in using HME for pharmaceutical products has grown exponentially over 
the years, the concept of PAT was introduced which can be combined with HME as a 
continuous manufacturing process in order to achieve real-time monitoring of the 
product. This means that the quality of the product can be monitored simultaneously as 
the product is being extruded from the HME. The implementation of PAT within an HME 
system can help in the discovery of more novel drug delivery systems and the approach 
of studies. The most common PAT tools integrated with HME are UV/visible (UV/VIS) 
spectrophotometry [119,143,144], near-infrared spectroscopy (NIR) [145,146], Raman 
spectroscopy [147,148]. Table 1.4 shows the information that can be obtained from the 
in-line PAT during the HME process which would be very useful to provide an insight 
into how different processing parameters (eg. screw speed, barrel temperature, residence 
time, feeding rate, etc.) would affect the quality of the extrudates. 
Table 1.4: Information obtained from different in-line process analytical technology 
(PAT) integrated with HME. 
In-line Process Analytical Technology 
(PAT) 
Information 
UV/Vis Spectrophotometer Particle size, solid state, drug concentration 
Near-infrared spectrometer Effect of processing parameters on product 
quality, process efficiency, drug content, solid 
state 
Raman spectrometer End point of mixing process, drug content, 
solid state characteristics, distribution 
patterns of formulations 
When an extruder is used for pharmaceutical applications, it is required to meet some 
regulatory requirements. Therefore, some parts are different from the extruder which is 
used for manufacturing plastics. The metallurgy of the contact parts must not be reactive, 
additive or absorptive with the product, and these parts are made of medical grade steel. 
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The oils and lubricants used are also fully FDA-conformant. The equipment needs to be 
configured for the ease of cleaning within a pharmaceutical environment [100]. A 
comprehensive documentation of the process is required for monitoring and controlling 
the parameters such as feed rate, temperature, screw speed, pressure, melt viscosity, drive 
amperage and torque. The temperature in the barrel needs to be optimised so that the 
viscosity of the melted material is low enough to be transported down the barrel, but still 
sufficient for proper mixing. Apart from that, the temperature should also be kept low 
enough to avoid thermal degradation of the materials. There are also good manufacturing 
practices (cGMP) guidelines for the cleaning of HME used for pharmaceutical 
applications. The extruder for pharmaceutical purposes has been redesigned to enhance 
the ease of disassembling and limit any dead spots, allowing for efficient cleaning and 
maintenance. The equipment must be cleaned at appropriate intervals and written 
procedures are required that must be specific and detailed. Cleaned equipment must be 
protected from contamination while in storage and inspected before being used. Records 
and equipment logs of all cleaning and inspection must be kept. The time between the 
end of processing and cleaning steps must be recorded [101]. During cleaning, the 
extruder assembly is disassembled and any materials present on the screw, barrel and die 
need to be removed. The surfaces then need to be swabbed and analysed to satisfy 
cleaning validation requirements [120].  
There are many advantages in using HME for pharmaceutical applications, which makes 
the technology more popular as a manufacturing method for pharmaceutical products. 
HME can be modified to include appropriate PAT tools, making it a continuous 
manufacturing process, which is a fabrication method that is highly encouraged by FDA 
as it meets the goal of PAT scheme to improve the efficiency and effectiveness of 
manufacturing process design, control and quality assurance [149]. One other reason for 
HME to be a preferred method is that the process does not require any use of solvent 
when producing solid dispersions. Traditional formulation methods, such as roll spinning 
and spray drying, require the use of organic solvents. These organic solvents can cause 
environmental issues when being disposed of. As HME is a solvent-free process, this 
makes it an environmentally friendly process, making it a preferred process over 
conventional methods [135]. Some other advantages of using HME in pharmaceutical 
applications include shorter production time, higher process efficiency, and increases 
drug delivery efficiency in patients [120]. The biggest advantage of using HME in 
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pharmaceutical is the prospect of being able to create new and novel formulations through 
this technique. 
However, there are a few drawbacks in the HME process. HME requires high energy 
input, which is required for the shear forces and the elevated temperature in the barrel of 
the extruder. The high temperature may also cause thermal degradation of the APIs and 
the high shear forces may also cause mechanical degradation to the polymers. However, 
there has been ongoing research work to overcome these issues, and they can be solved 
by proper formulation and equipment design, as well as different engineering approaches 
[118]. 
1.3 Coupling HME with FDM 3D Printing 
HME is now widely used in the pharmaceutical industry dues to its versatility and 
scalability. However, there is a limitation in terms of the flexibility in the design of the 
dosage forms or other pharmaceutical products it can produce. This is because the shape 
of the product produced using HME depends on the shape of the die. Some of the more 
complex shapes and designs would be impractical to be made into a die. 3D printing 
seems to be able to overcome this issue as it has large flexibility to produce any 
pharmaceutical products in any shapes. However, there is a very limited number of 3D 
printable materials that are suitable to be used for pharmaceutical applications. In the 
previous section, there were many reports about the ability of HME to produce new 
polymeric mixture and composition. HME is also the perfect technology to produce 
filaments that can be used in FDM 3D printers. As a result, HME has been coupled with 
FDM 3D printing to overcome the limitation of not having the suitable materials available 
commercially. Apart from that, HME can be used to effectively load drugs onto the 
filaments which have really made the local production of personalised medicines and 
implants cost-effective.  
The feeding materials in FDM 3D printers need to be in the form of a filament. However, 
most filaments currently available in the market are not suitable to be used for 
pharmaceutical applications. This issue has been a major obstacle for FDM 3D printing 
being used as the main manufacturing method for pharmaceutical products. Apart from 
that, most traditional polymer excipients that have been used in pharmaceutics do not 
have the appropriate thermal and mechanical properties that can be used to make into 
filaments that are needed for FDM 3D printing [150]. Some of the most common 
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pharmaceutical grade polymers that can be made into filaments are Polyvinylpyrrolidone 
(PVP), Polyvinyl alcohol (PVA), and PLA [151]. These are suitable to be made into 
filaments due to excellent mechanical and thermal properties, and have been used to mix 
with drugs to produce filaments that can be used in an FDM 3D printer to produce oral 
dosage forms [152,153]. Filaments that are being used in FDM 3D printers need to be of 
good quality in order to produce a good quality 3D printed product. During the feeding 
of the filament into the print head of an FDM 3D printer, the filament will experience 
tensile and compressive forces caused by the extruding gear, as well as a large amount of 
heat for melting. The filaments will need to be able to withstand the mechanical and 
thermal stresses in the FDM print head in order to achieve a good printing quality [65]. 
Good quality thermoplastic filaments can be effectively produced using the HME 
method. With twin-screw extrusion in the HME technology, almost any kind of polymer 
can be mixed during the HME process in order to produce polymeric filaments for the 
desired applications. Therefore, there has been increasing research interest in the 
development of different types of filaments from different materials for specific 
applications using the HME technology. For instance, pure Eudragit has not been a 
suitable material to be made into FDM printable filaments due to its brittleness. Sadia et 
al. have been able to develop Eudragit-based filaments by mixing it with a plasticiser 
(triethyl acetate) and a filler (tricalcium phosphate) using the HME technique [154]. The 
mechanical properties such as the flexibility of the Eudragit filament have been further 
improved and the filaments are suitable to be used in FDM 3D printers for the fabrication 
of tablets. The 3D printed tablets also possess excellent mechanical strength [154]. Due 
to the robustness of HME in producing novel polymeric filaments for use in FDM 
printers, much research has been carried out to explore the possibility of bridging HME 
and FDM 3D printing to increase the range of polymers that can be used with FDM 
machines. This approach is seen to be a very efficient and effective way of producing 
desired materials for FDM printers. It will also further improve the usability of FDM 
printers across many industries. 
The HME technology and 3D printing technology has shown many advantages when 
being used in pharmaceutical applications. These two technologies can streamline the 
complex processes of conventional manufacturing methods for pharmaceutical products. 
Therefore, there has been some research on combining these two technologies into a 
single continuous process in order to achieve a more effective and efficient manufacturing 
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process. When these two technologies are coupled into one single process, it opens up the 
possibility of creating any dosage forms in-house for immediate consumption. This is 
particularly useful for hospitals in remote areas. Combining these two processes makes 
the fabrication of dosage forms more cost-effective, efficient and economical. Figure 1.8 
shows a schematic of the HME combined with FDM 3D printing into a single continuous 
process. 
 
Figure 1.8: Schematic of a combined Hot-Melt Extrusion (HME) and FDM 3D printing 
into a single continuous process (Reproduced with permission from reference [98]). 
1.3.1 Pharmaceutical Dosage Forms produced using HME and FDM combined 
The study reported by Zhang et al. showed the combination in the use of two 
technologies, the HME and FDM 3D printing, in a single process to produce controlled-
release tablets [98]. Different types of pharmaceutical polymers were made into filaments 
using HME and they were loaded with Acetaminophen as a model drug. The drug release 
profiles of the 3D printed tablets and the directly compressed tablets were being 
compared. The study shows that the 3D printed tablets have better extended drug release 
rates than the directly compressed tablets as they have smoother surfaces and tighter 
structures. The study has proven that it is possible to produce different formulations 
required using a single process [98]. Zhang et al. have been able to develop controlled-
release 3D printed tablets by using hydroxypropyl methylcellulose (HPMC) as a 
hydrophilic matrix polymeric material in the drug [155]. HME was used to prepare solid 
dispersion filaments with an API dispersed in HPMC based matrix. The filaments 
produced are fed into an FDM 3D printer to produce controlled-release tablets with 
different structural design in order to obtain different drug release profiles. Nine tablets 
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with the same overall tablet dimensions (diameter, 10 mm; thickness, 4.5 mm) but with 
different outer shell thicknesses and core densities were 3D printed. The geometry of 3D 
printed tablets can affect the dissolution and drug release rates. The study has proven that 
3D structure design is effective and efficient for optimising controlled drug release rates 
[155]. Goyanes et al. have also fabricated controlled-release budesonide tablets using 
FDM 3D printing. The work is to explore the feasibility of using FDM with HME and 
fluid bed coating to fabricate modified-release budesonide dosage forms. Budesonide is 
loaded into PVA filaments using HME. An FDM 3D printer is then used to produce 
capsule-shaped tablets (caplets) containing 9 mg of budesonide. The caplets were then 
overcoated with a layer of enteric polymer. The 3D printed caplet formulation started to 
release the drug in the mid-small intestine, but release then continued in a sustained 
manner throughout the distal intestine and colon. This work has demonstrated the 
possibility of combining FDM 3D printing, HME and film coating for the fabrication of 
modified-release oral dosage forms [156]. 
The work by Okwuosa et al. coordinates FDM 3D printing and liquid dispensing for the 
fabrication of individualised dosage form on demand in a fully automated fashion. This 
work has the potential of modifying drug dose and release. Polymethacrylate shells 
(Eudragit EPO and RL) were made using FDM 3D printing and the shells were 
simultaneously filled using a computer-controlled liquid dispenser loaded with a model 
drug solution (theophylline) or suspension (dipyridamole). The shell thickness of 1.6mm, 
and concentric architecture allowed for successful containment of the liquid core whilst 
maintaining the release properties of the 3D printed liquid capsule. Modifying the shell 
thickness of Eudragit RL capsule allowed for a controlled extended drug release without 
the need for formulation change. This type of hard shell capsule is better for taste and 
odour masking, improving the patient’s compliance. This low cost and versatile approach 
can be adapted to a wide spectrum of liquid formulation such as small and large molecule 
solutions. This method also eliminates the need for material compatibility with the high 
temperature of FDM. This is the first time that an example of a fully automated additive 
manufacturing process for a liquid capsule with the ability to control the dispensed dose 
has been demonstrated. A dual head FDM 3D printer is used here. However, one of the 
printing heads has been modified to include a syringe-based liquid dispenser. The drug-
free Eudragit filaments were produced using HME. Dimethylaminoethyl methacrylate, 
butyl methacrylate, and methyl methacrylate (Eudragit EPO) are used for the shell of 
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immediate release dosage forms and Eudragit RL is used for time-controlled drug release. 
The dosage can be controlled by manipulating the dispensed volume and the capsule shell 
thickness. This work has again proved the capability of FDM producing individualised 
dosage forms [157]. 
Chai et al. have used HME to produce hydroxypropyl cellulose (HPC) filaments that are 
loaded with Domperidone (DOM) to be used in FDM 3D printers. The DOM loaded HPC 
filament is used to 3D print intragastric floating sustained-release tablets that have a 
hollow structure, which makes the tablet has a lower density and allows it to float. The 
hollow structure of the tablet can be achieved by adjusting the shell numbers and the infill 
percentage of the FDM 3D printing process. The study shows that the capability of FDM 
3D printers, a cost-effective platform, to produce hollow tablets is a promising 
manufacturing method to fabricate intragastric floating drug delivery devices [158]. 
Okwuosa et al. have also used FDM 3D printers to produce delayed-release shell-core 
gastric resistant tablets. A dual extruder FDM 3D printer has been used to produce an 
enteric-coated tablet in a single fabrication process. In this study, PVP has been used as 
a polymer for the core and methacrylic acid polymer for the shell for gastric protection. 
Similarly, the drug loaded filament for the core and the filament for the shell were 
manufactured using HME. This work has proven that the FDM 3D printer is able to 
perform enteric coating to produce delayed release solid dosage forms [152]. Goyanes et 
al. have been able to use FDM 3D printing to produce modified-release paracetamol 
tablets without the need of an enteric coating [159]. Again, HME has been used to 
produce paracetamol-loaded filaments for the use in FDM 3D printers. In this study, 
paracetamol is mixed with three different grades of excipients hypromellose acetate 
succinate (HPMCAS) (grades LG, MG and HG) respectively. The HPMCAS-based 
tablets exhibit delayed-release properties, and tablets made from lower pH-threshold 
release drug faster (LG has the lowest pH threshold of 5.5, MG at 6.0, and HG at 6.5). 
This study shows that FDM 3D printing is able to produce delayed-release tablets without 
the need for an outer enteric coating. The work by Li et al. has been able to combine 
HME and FDM to produce a novel controlled-release drug delivery device for diabetic 
treatment [160]. HME was used to load Glipizide onto PVA to form the drug-loaded 
filaments. A dual extruder FDM 3D printer was used to produce a double chamber device, 
where a tablet is embedded within a larger tablet (DuoTablet), and both chambers contain 
different doses of glipizide. The different concentration of the drug at two chambers is 
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able to achieve a sustained-release profile of the drug. The drug in the external layer is 
first released and the drug in the second layer will only be released when the first layer 
has been completely dissolved, delaying the drug release profile of the solid dosage form. 
This study shows the feasibility of producing a DuoTablet with controlled-release profile 
in a single process [160]. 
Verstraete et al. conducted a study to develop high drug-loaded (>30%, w/w), 
thermoplastic polyurethane (TPU)-based dosage forms using FDM 3D printing. This is 
because TPU has shown potentials for the manufacturing of highly dosed oral sustained-
release matrices via HME [161]. The drug-loaded TPU filaments were prepared using 
HME. Different grades of TPU were mixed with model drugs of different particle size 
and solubility. Only the TPU-based filaments that exhibit consistent filament diameter, 
smooth surface morphology and good mechanical properties were used in FDM printers 
to be printed into tablets. It is proven that TPU-based filaments could be loaded with 60% 
(w/w) fine drug powder. The hot-melt extruded hard TPU filaments were successful in 
producing 3D printed tablets with a high concentration of the crystalline drug (up to 60%, 
w/w). The drug release profile of the 3D printed tablet was dependent on the matrix 
composition and the tablet infill degree. The dosage and release rate can be adjusted 
according to the patient’s needs by changing the matrix composition and the percentage 
of tablet infill. The study shows that TPU-based filaments can offer much formulation 
freedom for the development of personalised dosage forms [162]. 
Although there is much work that has proven the ability of FDM 3D to produce various 
drug delivery systems, it has not been a favoured technique when it comes to the 
fabrication of immediate-release tablets. This is because FDM 3D printed tablets 
generally have a slower dissolution rate when compared to tablets produced using 
conventional methods [163]. For instance, the FDM 3D printed theophylline tablets by 
Okwuosa et al., which is made from Eudragit®E and PVP with plasticisers required 30 
min for the drug to be completely released [153]. However, Kempin et al. explored the 
possibility of improving the dissolution speed of FDM 3D printed tablets by using 
different types of polymeric carriers [163]. The study carried out shows that when suitable 
pharmaceutical grade polymer is being used, FDM can be used to produce immediate-
release tablets that contains thermolabile drugs. The drug release profiles of pantoprazole 
sodium tablets made from five different polymers (PVP K12, PEG 6000, Kollidon® 
VA64, PEG 20000 and poloxamer 407) were compared. The drug was loaded onto each 
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polymer using the HME technology to produce drug-loaded filaments. The results show 
that the drug incorporated in PVP has the fastest release and can be completed within 10 
min. The dissolution rate can also be further improved by reducing the infill rate during 
printing to increase the porosity of the tablet [163]. Apart from that, the study has also 
proven that FDM 3D can produce tablets at processing temperatures below 100C. FDM 
3D printers are known to have very high printing temperatures (170–230C) due to the 
high melting temperature of the traditional polymeric filaments used and could be 
inappropriate for the incorporation of thermos-sensitive drugs. However, the processing 
temperature of FDM 3D printers can be lowered when suitable polymers can be made 
into filaments chosen as a drug carrier. Kollamaram et al. have also been able to produce 
immediate-release formulations (Ramipril) through FDM 3D printing at a lower printing 
temperature. The drug is mixed with Kollidon VA64 and Kollidon 12PF to achieve the 
immediate-release effect. Drug loaded filaments were first produced using the HME 
technology at 70 °C. The 3D printer was able to print the tablets from the filaments 
produced at 90 °C and there were no signs of thermal drug degradation on the printed 
tablets. The work has proven that FDM 3D printing can also be used to produce 
thermolabile and low-melting point drugs when the drug is mixed with appropriate 
excipients [164]. The study by Solanki et al. have produced FDM 3D printed tablet for 
rapid drug release. The model drug used is haloperidol and the drug-loaded filaments 
were prepared using HME. Different type of polymers were used to be made into 
filaments (Kollidon® VA64, Kollicoat®IR, Affinsiol TM 15 cP and HPMCAS). Tablets 
of 100% and 60% infill were printed at 210 °C and dissolution test were conducted at pH 
2 and 6.8. For the 60% infill tablet, complete drug release was achieved in 45 min, which 
was significantly faster than the 100% infill tablet. This is because the 60% infill tablet is 
porous and the 100% tablet is non-porous. The filaments made of Kollidon®VA-64-
Affinisol TM 15 cP mixtures were flexible and had optimum mechanical strength for 3D 
printing. The 1:1 mixture of Kollidon® VA-64 and Affinisol TM 15 cP was the most 
suitable polymer system to be used for 3D printing and rapid drug release. The study has 
proven that FDM 3D printing can also be used to fabricate immediate release dosage 
forms [165]. 
1.3.2 Dosage Forms with Multiple Medications 
In recent years, there has also been increasing interest in developing a dosage form that 
contains multiple medications [150,166,167]. Having more than one API in a dosage form 
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can improve patient compliance and cost-effectiveness [168]. This type of multi-active 
solid dosage form, also known as polypill, is particularly useful for patients with 
complicated diseases, who are required to take multiple medications in a day. The polypill 
can reduce the frequency of medications intake in a day for the patient. The work by 
Gioumouxouzis et al. discovered the capability of FDM 3D printing to fabricate dosage 
form containing two APIs. The bilayer dosage form contains two anti-diabetic drugs 
(metformin and glimepride). Metformin was mixed with Eudragit®RL to achieve a 
sustained-release effect and glimepride was mixed with polyvinyl alcohol (PVA) for an 
immediate release system. In this study, the two APIs were incorporated into two different 
polymeric carriers to achieve distinct release characteristics. The 3D printed bilayer 
dosage form allows for the simultaneous usage of two APIs that are administered at 
different times of the day according to the patient’s needs. The drug-loaded filaments 
were also manufactured using the HME technology. This study shows that FDM 3D 
printing can be a promising technique for the fabrication of complex personalised 
medicine consisting of different APIs that exhibit different release patterns [169]. 
Goyanes et al. used a dual-extruder FDM 3D printer to fabricate two different capsule-
shaped oral drug delivery devices. One is a multilayer device and the other is a two-
compartment caplet (Figure 1.9). The multilayer device is designed in such a way, that 
two adjacent layers contain different type of drugs. The two-compartment caplet is a 
smaller caplet embedded in a larger caplet (Duocaplet), with each compartment 
containing a different drug. In this study, PVA-based filaments were used and they were 
loaded with paracetamol or caffeine. The filaments were prepared using the HME 
method. The drug release study shows that for the multilayer device, drug release rates 
were similar for both drugs. However, if one layer has a higher drug loading than the 
other, the release rate will be faster for higher drug loading. For the Duocaplet, the drug 
on the external layer is being released first. The time lag of the release of drug in the inner 
caplet depends on the characteristics of the external layer. The study has proven that 
tablets that are 3D printed in different shapes can have different release profiles [170]. 
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Figure 1.9: A 3D computer-aided design (CAD) model of capsule-shaped oral drug 
delivery device (a) multilayer device (b) two-compartment caplet (Duocaplet) 
(Reproduced with permission from reference [170]). 
Maroni et al. used FDM 3D printing to fabricate a two-compartment capsular device for 
two-pulse oral drug delivery purposes. The study carried out in this work involves the 
combination of two compartments with different wall thickness and compositions. 
Promptly soluble, gastroresistant and swellable/erodible compartments were developed, 
which allowed for immediate, enteric and pulsatile release to be achieved respectively. 
Therefore, different types of polymeric filaments have been used to achieve different 
effects. The polymeric filaments were prepared using twin-screw extrusion. Apart from 
different materials, the compartments were also made to be of different wall thickness 
(600 µm and 1200 µm) (Figure 1.10). Such a device is intended to yield multiple release 
kinetics. The two separate compartments are to be filled either with different APIs or with 
varying doses and/or formulations of one particular drug. These devices with different 
compartment characteristics show two pulse release patterns. These two-compartment 
capsular devices are able to convey incompatible drugs or different drug formulations 
[171].  
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Figure 1.10: Two-compartment capsular device (a) compartments with the same wall 
thickness (b) compartments with different wall thickness (Reproduced with permission 
from reference [171]). 
Tagami et al. were able to fabricate 3D-printed composite tablets consisting of two 
components, a drug and a filler, using a dual head FDM 3D printer. PVA containing 
calcein was used as the drug component and drug-free PVA or PLA was used as the 
water-soluble or water-insoluble filler respectively. The filaments were produced using a 
twin-screw extruder. Different designs of the tablets were being used. There were eight 
kinds of calcein-loaded PVA/PVA composite tablets and four kinds of calcein-loaded 
PVA/PLA tablets that were 3D printed. All composite tablets were designed to have 
different surface areas of calcein-PVA but all have a drug component/filler component 
ratio of 2/3 (v/v). The composite tablets showed various drug release profiles. The higher 
surface area of calcein-PVA had a higher dissolution rate. The study shows that the 
polymer filler component was effective in controlling drug release and will be particularly 
useful for personalised medicine [172]. The study carried out by Melocchi et al. has 
successfully proven the feasibility of FDM 3D printing in the manufacturing of capsular 
devices for oral pulsatile release using HPC-based filaments. Pharmaceutical grade HPC-
based filaments are not commercially available and they were produced using HME. The 
capsular device produced using FDM 3D printing exhibited satisfactory physico-
technological properties. The release test of the capsular device shows that there is a lag 
phase before the rapid and quantitative liberation of the drug. The morphological of the 
device when in contact with water and the release performance is comparable to the 
analogous systems fabricated using injection moulding. Since it is possible to rapidly 
prototype capsular devices using FDM 3D printing, the screening of formulation and 
design characteristics of these devices are also expected to be accelerated [173].  
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Pereira et al. carried out a study to demonstrate the ability of FDM 3D printing to produce 
patient-specific polypills as a treatment of cardiovascular diseases [174]. The polypill 
fabricated was PVA based and contained 4 model drugs (lisinopril dihydrate, indapamide, 
rosuvastatin calcium and amlodipine besylate). The PVA filaments containing each of 
these drugs were extruded using HME. Then a multilayer polypill was printed using FDM 
3D printer using the PVA filaments containing each drug. A novel approach of using 
distilled water as a plasticiser was used in this study and it was found that the extruding 
and 3D printing temperature was much lower due to the plasticising effect. The release 
profile of each drug depends on the position of its layer in the pill. This approach showed 
a low-cost manufacturing method of a multidrug delivery system for individualised 
medications, and the release profile of the drug can be modified by changing the sequence 
of the drug layer in the multiplayer polypill.  
As FDM 3D printing can be used to produce complex personalised medicines, Arafat et 
al. have been able to use 3D printers for flexible on-demand precision tailored dose 
adjustment [175]. This type of medication has been beneficial for anticoagulant therapy. 
For anticoagulation therapy, regular coagulation monitoring and dose modification is 
required in order to ensure the patient’s International Normalised Ratio (INR) remains in 
the target range. Therefore, dose modification is required from time to time, depending 
on the patient’s condition, as the patient’s INR profile may be constantly changing. The 
3D printing technology is able to produce a precise dose and has been a platform to 
fabricate personalised medicine with the required dose. The technology allows the 
administration of the lowest effective dose of the drug to maintain the target INR due to 
its flexible and precise manufacturing capability. Arafat et al. have used FDM 3D printers 
to produce a tailored dose of a narrow therapeutic index drug, warfarin, and have 
successfully fabricated this purposefully designed solid dosage form in ovoid tablets. The 
study showed that FDM 3D printing can be used to engineer and control the dose of 
immediate-release warfarin tablets by controlling the mass and volume of the 3D printed 
tablet. The drug-loaded filaments were produced using a twin-screw hot-melt extruder 
and Triethyl citrate was mixed into the drug-loaded filament formulation in order to lower 
to the glass transition temperature of the filament [175].  
Apart from that, the work done by Scoutaris et al. has also proven that a continuous 
process of HME coupled with FDM 3D printing can be used to prepare chewable tablets 
in the shapes of “Starmix®” sweets [76]. This is a very effective method to produce 
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paediatric medicines as the HME is able to provide taste masking of bitter APIs, and FDM 
3D printing has the capability to produce complex shapes tablets that could attract the 
attention of children. In this study, the drug used is Indomethacin and the thermoplastic 
polymer used is HMPCAS. HME has efficiently dispersed the indomethacin in the 
HPMCAS matrix, providing excellent taste masking efficiency. FDM 3D printing has 
shown to have high reproducibility, accuracy and content uniformity of the Starmix® 
shapes. This study has proven an alternative route of producing palatable paediatric 
dosage forms. Jamróz et al. carried out a study that used FDM 3D printer to prepare 
orodispersible films (ODFs) containing a poorly water-soluble substance, Aripiprazole. 
The study proves the feasibility of fabricating ODFs using FDM technology to improve 
the dissolution rate of the poorly water-soluble substance through 3D printed films. The 
Aripiprazole loaded PVA filaments were prepared using HME. The study shows the 
amorphisation of the aripiprazole and the porous structure of 3D printed film is able to 
improve its dissolution rate. The mechanical properties of the 3D printed films were also 
comparable to the films prepares using the casting method [176]. 
Beck et al. also carried out a study regarding an innovative approach to produce 
customised drug delivery systems using FDM 3D printing. This work produced a multi-
functional drug delivery system, which is a solid dosage form loaded with nano-sized 
carriers. The possibility of fabricating solid dosage form containing drug-loaded 
nanocapsules using FDM 3D printing has been discovered. This work integrates the FDM 
3D printing technology and nanotechnology to produce innovative nanomedicines. PCL 
and Eudragit®RL100 filaments were produced using HME. The 3D printed tablets were 
then loaded with polymeric nanocapsules. The study proposed a new platform for the 
development of oral dosage forms, biodegradable implants with tailored dose and drug 
release profiles, as personalised medicines [51]. 
1.3.3 Drug-loaded Implants Application 
Kempin et al. have used HME to produce quinine loaded filaments that can be used in 
FDM 3D printers to produce drug-loaded implants. The drug release of different type of 
polymers (Eudragit® RS, Polycaprolactone (PCL), poly(L-lactide) (PLLA), and ethyl 
cellulose (EC)) were being compared. The study shows that PCL has the fastest drug 
release whereas Eudragit and EC have the slowest drug release. The study has proven the 
feasibility of FDM 3D printing to manufacture drug loaded-implants as FDM 3D printing 
can produce a product of almost any shape, which could be designed to function as an 
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implant, and at the same time, be able to incorporate a desired drug delivery system [177]. 
Besides that, Genina et al. used ethylene vinyl acetate (EVA) as a drug carrier to produce 
drug-loaded EVA filaments using HME. The EVA filaments were loaded with 
indomethacin using HME. The filaments produced were used in FDM 3D printers to 
fabricate custom-made T-shaped intrauterine system (IUS) and subcutaneous rods (SR). 
The aim of this work is to investigate the printability of different grades of EVA 
copolymers as new feedstock material for FDM 3D printing in the fabrication of drug 
delivery devices. The IUS and SR were successfully printed at a temperature just above 
the melting point of the drug. The study has proven that EVA 5 polymer has the required 
properties to be made into filaments for the FDM 3D printing of drug delivery systems 
such as IUS and SR devices [178]. Holländer et al. have also been able to produce 
indomethacin loaded PCL filaments using HME. The drug-loaded PCL filaments were 
then used in FDM 3D printers to produce drug-containing T-shaped prototypes of IUS. 
This study shows that the fabrication of controlled-release implantable devices can be 
achieved using FDM 3D printing and HME technology [179]. Fu et al. have been able to 
use FDM 3D printing to produce personalised progesterone-loaded vaginal rings. 
Progesterone was mixed with Polyethylene Glycol (PEG) 4000 to form a solid dispersion 
and was cut into pieces. The mixture of PLA and PCL (8:2), Tween 80 and the 
progesterone-loaded PEG were mixed in a desktop single screw extruder and hot melt 
extruded in the form of filaments. The filaments were fed into FDM 3D printers to print 
vaginal rings in the shape of “O”, “Y”, or “M”. The work shows that “O” ring had a 
higher dissolution rate due to its higher surface area/volume ratio. The vaginal rings also 
have long-term sustained-release of progesterone for more than 7 days with diffusion-
controlled release behaviour. It is again been proven that HME and FDM 3D printing is 
an effective method to prepare personalised and customised medications [71].  
Stewart et al. developed several biodegradable subcutaneous implants that were loaded 
with different APIs and have different designs to achieve a prolonged drug release from 
the implants using FDM 3D printing [180]. A study on how the geometry of the implant 
can affect the drug release kinetics was also carried out. The materials used were PLA 
and PVA and the filaments were produced using HME from these materials. The printed 
implants have a different degree of porosity by the presence of a different number of 
‘windows’ to investigate the drug release. The main implant body was printed out of PLA 
filaments and the windows were printed out of PVA filaments. PCL was then used to coat 
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the implants in order to obtain a more sustained drug release pattern. The study 
successfully proved that how effective the HME and FDM 3D printing technologies are 
in terms of producing personalised drug delivery implants on-demand as the 3D printing 
technology can easily produce different implant design to achieve the desired drug release 
pattern. 
The work carried out by Melocchi et al. proposed a novel approach of 3D printing a 
retentive intravesical drug delivery system based on the water-induced shape memory 
response of PVA [181].  Shape memory polymers are considered as smart materials that 
carry a shape memory effect, which is the ability to deform and recover to their original 
shape when triggered by an external stimulus such as light, humidity, change in 
temperature, electric current or magnetic field [182–185]. The PVA filaments containing 
glycerol as plasticisers and caffeine as an active ingredient was produced using HME. 
The filaments were fed into an FDM 3D printer to print the desired shape of the implant. 
The printed implant required programming steps to change it into a temporary shape so 
that it will be suitable for administration via a catheter. It is then transformed to its desired 
permanent shape for bladder retention when it is in the human body caused by the body 
temperature of 37°C. The implant showed prolong release due to the material’s slow 
interaction with aqueous fluid. This new concept of 3D printing is now commonly known 
as 4D printing, where the 3D printed object is capable of self-transforming to achieve its 
designed functionality as a response to external stimuli. Such drug delivery devices which 
can self-transform are highly beneficial as it can be designed to a shape which can have 
administered conveniently into the human body. This study has shown the feasibility and 
possibility of using 4D printing for pharmaceutical applications.  
1.4 Sensors for Biomedical Applications 
Nowadays, sensors are ubiquitous and have been playing an important role in our daily 
lives. Sensors can be easily found in a wide range of applications, ranging from consumer 
products such as mobile phones to many manufacturing industries. Apart from that, 
sensors are also very critical in healthcare and biomedical applications. Sensors have 
always been important for health monitoring and diagnostic as we rely on sensors to 
provide us with information regarding our health.   
A widely used definition for a sensor is a device that can produce a useful output in 
response to a specified measurement [186]. Typically, the output of a sensor can be 
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optical, electrical, chemical or mechanical and the targeted measurement can be of 
physical, chemical or biological property  [187]. In biomedical applications, sensors have 
been used to measure much important information regarding the human body such as 
blood pressure, body temperature, oxygen level, glucose level, heart rate, different 
hormones and antibodies, magnetic and electric fields, etc [188–196]. The reliability, 
sensitivity and accuracy are highly important in the development of biomedical sensors 
in order to provide the most accurate health diagnostic and measurement of a person. One 
other key consideration is biocompatibility of the sensor, particularly for sensors that need 
to be implanted and have direct contact with the human body so that the sensor material 
will not cause any toxicity or harm to the human body.  
In recent years, the integration of sensors with traditional medical implants has gained 
much research attention. The purpose of integrating implants with sensors is to 
immediately detect and monitor the response of the human body in all conditions. This 
can play an important role in the detection of life-threatening diseases. Therefore, medical 
implants integrated with sensors are also called smart implantable devices. In general, 
smart medical implants are able to improve the functionality and longevity of implantable 
devices. The function of smart medical implants is to provide real-time information of 
any part of the human body that is of interest. This information is very useful as it can 
help to further improve the quality of life. 
As smart medical implants integrated with sensors are used to detect the changes in the 
body, the main functioning sensor is often called a biosensor. A biosensor can be known 
as a device that measures the biological and chemical reactions in the body which can 
also be used as a diagnostic tool in clinical applications. Biosensors are nowadays 
ubiquitous and have been widely used for point-of-care monitoring of treatment and 
disease progression [197]. The applications of biosensors are not only limited to 
biomedical application such as disease monitoring, drug discovery, detection of vitals or 
diseases in our human body [197], but also used in other fields such as national security 
[198], forensic studies [199] and environmental monitoring [200]. In general, the working 
principle of a biosensor can be explained in 5 components: analyte, bioreceptor, 
transducer, electronics and display (Figure 1.11). An analyte is a substance that is of 
interest and needs to be detected by the biosensor. For example, glucose can be an analyte 
for a glucose biosensor. A bioreceptor is a molecule that specifically recognises the 
analyte, where it could be enzymes, cells, deoxyribonucleic acid (DNA), antibodies etc. 
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The response or signal generated from the interaction of the analyte with the bioreceptor 
is called bio-recognition. The transducer is an element that converts a form of energy into 
another. In a biosensor, the transducer converts the bio-recognition event into a 
measurable signal. The process of energy conversion is called signalisation. Most 
transducers produce either optical or electrical signals. The electronics is where the 
produced signal is being processed and prepared for display. This is normally a complex 
electronic circuit that performs signal conditioning such as amplifying and converts the 
signals from analogue to digital. The display is where the detected information are being 
displayed in a form which is comprehensible by the user [197]. Some of the main features 
to consider when manufacturing a biosensor are selectivity, reproducibility, stability, 
sensitivity and linearity. 
 
Figure 1.11: Schematic diagram explaining the working principle of a typical biosensor. 
1.4.1 Examples of Smart Medical Implants 
Some orthopaedic implants, especially for artificial joints used for joint replacement 
surgery, are currently integrated with sensors. This is because there has been an increasing 
number of complications related to bacterial biofilm infections at the artificial joint 
prostheses which could cause chronic infection, resulting in aseptic loosening of the 
prostheses. By integrating sensors to these implants, it is then possible to detect and 
monitor the response of the human body to the implants after the surgery is performed. 
This could also help to monitor the progress of the patients’ recovery. The sensor can also 
detect any unusual activity at the implanted site through enzymatic reactions caused by 
the development of bacteria. The implant could have a drug reservoir where the drug will 
be released to target the infected area. The smart orthopaedic implants could prolong the 
life of the implant, reduce the risk the infection, and reduce the need for revision surgery. 
Another type of smart medical implant that has received much research attention contains 
sensors that could measure some metabolites through the body fluid to provide vital 
information regarding the health of the human body. Typically, these implants consist of 
a needle-type sensor which is inserted under the skin to measure the targeted information 
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from biomolecules in the body fluid. Our body fluid such as sweat and interstitial fluid 
contains several potential analytes related to human health status such as sodium, 
chloride, potassium, carbonates, ammonia, calcium, glucose, lactate etc [201–203]. The 
most commonly available sensors are used to detect the glucose level in the body. 
1.4.2 Temperature Sensing System 
The measurement of body temperature is very basic but also a very critical parameter for 
a diagnostic procedure in medical practice [204]. It is suggested that body temperature is 
one of the main vital signs and should be used as part of the initial assessment for acute 
illnesses in adults [205]. The human body regulates its temperature by balancing the heat 
generated through metabolism and the heat loss to ensure a stable body temperature [206]. 
This is known as the homeostatic thermoregulation mechanism which help maintain the 
core body temperature at around 37.5 °C [207,208]. A body temperature that is too high 
or too low may indicate some early signs of disorders and illnesses [209]. Therefore, the 
measurement of body temperature needs to be very accurate as inaccuracy can lead to 
misdiagnosis and compromise patients’ health.  
As the reliability and accuracy of temperature sensors are highly important particularly 
in the healthcare industry, there has been increasing effort in developing safe and reliable 
biomedical temperature sensors. Temperature sensors can be produced using different 
technologies and are often categorised into the following types: thermocouples [210], 
thermistors [211], resistance temperature detectors (RTDs) [212], fibre optic temperature 
sensors [213], and infrared sensors [214]. Table 1.5 below shows a brief summary of the 
different techniques that have been used for temperature sensing and their applications 
across various industries. However, the applications of all the temperature sensors are not 
limited to the applications mentioned. The approximation of the operating temperature 
range of each technology is very dependent on its application and the type of material it 
is made of. Hence, it is not an accurate representation of the actual temperature range that 
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Table 1.5: The different temperature sensing technologies and their applications. 
Type of temperature sensor 
Approximate operating 
temperature range (°C) 
Applications 
Thermocouple 
-40 – 1500 (depending on 
type of wire used) [215] 
Oil/Gas [216,217], 
Pharmaceutical [218], 
Kitchen appliances [219] 
Thermistor -55 – 150 [211] 
Textile manufacturing 
[220,221], Plastics 
manufacturing [222], medical 
applications [223,224], air, 




-250 – 1000 [228] 
Air conditioning [229], food 
processing [230], micro-
electronics [212,231], 
Nuclear plant [232] 
Fibre Optic Temperature 
Sensors 
-250 – 250 [233] 
Pharmaceutical [234], 
Medical [235,236], 
Aerospace [237,238], Wind 
energy [239], Oil/Gas [240] 
Infrared Temperature 
Sensors 
0 – 1000 [214,241] 
Heating/Air conditioning 




A thermocouple is typically made of two different metal wires that are of different 
electrical properties at different temperatures. One end of both wires are welded together 
to create a junction which is used to measure temperature. The other open ends of the two 
wires are used to measure the voltage created between the two dissimilar metal wires 
when there is a change in temperature. The change in voltage is used to measure the 
difference in temperature [250]. The set-up of thermocouples is very simple, easy to 
manufacture and inexpensive. They are offer good reliability and mechanical flexibility. 
As they are often made of extremely fine metal wires, thermocouples can be used to 
measure temperatures in locations that are difficult to access such as human organs, 
autoclave and nuclear reactors [251–253]. As an example, a flexible thermocouple 
temperature sensor integrated with a soft pneumatic balloon actuator to function as a 
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robotic microfinger for operations in inaccessible environments was demonstrated by 
Konishi et al. [210]. Such devices are particularly useful as minimally invasive surgeries 
are more preferred nowadays for safer operations [254].  
A thermistor is generally a thermally sensitive resistor, where its resistance changes when 
there is a change in temperature. Most thermistors have a negative temperature 
coefficient, which means the resistance decreases as the temperature increases. Some 
could also exhibit positive temperature coefficient, where the resistance increases as the 
temperature increases. Thermistors have been widely used in healthcare applications due 
to their stability, precision, reliability, fast response and low cost [255,256]. An example 
where thermistors have been used in medical application is that thermistors are used to 
measure the temperature of cells during cancer treatment when using heat to destroy 
diseased cells in tumours [257–259]. Thermistors can also be found in dialysis machines 
for diabetic patients where the temperature of the blood being filtered during dialysis are 
being monitored. The machine will then reheat the blood to normal body temperature 
after filtering before it is returned to the patient’s body [260]. Thermistors are used 
extensively in catheters as well which are inserted into the heart muscles to monitor the 
temperature during a heart surgery [261,262]. The catheters integrated with thermistors 
are important for cardiac diagnostic and procedures.  
RTDs are similar to thermistors as they also function like resistors in which the resistance 
changes as the temperature changes. RTDs often offer greater stability, accuracy and 
repeatability when compared to thermocouples. However, a power source will be required 
for RTDs to operate as it operates using electrical resistance. Yang et al. showed an 
example of a flexible implantable micro temperature sensor that is made of RTDs which 
can potentially be used in various biomedical applications [263]. This is because the 
RTDs were fabricated on a flexible polymer capillary with very thin layers of platinum, 
allowing the temperature sensor to be highly flexible for precise and sensitive temperature 
measurement. One example discussed by the authors where such implantable temperature 
sensors can be useful is for microwave hyperthermia during cancer treatment. The 
temperature sensor can be implanted into the tumour during treatment to monitor the 
temperature in order to prevent excessive heat from the hyperthermia to prevent the 
burning healthy tissues around the tumour [263].  
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Fibre optic temperature sensors use optical fibres to measure temperature. There are many 
types of fibre optic temperature sensors with different principles of operations. These 
sensors can be generally categorised into intensity-modulated sensors, phase-modulated 
sensors and wavelength-modulated sensors [264–267]. In an intensity-modulated 
temperature sensor. The intensity of the light through an optical fibre changes according 
to the change in temperature. For a phase-modulated sensor, the sensor compares different 
phases of light in the sensing fibre at different temperature. The wavelength-modulated 
sensors measure the change in the reflected wavelength of the light due to the change in 
temperature. One of the most widely used techniques is the Fibre Bragg Grating (FBG)-
based sensors [268]. The basic principle of this sensor is that it uses wavelengths that 
satisfy the Bragg condition, where these wavelengths are reflected using a grating inside 
the core of an optical fibre. When there is a change in temperature on the optical fibre, 
the spacing between the gratings will change resulting in a change in the refractive index. 
This means that a change in temperature will cause a shift in the reflected wavelength 
[269]. This type of temperature sensors are highly sensitive as they are able to measure 
extremely small temperature changes. Fibre optic temperature sensors have been very 
valuable for biomedical applications and can be found in various applications such as 
electromagnetic heating for cancer therapy, catheter with temperature sensors and patient 
temperature monitoring during magnetic resonance imaging (MRI) [270–273]. Fibre 
optic temperature sensors do not exhibit conductive properties, unlike the temperature 
sensors previously mentioned. As a result, it offers the advantage of not interfering with 
electromagnetic, radio waves or microwaves. Hence, it can be used with MRI and still 
provide stable and reliable temperature measurements [274]. Apart from MRI, fibre optic 
temperature sensors have also been used in radio frequency and microwave treatments 
[275–277]. The Luxtron fibre optic thermometer from LumaSense (LumaSense 
Technologies, Santa Clara, CA, USA) is an example of an optical fibre temperature sensor 
that uses the light fluorescent technique to provide real-time temperature measurements 
during ablation procedures involving MRI, radio frequency or microwave [278–280]. An 
in-depth review of how different optical fibre-based temperature sensing technologies 
have been developed for various biomedical applications have been prepared by Roriz et 
al.[233]. 
Infrared temperature sensors use a non-contact temperature and non-destructive 
measurement method as the technique involves the use of infrared radiant energy to 
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measure the temperature from a distance by measuring the energy of the wavelength 
being emitted [281]. It uses the principle that objects with the temperature above absolute 
zero (-273.15 °C = 0 Kelvin) emits electromagnetic radiation from its surface which is 
proportional to its intrinsic temperature [282]. This radiation is an infrared radiation and 
can be used to measure the temperature of the object. Infrared radiation is one of the 
electromagnetic waves as shown in the electromagnetic spectrum in Figure 1.12.  The 
wavelength of infrared is typically in the range of 0.78 – 1000 µm [283]. In an infrared 
temperature sensor, a lens is used to focus the infrared beams into a detector element 
which generates an electrical signal that is proportional to the infrared radiation. The 
signal is then transformed to produce a temperature value that corresponds to the 
temperature of the measured object. Examples of infrared temperature sensors are 
commonly found as fever thermometers such as ear thermometers and non-contact 
thermometers [284].  
 
Figure 1.12: A typical electromagnetic spectrum showing the types of electromagnetic 
waves and their respective wavelengths range (in m). 
Most current temperature sensors for medical applications are often integrated with some 
medical diagnostic and treatment devices [285]. For instance, some temperature sensors 
integrated sensors can measure the calorimetric flow of the blood or respiratory flow as 
well temperature at the same time [286–288]. Some of the temperature sensors are 
integrated with surgical tools for better surgical outcome [289]. Nevertheless, 
temperature sensors are highly important and have many applications, not just in the 
medical field.  
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1.4.3 Glucose Sensing System 
Glucose is the main energy carrier in the human body. It is a type of sugar that is derived 
from the digestion of carbohydrates in the body which is absorbed into the bloodstream 
and circulated throughout the body for cells to convert them into energy. The sugar level 
is regulated by a hormone called insulin which is produced in the pancreas by the Islet of 
Langerhans. Typically, the glucose level in a healthy person 4-5.9 mmol/L [290]. In some 
people, however, the body’s ability to produce or respond to insulin is impaired, resulting 
in a high concentration of sugar in the blood, also known as hyperglycaemia. This chronic 
condition is called diabetes. The two most common types of diabetes are Type I and Type 
II. Type I diabetes is an autoimmune disease where the body’s immune system attacks 
and destroys the cells that produce insulin. Type II diabetes is an condition where the 
production of insulin is insufficient or ineffective in regulating the uptake of glucose from 
the blood [291,292]. In general, Type II diabetes is more common than Type I. According 
to the report from the World Health Organisation (WHO), there were 422 million diabetic 
patients in the year 2014 around the globe. Diabetic can be fatal, and it is a major cause 
of blindness, kidney failure, heart attacks, stroke and lower limb amputation. WHO 
estimates that diabetes was the seventh leading cause of death in the year 2016 [293]. 
Diabetic patients need to constantly monitor their blood sugar level throughout the day 
so that they can manage their activities such as diet pattern, physical exercise and drug 
therapy in order to regulate their blood sugar level [294,295]. Therefore, systems that can 
efficiently monitor the glucose level in our body is essential and has received much 
research effort not just in academia but also in the pharmaceutical industry.  
The most conventional method of measuring glucose in the human body is by glucose 
meters. This method requires pricking of the fingertips with a lancet to access the 
capillary blood and a drop of blood is used to measure the sugar level [296]. The glucose 
meter measures the enzymatic reaction of blood glucose with glucose oxidase (GOx) that 
is on the strip of the glucose meter. GOx is a specific enzyme that oxidises glucose to 
form gluconic acid and hydrogen peroxide (H2O2) in the presence of water (H2O) and 
oxygen (O2). H2O2 is then electrochemically oxidised on an anode electrode to give an 
amperometric signal (current) which is proportional to the concentration of glucose in the 
blood. The glucose meter contains a current-to-voltage converter which converts the 
current produced into a voltage reading proportional to the glucose level in the blood 
[297].  
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Glucose + H2O + O2
GOx
→   Gluconic acid + H2O2  (Equation 1.1) 
H2O2 → O2 + 2H
+ + 2e- (Equation 1.2) 
The use of an enzyme, such as GOx and dehydrogenase, is the most common approach 
used in glucose sensors to convert glucose into a readable electrochemical signal [298–
301]. This is mainly due to its simplicity, efficiency, and reliability [302,303]. 
Unfortunately, this method of measuring glucose level is not the most patient compliant 
as the patients could easily forget to measure. Fingertips pricking can also cause a certain 
degree of pain. Apart from that, this method of measuring glucose level does not provide 
any information on how the glucose level changes with the activities carried out within a 
certain timeframe [304]. To better understand the fluctuation of the glucose level in the 
human body, an alternative approach involves the use of Continuous Glucose-Monitoring 
(CGM) systems. CGM systems are being used to live to monitor the glucose level in the 
human body and glucose readings can be taken at any time. The data obtained shows the 
history and the direction of the glucose level is heading in the body. The CGM can help 
patients to track the fluctuation of the glucose level throughout the day so they can adapt 
to the lifestyle that benefits them the most. CGM is also more patient-friendly as these 
technologies are mostly wearable and non/minimally invasive [305–308]. Given the 
many advantages of CGM compared to conventional methods of measuring glucose, the 
global CGM system is projected to reach around $9,000 million by 2027 [309].  
In-vivo measurements are attractive as it provides patients for quick self-assessment. 
Most CGMs currently available in the market employs the glucose-oxidase 
electrochemical sensing principle [310]. It uses a minimally invasive needle sensor which 
is usually inserted under the skin in the abdomen or on the arm. The device measures the 
electrical current generated by the glucose-oxidase reaction, which is proportional to the 
glucose concentration in the interstitial fluid. Some examples of the first commercially 
available CGM products are Medtronic Guardian (Medtronic Minimed, Northridge, CA, 
USA), the Dexcom Seven Plus (Dexcom, San Diego, CA, USA) and the Abbott Navigator 
(Abbott Diabetes Care, Alameda, CA, USA) [304]. Abbott and Dexcom are currently the 
main suppliers of CGMs for diabetes care in the market. The latest product from Abbott 
is a flash glucose monitoring system called the FreeStyle Libre System. The glucose 
sensor in a microneedle can is inserted under the skin which measures the glucose level 
every 5 minutes and stores the readings for up to 8 hours. A hand held device or a 
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smartphone can be used to read the glucose reading and the history of the glucose level 
[311]. The latest CGM from Dexcom is the G6 CGM System. The system can also 
transmit the readings wirelessly to the a smart device or a smartwatch which shows the 
direction of the glucose level is heading [312]. There are some challenges in using 
enzymes-based glucose. Enzymes are relatively expensive and are highly sensitive to its 
surrounding environment [313]. It can be easily denatured when there is a change in 
temperature, humidity and pH values [313,314]. Besides that, the need for the 
immobilisation of enzymes on the electrode surface is often a complicated process 
[315,316]. In order to overcome these limitations, researchers have been focusing on 
using enzyme-free approaches for glucose sensing. For instance, some CGM suppliers 
have employed the optical sensing approach which uses near infrared detection [317,318], 
Raman spectroscopy [319,320], or fluorescent-based sensors. One example of CGM that 
has successfully applied the optical sensing technique is the Senseonics (Senseonics, Inc., 
Germantown, MD, USA) which is a fully implantable CGM system [304]. Zhu et al. 
reported a nonenzymatic wearable sensor for electrochemical analysis of perspiration of 
glucose [314]. Human sweat has been widely used as a sampling medium for most 
wearable chemical sensors. The electrochemical detection method in sweat-base sensors 
are simple, sensitive and consumes low electrical power [321,322]. Hence, sweat or 
perspiration sensing has been focused as it is a promising alternative to invasive or even 
self-monitoring glucose tests [202,323,324]. The electrocatalytic oxidation of glucose 
often requires an alkaline condition, where pH is greater than 11, for acceptable 
selectivity and sensitivity. Multipotential steps including a high negative potential step 
for the pretreatment of the sample which produces a localised alkaline condition on the 
electrode surface, moderate potential for glucose detection under the alkaline condition 
and a positive potential to clean the electrode surface were applied onto the Au electrode. 
Fluorocarbon-based materials were coated onto the electrode for improving the 
selectivity and robustness of sensors [314].  
Some CGM are implanted subcutaneously which detects the glucose level of the human 
body through the fluid in the subcutaneous tissues. This allows the user to monitor 
glucose level under any conditions and determine how different activities carried out can 
affect the glucose level. Therefore, CGM has attracted intense research interest because 
of the need for better diabetes management. There has also been increasing effort to 
improve the accuracy, reliability, usability, size and the lifetime of CGM [304]. Some of 
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the CGM systems can only last for a small period of time and needs frequent changing of 
the sensors. These systems can become expensive and could compromise patients’ 
comfort due to continuous implantation procedures [325]. The continuous improvement 
of CGM is crucial and could revolutionize the treatment of diabetes. There is also a need 
for low-cost devices so that the smart CGM devices can be affordable by the public. These 
devices are not just suitable for diabetic or pre-diabetic patients, but also can be used my 
healthy individuals to monitor their own body conditions. 
1.4.4 Flexible sensors 
The miniaturization of implants, in particular for implants with continuous monitoring 
purposes, has become a hot research topic as it has proven to be beneficial not just for the 
patients, but also for the device performance. A miniaturized implant is more patient 
compliant as it can be implanted in a minimally invasive way. The presence of a 
miniaturized implant will not be noticed by the patient and would not affect the patient 
physically or mentally. In terms of the device performance, micro- to nano-scale sensors 
can provide a better signal-to-noise ratio and only small volumes of samples is required. 
Apart from that, a smaller sensor means the surface-to-volume ratio is increased, which 
could increase the sensing efficiency. Nowadays, there has been reported that biosensors 
can have very low limits of detection, some can even achieve single-molecule detection 
[326].  
However, there is a limit to the miniaturization of implants to ensure the device 
performance and reliability. Apart from that, most surfaces on the human body are not 
flat. The technologies developed for use in healthcare, particularly for implantable 
devices need to conform to convoluted surfaces. Hence, the development of flexible 
electronics has quickly emerged as the best solution to achieve this goal. Flexible 
electronics have shown many advantages such as being conformable, light-weight, 
biocompatible, biomimetic [327,328]. It has been very promising for novel and 
innovative application such as smart labels [329,330], wearable devices [322,331–334], 
smart patches [335], artificial skins [336–338], e-tattoos [339–341], and advanced 
surgical tools [342–344]. Apart from that, the development of flexible sensors has 
received much attention due to the increasing popularity of biosensors for non-invasive 
medical applications. This is because flexible sensors are thinner and flexible, which 
makes them to have higher conformability to uneven surfaces, especially to the human 
body [345]. An example where a flexible sensor has been used is to fabricate an all-
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printed tattoo-based glucose sensor for non-invasive glucose monitoring by Bandodkar 
et al. [346]. This non-invasive glucose monitoring system is worn on the skin. The 
glucose biosensor is functionalised using reverse iontophoretic extraction of interstitial 
glucose and an enzyme-based amperometric biosensor. Another 3D printed flexible 
electrochemical biosensor for glucose detection has been introduced by Nesaei et al. via 
a dual 3D printing method of Prussian modified electrode and glucose oxidase enzyme 
layer [347]. The electrodes were printed onto a temporary tattoo paper and the 
performance of the printed biosensor was compared with the conventional screen-printed 
electrodes. The study showed that the 3D printed electrodes have higher uniformity and 
defect-free surface which has improved the electrochemical sensing ability [348].  
Flexible electronics are made of circuits built on flexible materials such as plastic films, 
which can be rolled up or can conform to any non-planar surfaces. Transistor is one of 
the most common components in electronics and has been the building block of all 
electronics devices. It is also often deposited on top of the flexible films to form flexible 
electronics, often known as flexible thin-film transistors (TFTs). In general, the principle 
of a TFT is similar to a field effect transistor (FET). It consists of two electrodes (source 
and drain) and a semiconductor channel that bridges the source and drain. There is another 
electrode called the gate placed on top of the semiconductor channel which would 
determine the flow of the current through the channel depending on the electric field 
provided by the gate. The ratio of the current and the gate voltage dictates whether the 
transistor will turn on, or off, or amplify a signal. As for biosensors, the same 
configuration is used, but the gate is replaced with a functionalised receptor layer that 
selectively binds to a biomolecule analyte which changes the conductivity of the 
semiconductor. The source/drain voltage will be fixed and the electrical current changes 
according to the amount of analyte detected. Transistor has been used to fabrication 
biosensors due to its high sensitivity, rapid measurement, low power consumption, label-
free detection and compatibility with large-scale integrated circuit [349–353]. Biosensors 
that have high sensing capability, stability and sensitivity to biomolecules are important 
for the early detection of a disease. The first TFT was made of a metal oxide 
semiconductor on a glass substrate [354]. Since then, the interest in fabricating TFTs 
using different metal oxides for biosensing applications has grown rapidly [355–357]. 
Nowadays, TFTs can also be fabricated using organic materials [358–361]. There are also 
studies that have fabricated FET-based biosensors using nanowires (NWs) and carbon 
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nanotubes (CNTs) to detect several biomarkers, including cancer and proteins, in the 
concentration range of nM to fM [362–366]. Such high sensitivity nanoscale FET-based 
biosensor that can achieve fM-level limit-of-detection (LOD) of biomarker concentration 
could enable label-free, single-molecule-level detection of the trace-level amount of 
biomarkers. This would serve as a reliable lab-on-a-chip platform for precisely 
determining the kinetics of various biomolecule interactions. However, the main issue 
with using these one-dimensional nanostructures for the nanofabrication of the highly 
sensitive biosensor is its affordability and high processing costs. This is because high 
quality, small size NWs and CNTs are required and these materials are usually produced 
using the bottom-up synthesis methods (such as Chemical Vapour Deposition). The high 
processing cost makes it not suitable for practical clinical biosensing applications. A more 
affordable alternative for the fabrication of highly sensitive FET biosensor is by using 2D 
materials [367]. 2D materials are generally single layer crystalline materials and they 
exhibit excellent electrical, mechanical and optical properties. They have attracted great 
attention to electronics applications as these materials can be easily modified to achieve 
conducting, semiconducting and insulating properties [368,369].  
1.5 2D Materials 
2D layered materials, such as graphene and Transition Metal Dichalcogenides (TMDs) 
have received great attention due to their intrinsic properties and their great potential to 
be used in a wide range of applications such as nanoelectronics, optoelectronics, energy 
harvesting and storage [370], and most importantly biosensing and biomedical 
applications. Graphene is a type of carbon in which single sheets of carbon atoms are bind 
to each other in a honeycomb lattice [371](Figure 1.13). The unique structure of graphene 
has allowed it to exhibit excellent chemical and electrical properties, which makes it an 
interesting material for use in the development of highly sensitive and selective 
biosensors [372–374]. Interestingly, another category of 2D materials, TMDs, have also 
shown great potential for ultra-sensitive biosensor applications [353,375]. These 
materials are appealing due to their intrinsic electrical properties, excellent physical 
properties, large abundance and compatibility with planar nanofabrication processes 
[376–380]. These materials are also highly sensitive to external stimuli, which makes 
them suitable for the production of highly sensitive FET-based biosensors. FET made of 
2D layers has high quality FET channels with low densities of scattering centers (resulting 
in low Flicker noise level) due to the low density of dangling bonds on the surface. This 
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makes the biosensor to be highly sensitive and low noise level for the detection of 
biomolecules. 
 
Figure 1.13: Schematic illustration of 2D graphene in honeycomb lattice structure 
(Reproduced with permission from ref [371]). 
TMD is a family of 2D materials with a general chemical formula of   MX2. M are the 
transition metals from group VI-VII whereas X is a chalcogen from group VI (S, Se or 
Te) in the periodic table (Figure 1.14). Most TMDs have a layered structure. For layered 
MX2, each X-M-X layer contains three atomic layers. The M atoms layer is sandwiched 
between two X atomic layers with strong covalent M-X bonds (Figure 1.15). These X-
M-X layers are also bonded to each other by weak van der Waals forces [381]. Hence, 
TMDs can be easily thinned down and exfoliated to monolayer or several layers [382]. 
The oxidation states of M and X atoms are +4 and -2 respectively, forming a general 
formula of MX2. The stacking of layered MX2 can exist in two configurations: a trigonal 
prismatic (2H) phase or octahedral (1T) phase ( 
Figure 1.16). Depending on the combination of M and X, one of these two configurations 
will be more thermodynamically stable than the other. For example, 2H-MoS2 is a more 
thermodynamically stable phase whereas 1T-MoS2 is metastable. Although 2H-MoS2 can 
be converted to 1T-MoS2 via the intercalation of sodium or potassium ion [383,384], the 
1T phase will gradually return to the 2H phase at room temperature [385,386]. The 
versatility of TMDs and customizability makes it a promising candidate for the 
fabrication of 2D electronic devices with the potential for large-scale production [387]. 
Due to the layered structure of TMDs, the materials have a bandgap that can be adjusted 
by changing the layer thickness. The existence of a bandgap can contribute to the 
fabrication of a highly-sensitive FET-based biosensor [388]. The single layer or few 
monolayers structure of these materials cause it to have a high surface-to-volume ratio 
which could be used to produce highly sensitive and selective biosensors. Atomically 
layered TMDs also exhibit the potential for next-generation low-cost transistor biosensors 
Chapter 1 
   
56 
 
that allows single-molecule-level quantification of biomolecules. In order to achieve its 
biosensing capability, the device needs to be calibrated for the response to enable 
quantification of biomolecule interaction. 2D TMDs also opens up the opportunity for 
short channel FETs.  
Figure 1.14: Transition Metal Dichalcogenides materials formed of transition metals 
(group 4-7) with elements in Chalcogen group (S,Se,Te) highlighted in a periodic table. 
(Reproduced with permission from ref [376]). 
Figure 1.15: An illustration of a single layer of TMD material (Reproduced with 









Figure 1.16: Schematic representation of coordination of MX2 stacking a) 2H-MX2 
Trigonal Prismatic b) 1T-MX2 Octahedral (Reproduced with permission from reference 
[389]). 
1.5.1 Exfoliation of TMDs layers 
In order to achieve the potential of these 2D materials for the use in flexible electronics 
applications, an exfoliation process is required so that the 2D materials are in their 
monolayer or multilayer forms from their bulk material. Exfoliation can be achieved 
mechanically or chemically [390–392]. Some of the preparation methods currently 
available include mechanical exfoliation with scotch tape [393], chemical exfoliation in 
a liquid phase and coating [394,395], chemical vapour deposition (CVD) [396], and 
hydrothermal synthesis and coating [397]. The scotch tape method was first used to 
exfoliated graphene from bulk graphite [393]. It has also been used on TMDs and there 
are some high performance MoS2 devices using films of a few monolayers of MoS2 
produced by the mechanical exfoliation of MoS2 from bulk MoS2 single crystal using the 
scotch-tape method [379,382]. Although this method can produce high quality monolayer 
materials, it is not practical for large scale fabrications due to its low yield. The other 
limitation of this technique is that it is difficult to control the size and thickness of the 
flakes produced. Chemical approaches such as ion-intercalation can achieve a high yield 
of single-layer materials [398]. This method uses the concept of ion insertion in between 
the layers of 2D materials in order to widen the layer gaps. Generally, lithium ions are 
commonly used for intercalation. During the process, water is introduced to react with 
the intercalated ions, forming hydrogen gas in the layers that forces the layers apart [399]. 
Ion intercalation process can be time consuming and the process is extremely sensitive to 
environmental conditions, which could cause some structural deformation onto the 2D 
materials [400,401]. The removal of ions can cause the reaggregation of layers in the 2D 
materials.  
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The CVD approach is one of the more popular techniques as it has shown promising 
potential for practical applications in producing high quality layered materials [402,403]. 
This method can prepare a continuous layer with controllable uniform thickness directly 
onto a substrate from precursors of the 2D materials [404]. For example, the synthesis of 
MoS2 layers uses MoO3 as a precursor with the presence of sulphur [405,406]. The CVD 
process can eliminate the need for transferring the layered materials which could prevent 
interfacial contamination. Although CVD-grown 2D materials seem promising, they may 
cause some defect that could affect their electrical properties [407]. The process is also 
extremely expensive and has some limitation to scale up for massive production [408]. 
For practical concerns, the preparation of 2D material layers need to be low cost and 
easily scalable for large-scale production.  
Liquid Phase Exfoliation (LPE) is a powerful technique to produce defect-free 2D 
nanosheets in large quantities. Coleman et al. are one of the first to propose the 
effectiveness of LPE for large scale exfoliation for 2D layered materials using organic 
solvents such as (N-methyl-2-pyrrolidone) NMP, (Dimethylformamide) DMF and (Iso-
propanol) IPA [409]. In general, this method uses sonication or shearing of the 2D layered 
materials in selected suitable solvents to separate the layer of materials held together by 
VDW forces [391,409,410]. The presence of suitable ionic liquid in the exfoliation 
process also inserts ionic liquid molecules into the atomic layers, making the 2D materials 
into liquid suspensions [411]. These liquid suspensions can then be used to process into 
different structures such as films, coatings and composites [412–414]. This is a very cost-
effective technique especially when it is required for large-scale production [415]. The 
surface energy of the solvent chosen for LPE plays an important role in determining the 
quality of the dispersion. The solvent must have similar surface energies to the 2D 
material [416]. Studies have proven that ultrasonication of layered materials including 
MoS2 and graphene is an easy and effective way to obtain single and multilayer of these 
materials [391,409,417–419]. However, enhancing the yield of the single layers and 
maintaining the lateral dimensions of the exfoliated nanosheets can be challenging. In 
order to improve the yield, appropriate surfactant or polymeric solutions can be used to 
stabilise the nanosheets and prevent reaggregation [410,416,420]. Ideally, ionic 
surfactants are preferred as stabilisers as they will bind to the exfoliated nanosheets via 
VDW, allowing electrostatic stabilisation. Backes et al. reported a method based on 
iterative centrifugation cascades which could efficiently produce the desired nanosheet 
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size and also provide monolayer enrichment [410]. This method allows the production of 
nanosheets of desired sizes and thickness distribution which is particularly useful as the 
exfoliation of nanosheets can be controlled according to the need of the application. 
1.5.2 Molybdenum (IV) Sulphide (MoS2) 
MoS2 is a semiconductor and has been the most appealing material amongst all TMDs. 
This is mainly due to its unique intrinsic properties such as mechanical flexibility, high 
electron mobility properties and large tuneable bandgaps. MoS2 crystals are vertically 
stacked and the interacting layers are held together by weak van der Waals forces [379].  
The natural lamellar structure of MoS2 with three atom layers (S-Mo-S) stacked together 
allows the thickness of MoS2 layers to have good scalability. MoS2 also exhibit no surface 
dangling bonds and has thermal stability of up to 1100C, which makes it an attractive 
material for use in nanoelectronics applications [353,379]. The absence of dangling bonds 
is attributed to the lone-pair electrons on the sulphide atoms, terminating the surfaces of 
the layers. MoS2 also exhibit high mechanical flexibility (Young’s Modulus 240-270 
GPa) due to their 2D nanosheet structure [421]. This makes it a suitable material to be 
used as a flexible sensor and can be used for the development of wearable and implantable 
biosensor devices. MoS2 has a similar structure to graphene and has attracted great 
attention in the field of nanoelectronics [379]. Another material that is very similar to 
MoS2 is graphene, which is also a very popular 2D layered material that has been used in 
the fabrication of nanoelectronics. However, graphene has no bandgap, which causes 
insufficient current on-off ratio and little voltage gain. This can be a disadvantage as it 
compromised the sensitivity and selectivity when it is being used to fabricate sensors 
[352]. On the other hand, MoS2, in its monolayer, typically has a direct bandgap of 1.8eV. 
Unlike graphene, the presence of bandgap in MoS2 can be used to produce transistors 
with high on/off ratio and intrinsic voltage gain [378,422–424]. Studies have shown that 
MoS2-based transistor can have high on/off current ratios of up to 10
8, which is essential 
to produce a highly sensitive biosensor [379,425]. Moreover, MoS2 has great potential 
for biosensors as the binding event at the interface between MoS2 and the charged 
biomolecules can be monitored by a direct change of the transistor performance metrics 
[426]. As for graphene, the graphene surface needs to be functionalised to achieve high 
sensitivity which introduces additional complexity to the fabrication process [427]. The 
potential of MoS2 is so great that if it can be effectively used to fabricate large area and 
defect-free film, it could revolutionise the flexible electronics industry. MoS2-based 
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transistors fabricated on rigid silicon wafers or glass substrates have shown superior 
electronic properties [428,429]. However, the main challenge remains in the preparation 
of high quality monolayers or several layer MoS2. Currently available methods such as 
mechanical exfoliation and chemical vapour deposition (CVD) are suitable for lab 
settings and seems to be challenging for large scale production.  
The first high mobility single-layer MoS2 channel on SiO2/Si wafers of was reported by 
Perkins et al. The monolayer flakes of MoS2 were exfoliated from bulk samples using the 
scotch tape method and were used to produce a chemical vapour sensor. The results 
showed that the sensor had great selectivity and was unaffected by the presence of many 
other analytes or gases [427]. A highly sensitive glucose biosensor fabricated using a 
bilayer molybdenum disulphide (MoS2) based field-effect-transistors (FETs) was 
introduced by Shan et al. [430]. The study has shown that the biosensor has a sensitivity 
and can detect glucose even at extremely low glucose concentration solution. The MoS2-
based biosensor glucose biosensor also showed short response time (<1s), good stability 
and wide linear detection range (300nM to 30 mM). This study has proven the bilayer 
MoS2-based FET has a great potential to be used for the fabrication of next generation 
biosensor [430]. Sarkar et al. also demonstrated that MoS2 is a suitable material to be 
used as a channel material for a FET biosensor. A highly sensitive MoS2-based pH sensor 
was introduced. The sensor also showed specific protein sensing ability and the sensitivity 
of MoS2-based sensor surpassed the graphene-based sensor by more than 74-fold. The 
study has proven again that MoS2 exhibit excellent electrostatics and sensitivity due to its 
atomically thin nature and presence of bandgap. Its excellent mechanical properties also 
allows easy patternability and scalability [388]. Lee et al. also created a MoS2 biosensor 
that can electrically detect prostate-specific antigen (PSA) [426]. However, unlike to 
biosensor from Sarkar et al., the MoS2-FET-based biosensor has no dielectric layer which 
improves the sensitivity and simplifies the sensor design. This is because the dielectric 
oxide surface layer is hydrophilic which makes the surface functionalization difficult and 
binding event inefficient. On the other hand, the hydrophobic nature of MoS2 makes it an 
excellent candidate for functionalizing antibody and protein. The study has proven the 
potential of fabricating a highly sensitive dielectric-free MoS2-based biosensor [426]. The 
group also demonstrated an improvement in the reliability and the quantitative detection 
of biomolecules in a non-aqueous environment by excluding non-specific binding using 
this MoS2-FET biosensor can provide reliable and quantitative in a further work [431].  
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Yoo et al. have also reported the use of MoS2-FET biosensor for real-time biomolecule 
detection that can be used as a point-of-care diagnostic tool. The study presented an FET-
based biosensor that can allow real-time detection of PSA up to a concentration of 
1pg/mL without specific surface treatment for anti-PSA immobilisation on the MoS2 
surface. The anti-PSA antibody can be physically absorbed to the MoS2 channel without 
pre-surface chemical treatment due to the hydrophobicity of MoS2 surface [432]. Zheng 
et al. also reported a sensitive MoS2-based FET H2O2 sensor but was constructed using 
MoS2/reduced graphene oxide (RGO) interface. Here, MoS2 was used as a catalytic layer 
and RGO was used as the conductive layer [352]. However, the limitation of this method 
is that the nanosheet thickness distribution is broad monolayer content can be low. Wang 
et al. have also demonstrated that ultrasonication of MoS2 can produce MoS2 
nanoparticles which were then used to fabricate a sensitive biosensor that can detect small 
concentrations of H2O2 [419]. The high activity of MoS2 nanoparticle modified electrode 
toward the reduction of H2O2 creates the possibility of fabricating a glucose biosensor. 
Many research work has proven that MoS2 is a promising material and exhibit significant 
potential for the fabrication of next-generation low-cost electronic devices with high 
biosensing capabilities. Despite the promising results, these achievements are mostly 
limited to laboratory level.  
1.5.3 Printing of LPE MoS2 
MoS2 nanosheets produced using the LPE technique can be used as functional inks which 
is suitable to be used in printing [433,434]. Printing techniques can be effective for the 
fabrication of  electronic devices as it has the ability to produce well-defined shapes 
without masking which is often required for traditional screen printing or 
photolithography [435]. For instance, Direct-Ink-Writing (DIW) is an additive 
manufacturing technique that dispenses ink through a nozzle within the range of mm to 
m scale. This method is capable of depositing ink with high levels of spatial control and 
accuracy [436]. Printing of sensors is a promising method particularly for the fabrication 
of flexible sensing devices [437]. This is because the printing of flexible electronics has 
simplified processing steps, the ability to produced organised patterns, and can reduce 
materials waste [327,438]. The flexibility of printing technologies also opens up the 
possibility of developing sensors and electronics on non-planar surfaces. This has led to 
the development of printed electronics on flexible substrates that has been successfully 
used as electronic skin applications and other biomedical applications [439,440]. In 
Chapter 1 
   
62 
 
general, printing technologies can be categorised into two different methods: the contact 
printing and the non-contact printing. The contact printing process is where there is 
contact between the patterned structure of the inked surfaces with the substrate. In non-
contact printing, the ink is dispensed onto the substrate and the pattern structures are 
obtained through the moving substrate holder that is pre-programmed [437]. The non-
contact printing techniques are more popular as the process is more simple and easy to 
control with only a few parameters to adjust, the patterns have higher resolutions, and the 
process is quicker with less material waste [441–444]. 
Kelly et al. have demonstrated the feasibility of inkjet printing thin-film transistors 
(TFTs) using the LPE prepared nanosheets of various 2D materials [445]. The printed 
TFTs are vertically stacked, where graphene was used as source, drain and gate 
electrodes, a channel of TMD and boron nitride were used as a separator. It was shown 
that the nanosheet dispersion sprayed onto flexible alumina-coated polyethylene-
terephthalate substrates form a uniform porous nanosheet network over length scales 
greater than 10 µm. The study also showed that the nanosheets can be thermally activated 
as the electrical conductivity increases as the temperature increases [446]. The on-
currents of the nanosheet network channels depend on the network thickness and 
volumetric capacitance. It was found that the all-printed TFTs can carry high currents and 
relatively low drive voltages [445]. The suitability of LPE prepared MoS2 for inkjet 
printing has also been demonstrated by Li et al. [447]. In this study, MoS2 ink was 
prepared using solvent exchange and polymer stabilisation technique so that the prepared 
ink has the right viscosity for inkjet printing. The prepared multilayer MoS2 nanosheet 
has a thickness of 5-7 nm and can be used to print conformal and uniform patterns with a 
resolution of about 80 µm. The study managed to print MoS2-based TFTs integrated with 
printed silver nanoparticles to enhance the photoluminescence properties of the MoS2. In 
addition, Nam et al. were able to fabricate a highly sensitive transistor-based biosensor 
using few-layer of MoS2 as a sensing channel. The MoS2 transistor was fabricated using 
a microprinting method [448] and the channel thickness was controlled to be 15-20 nm. 
The MoS2 channel was then functionalised by depositing an HfO2 layer using atomic 
layer deposition (ALD). The biosensor was able to measure the concentration of analyte 
solutions and the affinity and kinetic properties of the analyte-receptor pair. The biosensor 
had a tumour necrosis factor – alpha (TNF-) detection limit of as low as 60fM  [326]. 
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1.6 3D Printing of Sensor 
3D printing seems to be a suitable technology to be used in the manufacturing of sensors 
as it is a highly precise technique and is known to be able to produce geometrically 
complex shapes easily. Comparing with the conventional fabrication techniques of 
sensors such as lamination and lithography, 3D printing seems to have the advantage of 
being low cost, less time consuming and fewer processing steps that are complicated. Due 
to these advantages, 3D printing has gained much attention in the fabrication of sensors. 
Researchers have successfully produced different types of sensors, including pressure 
sensors [449–451], biosensors [452–454], and wearable sensors [455–457] using 3D 
printing. There are two types of 3D printing of sensor, 3D printing the structure or 
substrate where sensors can be embedded onto it [458], and printing the entire sensor 
[459]. A study carried out by Emon et al. has developed a custom made 3D printer 
consists of 3 printing nozzle that is capable of fabricating a multimaterial soft pressure 
sensor [460]. This pressure sensor was built of an ionic liquid-based pressure-sensitive 
layer sandwiched between carbon nanotube-based stretchable electrodes and 
encapsulated with stretchable insulating layers printed out of a photopolymer TangoPlus. 
This method of printing the entire sensor without any manual handling could be 
revolutionary and allows design flexibility of the sensors  
The inkjet printing technology is one of the first successful applications for the fabrication 
of sensors via printing methods [461]. Inkjet printing has been successfully used to 
produce a flexible temperature sensor capable of measuring the temperature on the 
surface of the human body [462,463]. The low cost FDM 3D printing technology has 
been used for strain sensor fabrication [464]. Kwok et al. has successfully used FDM 3D 
printing to produce a 3D printed circuit using self-extruded conductive filaments [465]. 
The study showed that there is a potential for low-cost 3D printing to produce sensors. A 
study by Adams et al. showed the first attempt of 3D printing a graphene-based glucose 
sensor using a low-cost FDM 3D printer [454]. This is a proof-of-concept study that 
successfully showed that the 3D printed sensor was able to detect physiological glucose 
concentrations between 0 and 400 mg/dL. The study has shown that 3D printed glucose 
sensor is a promising alternative to self-monitoring blood glucose devices. Gowers et al. 
also used 3D printing technologies to produce a microfluidic platform that can be 
integrated with biosensors that can measure real-time glucose and lactate levels 
subcutaneously [466]. The microfluidic chip and the needle holders which is integrated 
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into the microfluidic platform were printed using two different 3D printers. The needle 
biosensors are removable and can be joined to a clinical microdialysis probe for 
continuous monitoring. The novel 3D printed microfluidic device is modular, which 
means the biosensors can be changed easily, making it suitable for a wide range of 
clinical, as well as fitness applications.  
Other 3D printing methods such as stereolithography has been successfully used for the 
printing of fluidic devices for various types of analysis [467–471]. A stereolithography 
based 3D printing technique was used to produce a plastic closed-channel fluidic device 
as part of a biosensor that can carry out electrochemiluminescence (ECL) measurements 
using DNA-coated graphite electrodes [472]. ECL typically has excellent sensitivity and 
specificity as the electrogenerated optical signal eliminate the background signals. The 
results showed that a relatively low concentration of co-reactant DNA can still be detected 
through ECL measurements. The 3D printed fluidic device is low-cost, customisable and 
allows quick modifications and revisions to be carried out to adapt other electrochemical 
sensing abilities. Another study by Li et al. used a multimaterial FDM 3D printer that is 
capable of printing up to 5 different materials to fabricate a fluidic device for the 
measuring of pharmaceuticals in biological fluids [473]. Such devices can be used as Lab-
on-Chip applications which have now attracted much attention due to their simplicity, 
portability and cost-effectiveness [468,474]. The whole fluidic device was printed using 
4 different materials and can be produced in a single uninterrupted 3D printing process. 
The device was capable to simultaneously extract and concentrate small molecule 
pharmaceuticals from urine samples. Electrophoretic separation can also be carried out 
on the sample on the concentrated targets for quantitative analysis. It was reported that 
this 3D printed fluidic device allowed the direct quantification of ampicillin in untreated 
urine sample within 3 min. 
Direct-ink-writing (DIW), which is similar to FDM has also been used to fabricate strain 
sensors [475,476]. Apart from that, a study to prove the concept of manufacturing a 
flexible electrochemical biosensor for glucose monitoring using the DIW printing method 
was carried out [347]. The study uses a custom-built DIW printer where the printing 
nozzle has a diameter of 200 µm. The printing head is connected to a positive pressure 
pump for ink dispensing. Prussian blue modified electrode was first printed onto a tattoo 
paper, then dried at 100 °C under vacuum condition before the printing of the glucose 
oxidase enzyme was carried out on top of the dried carbon electrode. The performance of 
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the electrode is compared with the conventional screen-printed electrodes for its glucose-
sensing capabilities. The study showed that the 3D printed electrodes were more uniform 
and have smoother surfaces, hence improving its sensitivity for glucose sensing. The 3D 
printed glucose biosensor was able to detect micro-molar levels of glucose with the 
presence of other interfering molecules. Conventional screen printing is more time-
consuming and material wastage as compared to DIW. Apart from that, the sensors 
produced by DIW also have better reproducibility, repeatability and long-term stability.   
Dirkzwager et al. demonstrated the possibility of 3D printing an aptamer-based point-of-
care diagnostic (POC) device which could potentially be used for the diagnosis of malaria 
[477]. This is a proof-of-concept study that was carried out to offer an alternative to the 
conventional malaria diagnosis using light microscopy which can only be used in a lab 
setting. The development of such POC devices have the advantages of being portable, 
simple to interpret, and require limited expertise. 3D printing was used to produce a 
paper-based syringe test and magnetic bead-based well test. The syringe test was more 
sensitive, but more preparation steps were required to prepare the sample, whole blood, 
before the testing was carried out. On the other hand, whole blood can be tested directly 
using the well test without any preparation steps prior to testing, which seems to be more 
suitable and convenient as a POC diagnostic device. These devices were designed with a 
simple colorimetric assay in which the results can be interpreted easily by visual analysis. 
The study has proven that such diagnostic devices are very cost-effective due to their 
simplicity and stability for storage of up to 2 months at room temperature.   
 
1.7 Outline of the thesis 
This thesis contains the research work that has been designed and carried out to fulfil the 
aims and objectives that will be discussed further in chapter 2. The research findings and 
results are discussed in detail in the following chapters and the content of the thesis can 
be summarized as follow: 
Chapter 1 provided an in-depth review on the technologies that are being used to carry 
out the research and a few other research topics regarding sensors for biomedical 
applications. The two main technologies being reviewed are the Fused Deposition 
Modelling (FDM) 3D printing and the hot-melt extrusion technology. The review on how 
these two technologies can be combined to help promote the applicability of FDM 3D 
Chapter 1 
   
66 
 
printing for pharmaceutical and biomedical applications was also carried out. Different 
biomedical sensors, the materials used for the sensors and the fabrication techniques of 
the sensors were also covered in this review.  
Chapter 2 discussed the aim and objectives of the research.  
Chapter 3 showed an investigation on the miscibility of a biocompatible polymer, 
polylactic acid (PLA), with a widely used pharmaceutical plasticiser, polyethylene glycol 
(PEG), to produce a biocompatible and biodegradable polymeric matrix that can be 
suitable for a wide range of biomedical applications. The study focused on the effect of 
different PEG grades when mixed with PLA to form PEG/PLA blends.  
Chapter 4 showed a preparation study for producing 3D printable biocompatible filaments 
made of PEG/PLA blends using a single-screw filament extruder.  
Chapter 5 extended the investigation of the PEG/PLA filaments with enhanced physico-
chemical properties by using a twin-screw extruder.  
Chapter 6 aimed to develop and optimise a polymeric composition that can be made into 
filaments in which the filaments can be loaded with a drug and used for the FDM 3D 
printing of a drug delivery device.   
Chapter 7 showed a study of loading metformin as an active ingredient in some polymeric 
blends extrudable into 3D printable filaments with the aim to produce sustain-release 
metformin containing medical device/implant.   
Chapter 8 showed two different simple techniques that can be used to fabricate flexible 
temperature sensors which can be used for biomedical applications.  
Chapter 9 investigated a simple preparation method of Molybdenum (IV) Sulphide 
(MoS2) solution which was then used as one of the materials for the fabrication of a 
flexible glucose biosensor. 
Chapter 10 contained a conclusion and a short summary of the research findings. 





Chapter 2 : Research aim and objectives 
2.1 Aim and objectives 
Three-dimensional (3D) printing, also known as additive manufacturing, has appeared as 
an emerging manufacturing technology across various industries. Unlike conventional 
fabrication methods such as injection moulding or Computer Numerical Control (CNC) 
machining, 3D printing can easily produce complex-shaped objects. Hence, the 
technology allows much more flexibility and freedom in designing an object. The most 
easily accessible 3D printers are the desktop 3D printers that use the Fused Deposition 
Modelling (FDM) printing technology. This type of 3D printers and the printing materials 
are low-cost and very affordable. Due to the affordability of this technology, it has gained 
much popularity across many industries. However, the use of the FDM 3D printing 
technique is somehow limited mostly to prototyping product. This is because the printing 
technique uses thermoplastic polymers as the feedstock material and most plastics do not 
exhibit excellent mechanical properties. Apart from that, most polymers used for FDM 
3D printing are not biocompatible and biodegradable, which makes it to have limited 
applications in biomedical and pharmaceutical applications.  
In recent years, much research has been carried out on developing biocompatible 
filaments in order to promote the usage of FDM 3D printing for biomedical and 
pharmaceutical applications. This is because there has been an increasing interest in 
personalised and patient-specific products in the biomedical industry. Personalisation in 
the biomedical application has been a much discussed topic as it can improve treatment 
efficacy, help reduce any treatment-related side-effects, and most importantly lead to a 
better quality of life. However, the production of personalised devices using traditional 
manufacturing method can be expensive and disruptive as most traditional manufacturing 
methods are designed for mass production. Hence, 3D printing has attracted much 
attention as its additive manufacturing technique is more suitable and cost-effective for 
producing customised devices.  
In addition to personalised medical devices, smart medical devices have become 
increasingly popular as well. Smart medical devices play an important role in healthcare 
monitoring and diagnostics as they are designed to continuously monitor and measure the 
vital signs of our human body. For example, various minimally invasive continuous 





level monitoring more patient-friendly as diabetes patients do not have to regularly 
measure their own blood sugar level by pricking their own fingers using the finger stick 
blood test. The continuous glucose monitoring system also shows the trend of the glucose 
level in the patients, which could provide warning signs of hypo and hyperglycaemic 
events to the patients [478]. There are many other examples of smart medical devices. 
Nevertheless, the function of these smart devices depends heavily on reliable sensors. 
Sensors that are used for biomedical applications can be called biosensors. There have 
been much interest on developing reliable biosensors using simple fabrication techniques 
in order to reduce the cost of biosensors [479–482]. Reducing the cost of biosensors can 
improve the affordability of such technologies so that more people can enjoy the benefit 
of improved healthcare.  
2.1.1 Aim 
The research aim is to utilise the potential of 3D printing technology as a simple and cost-
effective method to fabricate pharmaceutics and biomedical devices. The FDM 3D 
printing technique will be the focus as is the most affordable and widely available 3D 
printing technology. Apart from that, the fabrication of reliable biosensors using simple 
manufacturing techniques such as 3D printing and thin-film deposition is also 
investigated.  
2.1.2 Objectives 
As most of the widely available thermoplastic filaments used in FDM 3D printing are not 
biocompatible, the filaments cannot be used for pharmaceutical and biomedical 
applications. One of the objectives is to produce biocompatible filaments with enhanced 
physico-chemical properties so that the filaments can be used for a wide range of 
biomedical applications. The fabrication of filaments can be easily achieved in-house 
using a benchtop hot-melt extruder.  
Apart from that, most thermoplastic filaments require a relatively high temperature for it 
to melt or soften during the 3D printing process. The high heat exposure to the materials 
may not always be desirable especially for pharmaceutical applications. This is because 
most active pharmaceutical ingredients and excipients are thermally sensitive. Prolonged 
exposure to high temperature may cause degradation. Hence, the study to produce 





investigating the effect of a plasticiser on a biocompatible polymer that has been widely 
used to produce 3D printable filaments.  
The research also involved an investigation to fabricate customisable drug-loaded 
filaments for the 3D printing of pharmaceutics. The drug can exhibit different release 
patterns when being loaded onto different polymeric compositions. The ability to produce 
customisable filaments with a desired drug release profile using simple technologies such 
as the hot-melt extrusion and FDM 3D printing can promote the use of personalised 
treatments even in local hospitals situated in remote areas.  
The possibility of using 3D printing to fabricate other biomedical diagnostic devices such 
as temperature sensors was also investigated. 3D printing and thin-film fabrication 
technique were used to produce flexible temperature sensors than can be used for 
biomedical applications. The flexible temperature sensors are modular and can be 
transferred and integrated with other biomedical or drug delivery devices for better 
treatment efficacy. 
A novel and simple technique for fabricating a thin-film and flexible glucose biosensor 
was also investigated. The use of a novel 2D material, Molybdenum (IV) Sulphide, that 
exhibit intrinsic electrical properties was evaluated by using it to fabricate a conducting 
thin-film for glucose biosensing. The conducting thin-film was immobilised with glucose 
oxidase enzyme to perform glucose oxidation for glucose sensing purposes. Similarly, 
the thin-film glucose biosensor is modular and can be integrated with a drug delivery 
system to produce a smart medical device.   
In general, the major objectives and deliverables of the research work in this thesis can 
be summarised as follows: 
• Investigate the plasticising effects of different polyethylene glycol (PEG) grades 
on a biocompatible polylactic acid (PLA) polymer. 
• Evaluate the fabrication of PEG/PLA biocompatible polymeric mixture into 3D 
printable filaments using a single-screw filament extruder. 
• Evaluate the effectiveness of producing PEG/PLA mixture into filaments using 





• Develop and optimise polymeric compositions to achieve different release 
patterns for an API, theophylline. The drug-loaded polymeric mixtures were made 
into 3D printable filaments using the twin-screw extrusion technique to achieve 
better mixing efficiency. The drug-loaded filaments were then used to produce 3D 
printed tablets for the investigation on drug release. The study also investigates 
the effectiveness and feasibility of coupling the hot-melt extrusion (HME) 
technique with FDM 3D printing as a continuous manufacturing process.  
• Develop sustained-release metformin systems via twin-screw extrusion and 3D 
printing by utilising the optimised compositions for theophylline. Another 
polymeric composition that is capable of 3D printing at a much lower temperature 
and still exhibits sustained-release pattern was investigated.  
• Develop flexible temperature sensors for biomedical applications via FDM 3D 
printing and thin-film fabrication technique which is widely used for the 
production of microelectronics. The 3D printed temperature sensors were printed 
using conductive PLA filaments, one contains carbon black and the other contains 
graphene. The temperature sensors produced suing the thin-film fabrication 
technique is made of a thin layer of gold on a flexible polyimide film. The 
performances of the different temperature sensors were evaluated.  
• A flexible glucose biosensor was developed using a similar thin-film fabrication 
technique for the temperature sensor. The conductive electrode of the glucose 
biosensor consists of gold and MoS2. The glucose biosensor surface was 
functionalised with glucose oxidase enzyme, which would create electrons during 






Chapter 3 : Investigation on the miscibility of polylactic acid 
and polyethylene glycols 
3.1 Introduction 
Plastics are now very common materials that are used in daily lives and they are made up 
of long-chain of molecules called polymers. Polymers are a large chain of molecules 
made of repeating smaller units called monomers [483]. The monomers are bonded 
together to form polymers via a process called polymerisation [484]. Bioplastics have 
been a great area of interest for research due to environmental concerns [485,486]. They 
are usually produced from renewable sources such as derivatives from plants or 
microorganisms and are degradable by nature over a reasonable period of time [485,487–
490]. Bioplastics not only are better for the environment, but they are also suitable 
candidates to be used for the production of biomedical and pharmaceutical products [491–
494]. For the bioplastics to be used for biomedical and pharmaceutical applications, they 
need to be biocompatible with the human body. Biocompatibility means materials that 
are acceptable to the human body and are not harmful nor toxic when being used in the 
human body [495,496].  
Polylactic acid (PLA) is one of the most commonly available biopolymers that is typically 
made from plants such as corn starch, dextrose or other biomass [497,498]. There are 
many different methods of producing biocompatible PLA [499]. One of the more 
commonly materials used are corn kernels, which are milled to extract dextrose, and then 
further fermented to obtain lactic acid [500]. Typically, lactic acids are not directly 
polymerised into PLA as water will be produced. The water molecules can prevent the 
growing chain of lactic acid molecules from staying together. Therefore, smaller chains 
of polylactic acids are first formed, called polylactic acid oligomers, from the lactic acid 
monomers. The water produced from this processing step can be removed before the 
polymerisation reaction is carried out to produce PLA. The final long-chain PLA is 
produced via ring-opening polymerisation. Lactide is an intermediate product for the 
production of PLA, which is the ring-firmed dimer of lactic acid [501]. The process of 






Figure 3.1: Process of producing polylactic acid (PLA) from lactic acid monomer (n is a 
large number). 
PLA is classified as ‘not dangerous’ according to the European Directive 67/548/EEC. It 
is also being listed in the United State Food and Drug Administration (FDA) inactive 
ingredients for approved drug products database as well as being classified as generally 
recognised as safe (GRAS) material by the FDA [502,503]. PLA is a biodegradable 
thermoplastic polymer. It can be easily found as a material to produce carrier bags [504], 
food packaging [505], plastic containers [506], and textiles [507].  Apart from that, it has 
also received much attention from the medical industry to produce wound dressings 
[508], sutures [509], stents [510], scaffolds for tissue engineering [511], bone and dental 
fixations [512,513], as well as drug delivery systems [514]. PLA has been used in 
pharmaceutical applications as coating agents and controlled-release agents [515–517]. It 
has successfully been used to produce implants, injections and other drug delivery 
systems [518–521]. However, the applications in PLA for implants are often limited due 
to its poor mechanical properties. For instance, pure PLA is brittle in nature, exhibit poor 
flexibility and strength [522,523]. Therefore, additives were often used to produce a 





Plasticisers are one of the most commonly used additives in the polymer industry to 
improve the flexibility and processibility of polymers [525]. According to the council of 
International Union of Pure and Applied Chemistry (IUPAC), plasticiser can be defined 
as a substance or material incorporated in a material to increase its flexibility, workability, 
or distensibility [524]. The purpose of a plasticiser can help reduce the hardness, increase 
the chain flexibility, processability, resistance to fracture and dielectric constant of a 
polymer [526,527]. The addition of plasticisers can also lower the glass transition 
temperature (Tg) of the polymer as it acts as spacers between the molecules so that less 
energy is required for the molecules to rotate and move around [522]. Plasticisers are also 
commonly used in pharmaceutical applications as one of the ingredients in the 
composition of solid oral dosage forms. Biocompatible plasticisers are often preferred 
when designing polymeric compositions for use in pharmaceutical applications. Some of 
the most commonly used biocompatible plasticisers include polyethylene glycol (PEG), 
ethyl cellulose (EC), triethyl citrate (TEC), acetyl triethyl citrate (ATC) and glycerol 
[523,524,528–530]. In this study, the effect of PEG as a plasticiser on PLA was 
investigated.  
PEG has a general formula of H(OCH2CH2OH)nOH and the chemical formula is depicted 
in Figure 3.2. PEG polymers are formed via the ring-opening polymerisation reaction of 
ethylene oxide and water under pressure in the presence of a catalyst [531,532]. Similar 
to PLA, it is also listed in the FDA inactive ingredients for approved drug products 
database. PEG can exist in different molecular weights, ranging from 200 to 20000 
g/mole [533]. Depending on the molecular weight, PEG can exist in liquid or solid. 
Typically, low molecular weight PEG exists in liquid form at room temperature, whereas 
higher molecular weight PEG is in solid form at room temperature. The different 
molecular weight of PEG exhibit different functionalities. Bolourchian et al. carried out 
a study to investigate the effect of different molecular weights PEG as a drug carrier in a 
solid dispersion system on the dissolution behaviour. The study reported that PEG with 






Figure 3.2: Chemical formula for Polyethylene glycol (PEG), m represents the average 
number of oxyethylene group. 
PEG is commonly found in pharmaceutical products as an ointment base, plasticiser, 
suppository base, tablet and capsule lubricants [535–538]. PEG is hydrophilic in nature 
and can be used to enhance aqueous solubility or dissolution characteristics of poorly 
soluble compounds [534]. Higher molecular weight PEG is known to be more effective 
as tablet binders and it can better impart plasticity to the blend [539,540].  
It is a well-known issue that PLA has some poor mechanical properties such as brittleness, 
and blending PLA with plasticisers is cost-effective to improve its flexibility [541]. 
Improving its mechanical properties can improve the usability of PLA particularly for 
biomedical applications. PEG is generally regarded as non-toxic and non-irritant, hence 
it is suitable to be mixed with PLA to form a biocompatible polymer blend [531,542]. 
Some studies have shown that PEG is an effective plasticiser for PLA [543–545]. Other 
reports showed that incorporating PEG into PLA can lower the Tg of PLA [545–547]. 
This study aims to investigate the effect of different molecular weight PEGs on the 
properties of PLA. The PEG/PLA blend was produced using a low-cost solvent casting 
method. The PEG/PLA blends were produced in the form of films and the chemical, 
thermal and degradation properties of the PEG/PLA films were being studied.  
3.2 Materials 
Polylactic acid (PLA) pellets (IngeoTM Biopolymer 2002D grade) were purchased from 
NatureWorks (Minnetonka, US). Different grades of Polyethylene glycol (PEG) used 
were purchased from Fisher Scientific (Loughborough, UK). The different PEG grades 
used were 200, 400, 600, 1000, 6000, 8000, 10000. Analytical grade dichloromethane 






3.3 Experimental Methods 
3.3.1 Preparation of PEG/PLA Films  
The PEG/PLA films were prepared using the solvent casting method. PLA was mixed 
with different grades of PEG and the formulation for each PEG/PLA films were shown 
in Table 3.1. The higher the PEG grade, the higher the molecular weight of the PEG. PLA 
pellets were first dissolved in dichloromethane at a concentration of 10% w/v. The PLA 
was dissolved using a magnetic stirrer at around 800 rpm until a clear solution was 
obtained. PEG was then mixed into the clear PLA solution until fully dissolved. The 
concentration of PEG in PLA for all blends were 20% w/w. The PEG/PLA solution was 
then cast onto glass petri dishes and allowed to dry. The films were then dried in the oven 
at 45°C for 24 hours to ensure the full evaporation of dichloromethane.  









P1 200 Liquid 20/80 
P2 400 Liquid 20/80 
P3 600 Semi-solid 20/80 
P4 1000 Solid 20/80 
P5 6000 Solid 20/80 
P6 8000 Solid 20/80 
P7 10000 Solid 20/80 
3.3.2 Characterisation of PEG/PLA blends 
3.3.2.1 Differential Scanning Calorimetry (DSC) 
A DSC 4000 system (Perkin Elmer, Waltham, MA, US) was used to study the glass 
transition temperature and the melting temperature of the PEG/PLA films. The samples 
used were about 5mg. The samples were placed in an aluminium pan, and an empty 
aluminium pan was used as a reference. The chamber was heated from 30 C to 200 C 
at a rate of 10 C/min. Nitrogen gas was used as the purged gas at a flow rate of 20 
mL/min in all the DSC experiments. The data were collected and analysed with Pyris 
software (Perkin Elmer).  
3.3.2.2 Thermogravimetric Analysis (TGA) 
The thermal stability of PEG/PLA blends was analysed using TGA. The analysis was 
carried out using Q40 Thermogravimetric analyser (TA Instruments, New Castle, DE, 
US). The samples were weighed to be about 10 mg and were placed in an open aluminium 





was used as a purge gas at a flow rate of 20 mL/min. The results were collected and 
analysed using the Advantage/Universal Analysis Software (TA Instruments) 
3.3.2.3 Chemical structure characterisation  
Fourier Transform Infra-Red (FTIR) analysis was carried out to study the interaction of 
the intermolecular chains between PEG and PLA. The FTIR analysis was performed 
using a Spectrum Two FT-IR Spectrometer (PerkinElmer, Waltham, MA, USA). The 
spectra were collected using 16 scans between wavenumber 4000-500 cm-1 with a 
resolution of 4.0 cm-1. The results were analysed using the PerkinElmer SpectrumTM 10 
software and were displayed as a percentage of transmission. 
3.3.2.4 X-ray Diffraction (XRD) 
XRD was carried out on the PEG/PLA and pure PLA solvent cast films. The samples 
were first ground into smaller particles and were assessed using a Siemens D500 X-ray 
Diffractometer (Siemens, Germany). The samples were scanned between 2 Theta(θ) =5° 
to 50° using 0.01° step width and 1s time count. The divergence slit was 1mm and the 
scatter slit was 0.6mm. The X-ray wavelength was 0.154 nm in Cu source and at a voltage 
of 40 kV. 
3.4 Results and Discussion 
The PLA pellets used are yellowish-white opaque pellets which have a very high hardness 
and cannot be mechanically ground. It is insoluble in water, but is soluble in organic 
solvents such as dichloromethane, ethyl acetate, chloroform, and acetone. Since the 
pellets cannot be easily ground into fine powders, the most cost-effective way of mixing 
PLA with PEG is by first dissolving PLA in dichloromethane. The different PEG grades 
were then further mixed with the PLA solution. Examples of a dried PEG/PLA film 
obtained was shown in Figure 3.3. The films are white in colour and completely opaque 






Figure 3.3: An example of dried PEG/PLA film produced from solvent casting. 
3.4.1 Differential Scanning Calorimetry (DSC) 
 
Figure 3.4: DSC thermograms for different PEG/PLA films. 
Table 3.2: Glass transition temperature (Tg), melting temperature (Tm) and heat 
enthalpy value (∆H) extracted from the DSC curves in Figure 3.4 for different 
PEG/PLA films. 
Samples Tg (°C) Tm (°C) Heat enthalpy value (∆𝑯) for Tm (J/g) 
Pure PLA 73.66 175.78 47.6 
P1 - 160.19 70.5 
P2 - 166.43 73.0 
P3 - 166.42 61.7 
P4 - 169.29 72.0 
P5 61.53 172.01 98.4 
P6 61.03 170.94 50.7 
P7 60.90 169.49 38.9 
Figure 3.4 shows the DSC results for all the PEG/PLA blends and pure PLA. Pure PLA 









































formulations P1-P4 showed only one endothermic peak. The first smaller endothermic 
peak showed in pure PLA and P5-P7 happened at a lower temperature of between 60-70 
°C represents the glass transition temperature (Tg) of the samples. The second or larger 
endothermic peak that occurred at a higher temperature and was present for all samples 
represents the melting temperature (Tm) of the samples. The results showed that all 
PEG/PLA blends have Tg and Tm lower than the pure PLA film. This is due to the 
plasticising effect of PEG. PEG as a plasticiser occupies the intermolecular spaces 
between the PLA polymer chains, which could change the orientation of the molecules in 
the polymer blend. The decrease in Tg and Tm is caused by the increase in mobility within 
the polymer chains, causing the polymer to be in a more amorphous state. This is because 
less energy is required for the molecules in the blend to move around and to transition 
from one stage to another. Therefore, the molecules of PEG/PLA blends can change state 
at lower temperatures when compared to pure PLA as the molecular mobility is higher in 
the PEG/PLA blends than pure PLA. The lower Tg and Tm of the PEG/PLA blends 
showed the effectives of PEG as a plasticiser. Such compositions with lower Tm can be 
beneficial when thermal processes were employed as they can be processed at lower 
temperatures. This is particularly useful for processing polymers for use in 
pharmaceutical and biomedical applications as lower processing temperature can prevent 
the thermal degradation of materials. The benefit of PEG as a plasticiser in 3D printable 
filament compositions will be further investigated.  
However, the PEG/PLA blends that contain lower molecular weight PEG have lower Tm. 
As the molecular weight of PEG increases in the blend, the Tm increases. This shows the 
plasticising effect of lower molecular weight PEG is higher. The decrease in plasticising 
effect in the blends with higher molecular weight PEG could be caused by the decrease 
in solubility of the higher molecular weight PEG in PLA. This is because lower molecular 
weight PEG has lower Tg and Tm, causing them to exist in liquid form at room 
temperature. Formulations P1-P4 do not exhibit a Tg from the DSC results. This could be 
because the Tg of the material is much lower than the start temperature of the test (30 °C). 






Figure 3.5: DSC thermograms for different grades of PEG. 
Table 3.3: Melting temperature and heat enthalpy value for different grades of PEG. 
Samples Tm (°C) Heat enthalpy value (∆𝑯) for Tm (J/g) 
PEG 200 - - 
PEG 400 - - 
PEG 600 26.2 920.2 
PEG 1000 45.1 617.3 
PEG 6000 65.4 252.7 
PEG 8000 69.4 488.2 
PEG 10000 67.2 361.7 
DSC was carried out for the different PEG grades being used as a plasticiser for different 
PEG/PLA blend. The DSC curves obtained were shown in Figure 3.5 and the extracted 
values of Tm for each PEG grade were shown in Table 3.3. PEG 200 and PEG 400 did 
not show a melting endothermic peak. This could be the actual melting point of these 
lower molecular weight PEGs that are out of the operating temperature range on the DSC. 
PEG 200 and 400 exist as colourless viscous liquid at room temperature. It was reported 
that the melting/softening point of PEG 200 and PEG 400 could be around the range of -
65 °C to -50 °C and -6 °C to 8 °C respectively [548]. As the molecular weight of the PEG 
increases, the melting temperature increase. The measured melting temperature of PEG 
600 was around 26.2 °C. Hence, PEG 600 seems to be at a semi-solid paste at room 
temperature (~20 °C). PEGs above 1000 are all white solid flakes at room temperature 
and their melting temperature are above 45 °C. The DSC results of the different PEG 








































3.4.2 Thermogravimetric Analysis (TGA) 
 
Figure 3.6: TGA profiles for different PEG/PLA films. 
Table 3.4: Temperature at three different degradation points extracted from TGA 
profiles for all PEG/PLA films. 
Temperature at 
weight % 
t90 (°C) t50 (°C) t10 (°C) 
P1 218.79 296.23 327.89 
P2 265.55 304.87 355.13 
P3 272.75 312.25 363.67 
P4 270.71 320.85 354.44 
P5 310.19 340.94 364.34 
P6 301.2 336.6 365.81 
P7 282.5 313.31 368.94 
Pure PLA 340.43 358.09 367.89 
The thermal degradation profiles of the different PEG/PLA blends and pure PLA were 
measured using TGA and the obtained profiles were shown in Figure 3.6. Three different 
degradation points were extracted from the TGA profiles and the temperatures were 
shown in Table 3.4. The three degradation points were the temperature when 10% of the 
sample had degraded (t90), 50% of the sample had degraded (t50), and 90% of the sample 
had degraded (t10). The degradation study shows that pure PLA has the highest resistance 
to thermal degradation since 340.4 °C is required to degrade 10% of the sample. The 
PEG/PLA film with lower molecular weight PEG seems to have a lower degradation 
temperature. This is because low molecular weight PEG has smaller polymeric chains 
which require less heat energy to break. One interesting observation from the TGA results 
is that the PEG/PLA films containing higher molecular weight PEG exhibit a second 





























profile such as the ones for P1-P4 and pure PLA. P5, P6, P7 showed another step 
degradation at around 364 °C,357 °C, 327 °C respectively.  The higher second 
degradation temperature in these blends could be caused by the longer polymeric chain 
of PEG which in turn act as a barrier protective layer on the surface of the polymer matrix. 
The protective layer could delay and slow the degradation process as the plasticiser can 
increase the permeability of the volatile compound during the degradation process 
[549,550]. However, all PEG/PLA blends showed good thermal stability and could be 
thermally processed up to 200 °C before experiencing any degradation.  This information 
is important as the PEG/PLA blends will be used for thermal processing as described in 
the latter chapters.  
3.4.3 Fourier Transform Infrared (FTIR) 
 
Figure 3.7: FTIR spectra for different PEG/PLA films. 
 
Table 3.5: Characteristic peaks/wavenumber of different PEG/PLA films. 
Formulation Wavenumber (cm-1) Vibration 


































































































FTIR was carried out to analyse the chemical interaction of PEG with PLA for every 
PEG/PLA solvent cast films. The FTIR spectra of all the PEG/PLA films and pure PLA 
were shown in Figure 3.7. The characteristic absorption peaks for each formulation were 
extracted from the spectra and shown in Table 3.5. The FTIR spectra contained all typical 
absorption features of a semicrystalline PLA. The characteristics peaks for C-O and C=O 
of pure PLA were found at wavenumber 1081 cm-1 and 1747 cm-1 respectively, whereas 
the absorption at wavenumbers at 2997 cm-1 and 2946 cm-1 corresponds to the band 
absorption of asymmetric and symmetric stretching of C-H in pure PLA respectively. In 
the PEG/PLA films, the presence of PEG was reflected as the presence of a broader peak 
that corresponds to the -OH stretching in the FTIR spectra. The broader peak occurred at 
around a wavenumber of 3500 cm-1 for all the PEG/PLA films, which was a confirmation 
of the chemical interaction between the PEG and PLA [544,551]. This also showed that 
PEG is compatible with PLA and the interaction between these two polymers could be in 
the form of hydrogen bonding. The hydrogen bonding between PLA and PEG occurs 
between the oxygen on the carbonyl group (C=O) of PLA and the hydroxyl end group (-
OH) in the PEG chain, and the interaction is depicted in Figure 3.8. The smaller peak was 
seen for P6 and P7 where the blends contain higher molecular weight PEG. The smaller 





caused by a reduction in solubility of higher molecular weight PEG in the PLA matrix 
[546]. The results were consistent with the DSC analysis that showed lower molecular 
weight PEG was more effective in depressing the melting temperature of PLA.  
 
Figure 3.8: Illustration of hydrogen bonding interaction between PLA and PEG 
molecules. 
3.4.4 X-Ray Diffraction (XRD) 
 
Figure 3.9: XRD spectra for all PEG/PLA films. 
XRD was used to study the crystallinity of the PEG/PLA films. It has been reported that 
the introduction of PEG can improve the crystallinity behaviour of the PLA polymer 
matrix [551]. The XRD spectra for all PEG/PLA and pure PLA films were shown in 
Figure 3.9. Pure PLA showed very weak intensity for crystallinity, indicating that pure 
PLA is almost amorphous. This corresponds to the semicrystalline nature of PLA. All 
PEG/PLA blends showed strong crystallinity peaks as compared to pure PLA. PEG is a 

































blends reflects the plasticising effect of PEG on PLA, causing the PLA to be more 
crystallised. However, it was shown that increasing PEG molecular weight causes a 
reduction in the crystallisation ability of PLA/PEG blend. This may be due to the smaller 
PEG molecules at lower molecular weight, allowing the PEG molecules to be easier to 
insert into PLA molecules thus introducing a better plasticising effect. This finding is 
consistent with the DSC results, where lower molecular weight PEG seemed to have more 
effectively depressed the melting point of PLA.   
3.5 Conclusion 
PLA is a very popular biocompatible polymer that has been extensively used in the food 
and industrial packaging industry. It has also received much attention to be used in the 
biomedical field due to its excellent biocompatibility, biodegradability, and non-toxic 
degradation products. However, its application in the biomedical industry is somewhat 
limited due to poor mechanical properties, degradation rate and hydrophobicity. To 
overcome these drawbacks of PLA, blending it with plasticisers such as PEG is a simple, 
practical and efficient way. PEG also exhibit excellent biocompatibility and 
hydrophilicity. Hence, it is a preferred plasticiser to be blended with PLA to preserve its 
biocompatibility. A simple solvent casting method was used in this study to prepare 
different PEG/PLA blends with different PEG grades for characterisation.  
It was found that lower molecular weight PEG seemed to have better plasticising 
efficiency to PLA. The PEG/PLA blends with lower molecular weight PEG showed lower 
melting temperature, lower degradation temperature, stronger -OH vibration and higher 
crystallinity. This is because lower molecular weight PEGs have a smaller molecular 
chain which could be easier to interact within the intermolecular space of PLA. 
Nevertheless, the studies confirmed that PEG has very good miscibility with PLA as the 
terminal hydroxy group in PEG can interact with the carboxyl groups in PLA molecules 
to form a hydrogen bond. The presence of PEG can reduce the intermolecular force and 






Chapter 4 : Preliminary study on preparing biocompatible 
PEG/PLA filaments using a single-screw filament extruder 
4.1 Introduction 
Three-dimensional (3D) printing, also widely known as “additive manufacturing” or 
“rapid prototyping”, is a manufacturing technique whereby an object is constructed in a 
layer-by-layer fashion. It is currently being used as a fabrication method in many different 
fields and industry, including aerospace, defence, automotive [17], consumer products 
[552,553], construction [16], healthcare [5] and many others. It has been projected that 
the 3D printing market is expected to reach USD 34.8 billion by 2024 [554]. Some experts 
also forecast that 3D printing has the potential to become the next industrial revolution 
[69]. 3D printing has now changed the way many things are being created, transported 
and stored [170]. This is because 3D printing allows people to create and build things 
easily and quickly, which can also be done at home. People can also easily share the 
things that they have made on the internet so that other people can reproduce the same 
thing on a 3D printer by just simply clicking and downloading the file that needs to be 
printed.  
Currently, the main challenge that has hindered the growth of 3D printing in the medical 
and pharmaceutical field is the availability of medical grade materials. Most of the 
commercially available filaments are not compliant with the requirement to be made into 
medical products. The materials available are mostly toxic and not suitable to be used in 
the human body as the filaments contain many types of additives to achieve the required 
mechanical properties.  
Many researchers are trying to improve the availability of medical and pharmaceutical 
grade filaments. The two most common and widely used filaments are made of 
Acrylonitrile Butadiene Styrene (ABS) and Polylactic Acid (PLA). ABS is mainly 
derived from petroleum and it is not biocompatible. PLA is a corn-based plastic and is 
considered biodegradable and biocompatible [556]. This is because monomers used for 
the polymerisation of PLA, lactic acid, is mainly produced via the fermentation of sugar 
obtained from bioresources such as corn starch [557,558]. Hence, PLA is safe to be used 
in medical products as it has obtained FDA approval for use in medicines and the human 





sustainability, and renewability and is environmentally friendly. Due to its 
biocompatibility and biodegradability, it is suitable not just for the industrial packaging 
field, but also for medical applications.  
PLA is a biodegradable polyester and exhibits semicrystalline properties in nature 
[562,563]. It is one of the most widely used materials in clinical applications due to its 
tuneable mechanical properties, wide availability, and its ability to degrade into natural 
metabolites [564,565]. The semicrystalline properties of PLA have allowed it to be made 
into filaments for use in FDM 3D printing. However, the printing of PLA requires a 
relatively high temperature of up to 200 °C, hence it may not be suitable for many 
pharmaceutical applications. This is because some drugs are thermally sensitive and 
printing at such a high temperature can cause thermal degradation. Apart from that, the 
limited ductility of PLA is a limitation for its use in a wide range of medical and 
pharmaceutical 3D printing applications. Therefore, PLA has limitations as it can break 
at very low stress and has poor thermal stability [541]. The mechanical and thermal 
properties of PLA can be improved by adding plasticisers to the PLA polymer matrix 
[566]. A plasticiser improves the mechanical properties by acting as a spacer between the 
molecular chains of the polymers. Some of the most commonly used plasticisers include 
polyethylene glycol (PEG),  triethyl citrate (TC), acetyl triethyl citrate (ATC) and 
glycerol [20–24].   
The most effective way of producing polymeric filaments for 3D printing is through Hot 
Melt Extrusion (HME). The HME technique is a long-established technology that has 
been used to produce plastics since the 1930s [105]. HME has also been used in the 
pharmaceutical industry to produce a wide variety of drug delivery systems and modified 
release solid dosage forms [101,118]. 
This chapter describes a preliminary study of an attempt to produce a type of PLA-based 
filaments that can be printed a lower temperature when being used in an FDM 3D printer. 
The aim is to demonstrate the used of HME to produce a type of biocompatible filament 
suitable for pharmaceutical applications. PLA is mixed with a plasticiser, polyethylene 
glycol (PEG), to produce a PEG/PLA blends. This polymeric composition can improve 
the mechanical properties of pure PLA and can be used for pharmaceutical applications. 
PEG can be blended with PLA to form a polymer matrix as PEG has good miscibility 





hydrophilic group interacts with the hydrophobic group in PLA. The PEG/PLA blend can 
also act as an effective drug carrier as it improves the hydrophilicity of the pure PLA. The 
PEG/PLA blend can release drug easier than pure PLA.  
The PEG/PLA blend filaments were produced using a single screw FilaFab filament 
extruder. Three compositions of PEG/PLA filaments were produced (10%, 20%, 30% 
w/w PEG/PLA) and were compared with pure a PLA filament and a commercial PLA 
filament. The PEG grade used in this study was PEG 6000. This is because PEG 6000 
exists in solid form at room temperature and can be processed more easily than other 
lower molecular weight PEGs that typically exist in liquid or semi-solid at room 
temperature. Apart from that, PEG 6000 exhibit excellent thermal degradation behaviour 
according to the thermal degradation study carried out in Chapter 3. As the extrusion 
process and FDM 3D printing process expose the materials being processed to high 
temperatures, the materials need to exhibit excellent thermal properties.  
The presence of PEG in PLA was confirmed by Fourier transform infrared (FTIR) 
spectra. The thermal properties of the different filaments were investigated through 
differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). The 
printability of the filaments was also investigated by printing a cylindrical shape object 
using the different filaments. The study shows that 30% w/w PEG/PLA filaments has the 
best properties among the three blends and all PEG/PLA filaments can print at 175°C, 
lower than pure and commercial PLA (190°C). The PEG/PLA filaments can have a wider 
medical and pharmaceutical applications than pure PLA.  
4.2 Materials 
Biodegradable high molecular weight polylactic acid (PLA) pellets (IngeoTM Biopolymer 
4032D, made of >98% of polylactide resinCAS: 9051-89-2) were purchased from 
(NatureWorks, Minnetonka, MN, US). Poly(ethylene glycol), average M.W. 6000 was 
purchased from Fisher Scientific (Loughborough, UK). Commercial Makerbot Red PLA 






4.3 Experimental methods 
4.3.1 Coating of the PLA pellets with PEG  
 
Figure 4.1: Images to show the original form of a) PLA pellets b) PEG 6000. 
The preparation of PEG/PLA was required to ensure the mixing can be homogenous when 
being fed into the single screw extruder. As shown in Figure 4.1, PLA are in the form of 
small round pellets of around 3 mm whereas PEG 6000 used were in the form of thin 
waxy flakes. The PLA pellets are very hard whereas the PEG solids are very fragile which 
could be easily ground into powder. Due to the difference in size and mechanical 
properties, an extra step was required to better prepare the samples before extrusion. This 
is because during the extrusion process, it is highly likely that the rotating single screw 
will segregate the PLA pellets from the PEG instead of mixing due to the screw 
configuration. Coating the PEG on the surface of PLA can ensure both PEG and PLA can 








Figure 4.2: Set-up of a Caleva mini coater for the coating of PLA pellets with PEG. 
For the coating process, PEG 6000 was dissolved in distilled water using a magnetic 
stirrer at a temperature of 60C and rotation speed of 400 rpm for 10 mins. The 
concentration of PEG in water is 20% w/v. The dissolved PEG was then used to coat the 
PLA pellets using the Caleva mini coater (Sturminster newton, UK) (Figure 4.2). Three 
different compositions were produced (10%, 20%, 30% w/w PEG/PLA blends) (Table 
4.1). Each batch size of 25 g PLA coated with PEG was produced. The mass of the PLA 
pellets was weighed before the coating of PEG and after the coating of PEG to quantify 
the amount of PEG being coated onto the PLA pellet were as desired. For the coating 
process, the peristaltic pump was set to 2.2 rpm. The agitator was set at a frequency of 
20.5 Hz. The fan speed was set to 16 m/s and the air temperature was set to 35C. The 
atomizing air pressure was set to 0.7 bar. The PEG solution was kept under stirring 
condition throughout the coating process to prevent any possible PEG precipitation or 
clogging up of tubes. The PLA pellets were coated with PEG to ensure homogeneous 
mixing during the single-screw extrusion process. PLA pellets are much larger than PEG 
solids and a simple blend of both materials may not be the most effective to achieve a 
homogeneous mixing of both materials. This is because the PEG powder will segregate 
from the PLA pellets in the blend during the extrusion process due to the very large size 





ensure all PLA pellets are coated with a layer of PEG so that both materials are effectively 
mixed during the extrusion process. 
Table 4.1: Percentage of composition for the three PEG/PLA samples. 
Sample code wt (%) 
PEG PLA 
S10 10 90 
S20 20 80 
S30 30 70 
 
4.3.2 Preparation of PEG/PLA filaments and pure PLA filaments  
 
Figure 4.3: Benchtop single-screw filament extruder (FilaFab extruder). 
The coated pellets were then being extruded into 3D printable filaments using a single-
screw extruder, Filafab extruder (D3D Innovations Ltd, Bristol, UK) (Figure 4.3). PLA 
pellets without PEG coating were also used to be made into pure PLA filaments. The 
extruder is heated up to 190C and soaking was allowed for 10 mins before the extrusion 
process. The nozzle on the dies of the extruder is 1.75 mm.  
4.3.3 Differential scanning calorimetry (DSC) 
A DSC 4000 system (Perkin Elmer, Waltham, MA, US) was used to study the glass 
transition temperature and the melting temperature of the filaments. The samples used 
were about 5 mg. The samples were placed in an aluminium pan, and an empty aluminium 
pan was used as a reference. The chamber was heated from 25 C to 250 C at a rate of 
10 C/min. Nitrogen gas was used as the purged gas at a flow rate of 20 mL/min in all the 
DSC experiments. The data were collected and analysed with Pyris software (Perkin 
Elmer).  
4.3.4 Thermogravimetric analysis (TGA) 
TGA was carried out using Q40 Thermogravimetric analyser (TA Instruments, New 
Castle, DE, US) to obtain the degradation profile of the filaments. The samples used were 





from 30 C to 550 C at a rate of 10 C/min. Nitrogen gas were used as purge gas at a 
flow rate of 20mL/min. Data were collected and analysed using the Advantage/Universal 
Analysis Software (TA Instruments). 
4.3.5 Fourier Transform Infra-Red (FTIR)  
Fourier Transform Infra-Red (FTIR) analysis was carried out to study the interaction of 
the intermolecular chains between PEG and PLA. The FTIR analysis was performed 
using a Spectrum Two FT-IR Spectrometer (PerkinElmer, Waltham, MA, USA). The 
spectra were collected using 16 scans between wavenumber 4000-500 cm-1 with a 
resolution of 4.0 cm-1. The results were analyse using the PerkinElmer SpectrumTM 10 
software and were displayed as percentage of transmission. 
4.3.6 Mechanical testing of filaments 
 
Figure 4.4 Texture analyser for mechanical testing a) set-up of tensile testing (before 
test) b) after tensile testing. 
Tensile testing was carried out on all the extruded filaments using TA.XT Plus Texture 
Analyser (Stable Micro Systems, Godalming, UK) as depicted in in Figure 4.4. For each 
formulation of extruded filaments, five 10 cm samples were cut at random from the same 
batch of filaments produced. All samples have a diameter of 1.5 mm ± 0.1 mm. The 
samples were then stretched using the texture analyser as shown in Figure 4.4. A load cell 
of 50 kg was used and a tensile grip probe set was used to measure the tensile strength of 
the filaments. The test was set up as a tension test with a maximum applied force of 50 





analysed using the Exponent Software version 7.0.3.0 (Stable Micro Systems, 
Godalming, UK). 
4.3.7 Sample printing using filament produced 
A cylindrical-shaped CAD model with a diameter of 0.8 mm and length of 15 mm was 
created in Solidworks (Dassault Systemes, Waltham, MA, US). A schematic diagram 
containing the front and side view of the cylindrical model was depicted in Figure 4.5. 
The 3D model was then saved as an .STL file and imported to Cura for Robo 2.5.0 
software (Robo3D, San Diego, CA, US) for slicing. The sliced 3D model saved as .gcode 
file and is printed using a Robo R2 FDM 3D printer (Robo3D, San Diego, CA, US). The 
cylinder has a diameter of 0.8 mm and a length of 15 mm. The layer height for printing 
was set to 0.06mm. A printing temperature of 190 °C and bed temperature of 60 °C is set 
when pure PLA and commercial PLA are used. When filaments of PEG/PLA blends are 
used, the printing temperature is set around 175 °C. The bed temperature is set at 60 °C.   
 
Figure 4.5: Schematic diagram of cylindrical-shaped model for 3D printing a) front-
view b) side-view. 
4.3.8 Scanning Electron Microscopy (SEM) 
SEM was carried using the JEOL JMS 820 (Freising, Munich, Germany) to obtain a 
close-up image of the structure of the printed sample. The samples were sputter-coated 
with gold under vacuum conditions using the Edwards S-150 sputter coater (Edwards 
High Vacuum Co. International, Albany, NY, US). The accelerating voltage was at 3 kV 
and the magnification was 20X.  
4.4 Results and Discussion 
4.4.1 Extrusion of filaments 
Filaments of three different PEG/PLA blends and pure PLA were successfully prepared 
using the single screw extrusion method. The Filafab single screw was built specifically 
for filament extrusion to be used in FDM 3D printers. Therefore, the control settings were 





extruded, from the hopper to the extruder die. The minimum temperature required to 
process the PLA pellets were 190 °C. The time taken for the whole extruder to reach the 
temperature suitable for extrusion was approximately 10 mins. The extruder screw for the 
Filafab extruder has a wide screw pitch and channel depth. Such a screw configuration 
does not provide a homogeneous and even mixing of different materials. Therefore, the 
preparation of PEG/PLA pellets using the coating method was required. This will ensure 
the extruded filaments have a more even PEG mixing in PLA. SEM was used to image 
the morphology of the filaments at the cross-section and the images were displayed in 
Figure 4.6.The images showed that the filaments produced have smooth surfaces and a 
very consistent round shape.   
 
Figure 4.6: SEM images of extruded filaments with different compositions a) S10, b) 






4.4.2 Differential scanning calorimetry (DSC) 
 
Figure 4.7: DSC profiles for PEG, PLA pellets and different PEG/PLA pellets 
compositions. 
DSC is a highly sensitive technique to study the thermal transition as a function of 
heating. DSC is the most often used thermal analysis method, primarily because of its 
speed, simplicity and availability. It is mostly used for quantitative analysis. The 
thermograms obtained show information for the glass transition and melting temperature 
of the studied material. The DSC analysis of PEG 6000 which was blended with PLA to 
form 3 different concentrations of PEG/PLA blends is depicted in Figure 4.7. The analysis 
shows that PEG 6000 has a melting point of 65.4 °C. The calculated heat enthalpy value 
(∆H) of PEG is approximately 252.7 J/g. PEG is known to be a semicrystalline polymer. 
However, the plot of PEG did not show any glass transition temperature. According to 
the literature, PEG 6000 has a glass transition temperature of -22.7 °C. PEG 6000 is a 
semicrystalline solid at room temperature and will transition into a liquid state when the 
temperature reaches its melting point [568,569].  
Table 4.2: Glass transition temperature (Tg) and melting temperature (Tm) of pure PLA 








value (∆𝑯) for 
Tm (J/g) 
Pure PLA 72.8 175.6 20.2 
10% PEG/PLA (S10) 67.7 175.5 14.1 
20% PEG/PLA (S20) 67.3 174.9 18.1 




































The DSC analysis depicted in Figure 4.7 also shows the thermographs of pure PLA pellets 
and the 3 different compositions of PEG-coated PLA pellets. The graph shows that all 
PLA pellets exhibit two endothermic events. The first endothermic event that happened 
around 70 °C shows PLA was going through the glass transition state. At this temperature, 
the molecules in the polymer received enough heat energy to move around, transitioning 
from a hard, brittle state into an elastic or rubbery state. The second endothermic event 
occurred around 170 °C, here the PLA started to melt. Figure 4.7 shows that with 
increasing concentration of PEG in the blend, the glass transition temperature (Tg) and 
melting temperature (Tm) of the PLA pellets were not affected. The Tg and Tm of all the 
pellets can be found in Table 4.2. This was expected as the PEG was only coated onto the 
surface of the PLA pellets with no molecular interaction between the two polymers. This 
can also explain the increase in the size of the peak for the glass transition event. This is 
because PEG 6000 has a melting point around the same temperature as the Tg of PLA. 
Hence, the overlapping melting of PEG and glass transition of PLA was reflected by a 
larger peak at around 70 °C. The size of the endothermic peak increases as the 
concentration of PEG increases. 
 
Figure 4.8: DSC profiles comparison for different composition of PEG/PLA filaments, 
pure PLA filaments and commercially available PLA filaments. 
Figure 4.8 shows the DSC thermographs of the PEG/PLA filaments and pure PLA 





































PLA and PEG polymer. The screw provides the effect of kneading and mixing of the two 
polymers, forming a PEG/PLA polymer matrix. The polymer mixture was then forced 
through a die, producing a continuous filament. Unlike the DSC results in Figure 4.7, the 
results in Figure 4.8 showed 3 peaks, 2 endothermic events and 1 exothermic event, which 
occurred between the 2 endothermic events. The first endothermic peak is the glass 
transition temperature and the second endothermic peak would be the melting point of 
the filaments. The exothermic occurred could possibly be the cold crystallisation 
temperature (Tcc) of the filaments. In addition, the results showed the melting temperature 
of the PEG/PLA filaments is slightly lower than the melting point of pure PLA. The glass 
transition temperatures of the PEG/PLA filaments are also significantly lower than the 
pure PLA filaments. The Tg and Tm extracted from the thermographs in Figure 4.8 were 
tabulated in Table 4.3.  
As the concentration of PEG increases in the blend, the Tg decreases. This is caused by 
the plasticising effect of PEG in PLA. This is because the plasticiser reduces the 
intermolecular forces in PLA, improving the flexibility and ductility of the polymer at 
lower temperatures [570]. The pure PLA has a melting point of 174.5 °C. The 10% 
PEG/PLA blend (S10) shows a melting point of 170.7 °C. The 20% PEG/PLA blend 
(S20) shows the melting point to be 172.7 °C. The 30% PEG/PLA blend (S30) shows a 
melting point of 170.9 °C. There was only a slight decrease in the melting point of all 
three PEG/PLA filaments as the filaments were still predominantly PLA. The lower 
melting point means that the printing temperature can also be lowered. A lower printing 
temperature is particularly beneficial for medical and pharmaceutical applications. This 
is because thermal degradation can be avoided when printing at lower temperatures. The 
Tcc peaks showed in the DSC thermographs for the filaments could be associated with the 
change in the distribution of crystallinity in the polymer after the extrusion process. This 
is because there were no exothermic peaks shown on the PEG/PLA pellets in Figure 4.7. 
The results from DSC shows that PEG has effectively mixed with PLA in the filaments 






Table 4.3: Glass transition temperature (Tg) and melting point (Tm) of different 








value (∆𝑯) for 
Tm (J/g) 
Pure PLA 62.3 174.5 22.3 
10% PEG/PLA (S10) 58.9 170.7 33.1 
20% PEG/PLA (S20) 47.9 172.7 33.0 
30% PEG/PLA (S30) 49.2 170.9 39.5 
4.4.3 Thermogravimetric analysis (TGA) 
 
Figure 4.9: TGA analysis for different compositions of single-screw extruded PEG/PLA 






































Table 4.4: Temperatures at three degradation points (90%, 50%, 10% wt. remaining) for 
all compositions of filaments. 
Filaments T90 (C) T50 (C) T10 (C) 
S10 306.4 343.6 366.7 
S20 317.4 350.2 371.3 
S30 332.2 363.3 379.0 
Pure PLA 340.4 358.1 367.9 
PEG 338.3 406.7 427.8 
 
TGA was carried out on the different compositions of PEG/PLA filaments, pure PLA 
filament, and PEG 6000. The results from Figure 4.9 shows the degradation profile of the 
different filaments and PEG. The TGA data shows excellent stability for PEG/PLA 
blends, PLA and PEG. The presence of PEG did not affect the stability of PLA. T90 is the 
temperature when 10% weight loss is observed. T50 is the temperature when the polymer 
has 50% weight loss and T10 is the temperature when the polymer has 90% weight loss. 
The temperature at these three stages of degradation for the filaments was shown in Table 
4.4. 10 % weight loss of all the filaments were observed around 300C and 90% weight 
loss occur around 400C. The results show that both PEG and PLA polymers when being 
mixed still have excellent stability in the presence of high temperature which would be 
suitable to be used in 3D printing for pharmaceutical applications. The study also showed 
that when PEG was added to PLA, the PEG/PLA blends starts to degrade at a lower 
temperature than pure PLA. The results show that as the concentration of PEG increases, 
the temperature at which the sample starts to degrade decreases. As the temperature at 
which degradation starts is still around 300 °C, the blends are still considered stable for 
thermal processes such as hot melt extrusion and FDM 3D printing. The maximum 





4.4.4 Fourier Transform Infrared Analysis (FTIR) 
 
Figure 4.10: FTIR results for different compositions of PEG/PLA filaments, PLA 
filaments and PEG. 
FTIR is used to determine the molecular composition in the different compositions of 
PEG/PLA filaments and pure PLA filament. The FTIR uses the absorbance of infrared 
light of the sample at different wavelengths to determine its composition. Figure 4.10 
shows the results from the FTIR analysis for all PEG/PLA filaments, pure PLA filaments, 
and PEG 6000.  In all the PEG/PLA and PLA filaments, the absorption of wavenumber 
of around 2996 cm-1 and around 2940 cm-1 shows the characteristic absorption bands 
corresponding to the band absorption of asymmetric and symmetric stretching of C-H.  
The C=O stretching occurs around 1746 cm-1 and The CH3 stretching occurs at 1453 cm
-
1, C-H deformation at 1362cm-1 and CH asymmetric at around 1359 cm-1. The C-O 
stretching modes of the ester group appear at around 1265 cm-1. The C-O stretching bands 
in -CH-O- and -O-C=O of PLA also appear at around 1181 cm-1 and 1080 cm-1 
respectively. The absorption bands at 869 cm-1 can be attributed to the amorphous phase 
whereas the band at 755 cm-1 is the crystalline phase. These peaks found in the FTIR 





In PEG 6000, the absorption band at around 2882 cm-1 is attributed to the aliphatic C-H 
stretching of PEG. The C-O-C groups can be found at the peak around 1096 cm-1. From 
the FTIR results, the three PEG/PLA blends have a similar spectra pattern as the pure 
PLA. One of the reasons is because of the similarity in the structure of PLA and PEG as 
they both consist of carbon and oxygen atoms. As the PEG is mixed with the PLA 
polymer matrix, it shows that the PEG has good compatibility as it mixed well with PLA. 
There are slight differences in the intensity of the peak, which is the absorption at the 
infrared, for different compositions of PEG/PLA blends. The absorbance intensity 
increases as the concentration of PEG increases in the PEG/PLA blend. The 10% 
PEG/PLA blend (S10) has the lowest absorbance and the 30% PEG/PLA (S30) filament 
has the highest absorbance. The increased intensity is due to the presence of PEG as PEG 
has very high absorbance itself. The incorporation of PEG into PLA did not produce any 
new configuration or chemical properties on the filaments. This also means that there are 
no significant changes occur in the surface chemistry of the PLA. The increase in intensity 
can be explained by improving bonding in the polymer when PEG in blended with PLA. 
The results from FTIR confirmed the compatibility and miscibility of PEG with PLA. 
4.4.5 Mechanical analysis 
Table 4.5: Strength of extruded filaments 
Filament Yield Strength 
(kPa) 
Elongation at break (%) 
S10 507.5 ± 211.6 16.4 ± 6.4 
S20 239.6 ± 155.7 20.9 ± 3.8 
S30 359.9 ± 62.1 30.7 ± 2.2 
Pure PLA 437.3 ± 61.6 27.9 ± 3.6 







Figure 4.11: Strength of all extruded PEG/PLA filaments compared with pure PLA 
filament and commercial PLA filaments. 
Tensile testing was carried out to determine the mechanical resilience of the different 
PEG/PLA filaments, pure PLA filament and a commercial PLA filament. The strength of 
the PEG/PLA filaments were compared with pure PLA filament and commercially 
available PLA filament. The mechanical properties of the filaments are important to 
determine their printability in FDM printers. This is because the FDM printing process 
stretches the filament as gear is used to feed the filament into the printing head. Hence, 
the filaments require adequate ductility to ensure they would not break easily while being 
stretched. The results from the tensile testing of the filaments were expressed as the yield 
strength and the maximum strain values of each of the filaments. The strength of the 
filaments was displayed in Table 4.5 and Figure 4.11. Yield strength is the minimum 
stress under which the material deforms permanently (i.e. the stress at which the material 
stops behaving elastically is called the yield strength). This is the highest point where the 
strain increases proportionally with stress. Typically, materials undergo elastic 
deformation below the yield stress, which means the material being stretched will be able 
to return to its original length. When the force applied is above the yield strength, the 
material will be plastically deformed, which means the material will not be able to return 
to its original form when the force stretching it was released. The testing showed that, the 
yield strength of S10 filaments was the highest amongst all the filaments. However, as 
the concentration of PEG increased, the yield strength decreased. This means that 
filaments with a higher concentration of PEG has a lower elastic limit. This could be that 





































strength of the material, representing the amount of force it could withstand before 
breaking.  Hence, a better reference for the strength of the filaments may be the rupture 
strain.  
Strain is often a better measure as it is used to determine the ability to stretch from its 
original length before breaking, representing the plasticity and elasticity of the material. 
It can be defined as the change in length over the original length (
Change in length
Original length
×  100 =
Strain(%)) of an object [572]. As the concentration of PEG increased, the rupture strain 
of the filaments increased. The highest concentration of PEG blend seems to have a better 
ability to be stretched as compared to pure PLA. This showed the plasticising effect of 
PEG in PLA. Nevertheless, PEG/PLA blends have proven to have good mechanical 
properties and they are quite similar to the pure PLA filament, which could be suitable to 
be used in the FDM 3D printers. The strength of the self-prepared filaments was 
comparable to a commercially available filament that can be readily used for FDM 3D 
printing. The PEG/PLA filaments even make more superior strain values, meaning they 
can be stretched much more than the commercial PLA filament before breaking. 
Nevertheless, the PEG/PLA filaments and pure PLA filaments showed adequate 





4.4.6 Printability of filaments 
 
Figure 4.12: Cylindrical shaped object printed using different filaments a) 10% w/w 
PEG/PLA filament b) 20% w/w PEG/PLA filament c) 30% w/w PEG/PLA filament d) 
pure PLA filament e) commercial PLA filament. 
 
Figure 4.13: Image of a 3D printed cylindrical shape sample removed from the 
raft/base. 
 
Figure 4.14: SEM images of the cylindrical shaped object printed using different 
filaments a) S10 filament b) S20 filament c) S30 filament d) pure PLA filament e) 





Figure 4.12 shows the printability of the different PEG/PLA filaments, pure PLA 
filament, and commercial filament. The object being printed is a cylindrical shape which 
has a diameter of 0.8 mm and a length of 15 mm. The layer height for printing was set to 
0.06 mm. The miniaturised cylinder was printed on a raft as a base for the printed object 
to attach to whilst printing. The cylinder can be removed from the base as shown in Figure 
4.13. The quality of the printed cylindrical shape object was considerably good as 
compared to the pure PLA and commercial PLA. Figure 4.14 are the SEM images of the 
printed cylindrical shape object. The layers of printing can be seen very clearly and it can 
form the shape required. A printing temperature of 190°C and bed temperature of 60°C 
was set when pure PLA and commercial PLAs are used. When filaments of PEG/PLA 
blends are used, the printing temperature is set around 175°C. The bed temperature is set 
at 60°C.  The printing temperature is critical for the success of a print when using the 
PEG/PLA blend filaments. The printing temperature is around 175°C. The temperature 
needs to be adjusted accordingly in order to obtain the right viscosity of the melted 
filament that can successfully print an object. When the printing temperature is too high, 
the filament will become too viscous when melted. The extruded material cannot rapidly 
cool down and solidify when being laid on the print bed. This will cause the print to fail 
as the material will fail to lay on top of each layer as shown in Figure 4.15. With the right 
printing parameters, it was showed that 3D printing was able to produce an object with 
intricate details up to a resolution of 0.06 mm. This may be useful for pharmaceutical and 
biomedical applications particularly for producing personalised items as these items will 
need to fit the patients’ requirements. Apart from that, the ability to print such a 
miniaturised object showed the potential of 3D printing miniaturised implants.  
One thing to note from Figure 4.12a-c, which were the samples printed using the 
PEG/PLA filaments showed some darker colour than the one printed using pure PLA. 
This is discolouration of the PEG through the thermal process of 3D printing. PEG is 
generally stable up to 300 °C as shown from the TGA analysis. The darkening of the 
polymer after being processed at elevated temperature is most probably caused by 
oxidation during heating. It has been reported that the darkening can be prevented by 
preventing the oxidation of PEG using suitable antioxidant to the blend or processing the 






Figure 4.15: Failed printing due to high printing temperature. PEG/PLA blend filaments 
were used. 
4.5 Conclusion 
PLA is one of the most common materials that is being made into 3D printable filaments. 
However, commercially available PLA filaments are not biocompatible and cannot be 
used for the 3D printing of biomedical application. Apart from that, pure PLA often have 
poor mechanical properties. The properties of PLA can be improved by blending the 
polymer with plasticisers such as PEG using a simple HME method. A single-screw 
Filafab filament extruder was used to produce PEG/PLA filaments at different 
concentrations of PEG, as well as pure PLA filaments. The study showed that PEG/PLA 
filament shows good mechanical and thermal properties. The presence of PEG was 
confirmed and showed good miscibility with PLA in the polymer matrix. The PEG/PLA 
blend filament has a lower melting point than the pure PLA filament. The printing 
temperature of the PEG/PLA filament is also lower than the pure PLA filament. Pure 
PLA is hydrophobic and PEG is hydrophilic. By incorporating PEG into PLA, the 
PEG/PLA has better hydrophilicity which is expected to have better drug release. 
Therefore, the PEG/PLA filament can be used to carry drugs and used for the 3D printing 
of drug delivery systems. The lower printing temperature allows the loading of 
thermolabile drugs. The PEG/PLA filament is suitable to be used in 3D printing for a 
wide range of medical or pharmaceutical applications. The filaments can be used to 3D 






Chapter 5 : Twin-screw extrusion of PEG/PLA filaments 
5.1 Introduction 
Hot-melt extrusion (HME) was first introduced in the food plastics industry since the 
1930s. industries [100,114]. In general, HME is a process of shearing and mixing 
different materials using the screw elements at an elevated temperature to melt and 
intimately mix two or several compositions. It has then been introduced into the 
pharmaceutical industry in the 1970s and many patents related to the use of HME in 
pharmaceutical applications have been filed since then [120,574,575]. HME can be 
generally classified into two categories: single-screw extrusion and twin-screw extrusion. 
The single-screw extruder is commonly used to produce filaments [576] and films 
[577,578], whereas the twin-screw extruder has found utility in producing pharmaceutical 
products such as amorphous solid dispersions [579] (ASD) and pharmaceutical co-
crystals [580]. In most applications, twin-screw extrusion is often preferred when mixing 
of materials is involved as it is more effective in achieving homogeneous mixing of 
several different materials. It is also more versatile and allows more control on the process 
parameters which could ensure better consistency and repeatability [581]. Twin-screw 
HME is also easily scalable which allows cost-effective large volume production. 
One of the main drawbacks of HME is the high processing temperature may not be 
suitable for certain materials that are thermally sensitive. However, this issue only applies 
when there are materials with high melting point studies involved in the mixture that is 
processed. Studies have shown that this can be overcome by adding suitable plasticisers 
or surfactants to the mixture [585,586]. The addition of plasticiser or surfactant can lower 
the processing temperature as the API and the polymer that melts at higher temperatures 
were solubilised [120]. For instance, the study by Zhang et al. successfully lowered the 
HME processing temperature to produce an amorphous solid dispersion (ASD) of 
Baicalein (BAC), with the use of a plasticiser, Cremophor RH, to improve the 
bioavailability of the API [587]. The plasticiser was able to soften the polymeric carrier 
and decrease the glass transition temperature as well as the melt viscosity of the polymeric 
carrier, allowing BAC to solubilize at a lower temperature. In addition to improving the 
API’s dissolution and bioavailability, the study showed that careful selection of a 





Zhao et al. also studied the effect of plasticisers on the ASD of ritonavir as API and 
copovidone as a polymeric carrier produced via HME [588]. The study investigated the 
impact of two different plasticisers (Span 20, hydrogenated soybean phosphatidylcholine 
(HSPC)). The results showed that the plasticisers are effective in not just in lowering the 
extrusion temperature, but also in improving the dissolution profile and bioavailability of 
the ritonavir ASD.  
In this chapter, the twin-screw extrusion method of producing biocompatible polymeric 
composition was investigated. Biocompatible and biodegradable polymers have attracted 
increasing attention due to their suitability to be used in biomedical applications as well 
as environmental concerns. However, biopolymers typically have poor physical and 
chemical properties that could limit thier potential for applications. In the previous 
chapter, a study to enhance polylactic acid (PLA) was carried out by blending PLA with 
a plasticiser, polyethylene glycol (PEG). The blend was produced in the form of filament 
using a single-screw extruder. The fabricated filaments were used in a Fused Deposition 
Modelling (FDM) 3D printing to investigate the suitability of the polymeric composition 
being used for the 3D printing for biomedical applications.    
The aim of this study is to compare the properties of filament extruded using twin-screw 
extrusion with single-screw extrusion from the previous chapter. The twin-screw 
extrusion equipment available can only be fed with materials in smaller particle size. The 
PLA pellets were too large to be processed. Therefore, the PLA pellets need to be ground 
into smaller particle sizes before being fed into the twin-screw extrusion. However, PLA 
pellets are naturally very hard and require expensive equipment and processes such as 
cryo-milling to properly grind them. Hence, a more cost-effective method is required. 
Smaller PLA particles were produced through grinding solvent cast PLA films using a 
normal coffee grinder. The solvent casting method is cost-effective compared to other 
grinding or milling technologies. In the solvent casting method, PEG was mixed into PLA 
solution. The solution was then poured onto a petri dish and allowed to dry to obtain a 
thin film. The dried films were ground into smaller particles that can be fed into the 
feeding zone of the twin-screw extruder. The solvent casting method offers the benefit of 
providing better miscibility and mixing in addition to shear mixing provided through 






Biodegradable high molecular weight polylactic acid (PLA) pellets (IngeoTM Biopolymer 
4032D, made of >98% of polylactide resin CAS: 9051-89-2) were purchased from 
(NatureWorks, Minnetonka, MN, US). Poly(ethylene glycol), average M.W. 6000 was 
purchased from Fisher Scientific (Loughborough, UK). Dichloromethane was purchased 
from Sigma Aldrich (Gillingham, UK). Commercial Makerbot Natural PLA filaments 
were purchased from Creat3d Ltd (Wokingham, UK).  All chemicals and materials were 
used as received. 
5.3 Experimental Methods 
5.3.1 Preparation of PEG/PLA films 
The PEG/PLA films were prepared using the solvent-casting method. PLA pellets were 
dissolved in dichloromethane (DCM) at a concentration of 10% w/v. The PLA pellets 
were dissolved in DCM using a magnetic stirrer at a rotation speed of 800 rpm until a 
clear solution was obtained. PEG was then mixed into the clear PLA solution until fully 
dissolved. Three different concentrations (10%, 20% 30% w/w) of PEG/PLA blends were 
prepared. The PEG/PLA solution was then cast onto glass petri dishes and allowed to dry. 
The films were then dried in the oven at 45°C to ensure the full evaporation of 
dichloromethane. Table 5.1 shows the three formulations of PEG/PLA films.    
5.3.2 Preparation of PEG/PLA filaments 
The prepared films were blended into smaller particle size using an 800W Cookhouse 
coffee blender (UK). The ground PEG/PLA produced then were made into filaments 
using a customised 10mm L/D  co-rotating twin-screw extruder by Twin Tech Extrusion 
Limited (Stoke-on-Trent, UK). The extruding temperature for the 4 zones (Z1 : Z2 : Z3 : 
Z4) were (120°C : 140°C : 150°C : 150°C) and the die was set to 150°C. The heat soak 
time of the extruder was set to 5 minutes. The extruding hole on the die has a diameter of 
2.0mm and the screw speed was set to 50 rpm. Table 5.1 shows the formulation for the 








Table 5.1: Composition of different formulations of PEG/PLA blends. 
5.3.3 Characterisation of filaments  
5.3.3.1 Differential Scanning Calorimtery (DSC) 
DSC was carried out on a DSC 4000 system (Perkin Elmer, Waltham, MA, USA) to study 
the thermal properties of the PEG/PLA blends. The measured samples used were about 5 
mg and were placed in an aluminium pan, with another empty aluminium pan used as a 
reference during measurement. The chamber was heated from 25 °C to 250 °C at a heating 
rate of 10 °C/min. Nitrogen gas was used as a purge gas at a flow rate of 20 mL/min in 
all DSC measurements. All results were collected and analysed with Pyris software 
(Perkin Elmer).  
5.3.3.2 Thermogravimetric analysis (TGA) 
TGA was carried out using a Q40 Thermogravimetric analyser (TA Instruments, New 
Castle, DE, US) to obtain the degradation profile of the PEG/PLA blends. The samples 
used were about 10 mg and were placed in an open aluminium pan. The furnace was then 
heated from 30 C to 550 C at a rate of 10 C/min. Nitrogen gas were used as purge gas 
at a flow rate of 20mL/min. Data were collected and analysed using the 
Advantage/Universal Analysis Software (TA Instruments). 
5.3.3.3 Fourier Transform Infrared (FTIR) 
Fourier Transform Infra-Red (FTIR) analysis was carried out to study the interaction of 
the intermolecular chains between PEG and PLA. The filament sample was cut to 
approximately 5 mm in length for characterisation. The FTIR analysis was performed 
using a Spectrum Two FT-IR Spectrometer (PerkinElmer, Waltham, MA, USA). The 
spectra were collected using 16 scans between wavenumber 4000 cm-1 and 500 cm-1 with 
a resolution of 4.0 cm-1. The results were analysed using the PerkinElmer SpectrumTM 10 
software and were displayed as a percentage of transmission. 






Filaments PEG PLA 
P10 PF10 10 10 90 
P20 PF20 20 20 80 





5.3.3.4 X-ray Powder Diffraction  
The crystallinity of the solvent cast films was assessed using a Siemens D500 X-ray 
Diffractometer (Siemens, Germany). The samples were first ground into powder form 
and were scanned between 2 Theta(θ)=5° to 50° using 0.01° step width and 1s time count. 
The divergence slit was 1mm and the scatter slit was 0.6mm. The X-ray wavelength was 
0.154 nm in Cu source and at a voltage of 40 kV. 
5.3.3.5 Mechanical Characterisation (Texture Analyser) 
Tensile testing was carried out on the filaments using a TA.XT Plus Texture Analyser 
(Stable Micro Systems, Godalming, UK). A load cell of 50 kg was used and a tensile grip 
probe set (A/TG) was used as an attachment to measure the strength of the filaments.fFor 
each formualtion, Five 10 cm filaments were randomly cut at different sections to be used 
for sample measurements. The test was set up as a tensile test with a maximum applied 
force of 50 kg. The test was stopped as soon as the filament broke or until the maximum 
length of the texture analyser was reached. The data were collected and analysed using 
the Exponent Software version 7.0.7.0 (Stable Micro Systems, Godalming, UK). 
5.4 Results and Discussion 
5.4.1 Solvent cast films and extruded filaments 
A combination of solvent casting and twin-screw extrusion tehcnique was used to produce 
biocaomptible PEG/PLA filaments. Solvent casting is a simple method that involves the 
use of an organic solvent to produce polymeric films containing a mixture of different 
polymers. This is an effective way to produce PEG/PLA films as described in Chapter 3. 
Once the PEG/PLA films were produced using the solvent casting method, they were 
ground into smaller particles and fed into a tabletop twin-screw extruder to produce 
biocompatible PEG/PLA filaments. As PLA has poor mechanical properties, it may have 
limited applications particularly for biomedical and pharmaceutical applications. Hence, 
blending it with plasticisers should improve its mechanical properties, as well as physical 
properties such as its degradation behaviour. This is because the presence of PEG as a 
plasticiser may affect the crystallisability and morphology of PLA [589]. The maximum 
concentration of PEG in the PEG/PLA blends being studied was 30%. This is because 
plasticisers are typically required at lower concentration in a polymeric composition to 
be effective. A study by Yang et al. suggested that PEG were miscible in PLA up to 30 





However, the method of preparation was slightly different. The method described in 
Chapter 4 uses a single-screw filament extruder whereas the method described in this 
chapter uses a twin-screw extruder. The image of the twin-screw extruder used can be 
seen in Figure 5.1. The twin-screw extruder used here extruder has a smaller feeder and 
screws with smaller pitch and depth. Hence, it was not possible to process the PLA pellets 
directly. The PLA pellets itself had a very high hardness and cannot be mechanically 
ground. A cost-effective way to pre-process the PLA pellets is by dissolving it in a 
suitable solvent which has a low boiling point so that the solvent can be easily removed. 
Hence, the solving casting method was adapted by using DCM as it has a high vapour 
pressure, and its boiling point is approximately 39.6 °C [590]. PLA was first dissolved in 
DCM, then PEG was added to the PLA solution. The PEG/PLA solution was then cast 
onto a petri dish and allowed to dry, forming PEG/PLA dry films as shown in Figure 5.1a. 
The PEG/PLA films produced were then mechanically ground using a domestic coffee 
grinder to obtain a powder form of the blends (Figure 5.1b), which could then be 
processed using the twin-screw extruder. As the PEG/PLA blends were pre-mixed using 
the solvent casting method and thin films were produced, the films were much easier to 
be broken and ground as compared to the PLA in pellet form.  
The twin-screw extruder has 5 different temperature controls, one at each zone (i.e., Z1, 
Z2, Z3, Z4, Die). The separate temperature controls allow more effective heating of the 
extruder and each zone can be controlled individually to set the temperature that is 
required. This can prevent the overheating of the samples and thermal degradation. The 
time taken for the whole extruder to achieve the desired temperature was shorter than that 
of the single-screw extruder, as it can be achieved in approximately 5 mins. The 
maximum temperature used for processing the PEG/PLA filaments was 150°C, which 
was much lower than the temperature used in the Filfab single-screw extruder (190 °C). 
This showed that the twin-screw extruder zone heating is much more effective and even 
across the barrel. Apart from that, the shearing forces provided from the two screws 
placed side-by-side also contributed to the mixing and melting of the polymeric mixture. 
Hence, the temperature can be lowered as less heat energy may be required. The heat and 
shearing action of the screws both contributed to the energy required to mix and melt the 
polymeric mixture in the twin-screw extruder. The extruded filaments showed excellent 
consistency round shape with smooth surfaces and have an average diameter of 1.5 mm 






Figure 5.1: a) Example of solvent cast PEG/PLA film, b) PEG/PLA films ground into 
powder form to be fed into the extruder c) twin-screw extrusion process of PEG/PLA 
filaments. 
5.4.2 Diffrential Scanning Calorimetry (DSC) 
 
Figure 5.2: DSC thermograms for solvent cast PEG/PLA films, PLA film and PEG. 
 
Figure 5.2 shows the DSC curves for the three different compositions of PEG/PLA 
solvent cast films, solvent cast PLA film and PEG. The DSC results showed two 
endothermic events for all films. The peaks for the first endothermic event are associated 
with the glass transition temperature of the films and the second peak can be interpreted 
as the melting point of the blends. The size of the glass transition peak seems to increase 
as the concentration of PEG increases. This could be caused by the overlapping of melting 
point of PEG with the glass transition of PLA. The DSC results of PEG shows that PEG 
has a melting temperature of around 66.67°C. The amount of energy required for melting 
is larger than the amount of energy required for glass transition in the polymer. Hence, 
the peak of melting is larger. The films with a lower concentration of PEG showed that 






































5.2. Comparing the DSC results from the PEG/PLA films to the pure PLA, PEG seems 
to have a plasticising effect on the PLA. This is because the Tg of the PEG/PLA blends 
were much lower than the Tg of pure PLA. The Tg of pure PLA is around 73.66 °C 
whereas the P10, P20 and P30 showed a Tg of 61.36 °C, 61.69 °C, and 63.92 °C 
respectively. The lower Tg reflects that the amount of energy required for the molecules 
to move from the glassy state to the elastic state is lower. This also means that PEG has 
been effective as a plasticiser and the PEG/PLA blends are more flexible than PLA 
[522,591]. The Tm of all PEG/PLA films were slightly lower than pure PLA film. 
However, the decrease in Tm is smaller than the decrease in Tg. This is because the 
concentration of the PEG is still considerably low and the compositions are still 
predominantly PLA.  
  
Figure 5.3: DSC for PEG/PLA filaments and pure PLA filaments produced using twin-
screw extrusion. 
Figure 5.3 shows the DSC results for PEG/PLA filaments and PLA filament using twin-
screw extrusion. The Tg and Tm of PLA filament are around 61.9°C and 175°C 
respectively. However, the PEG/PLA filaments (PF10, PF20, PF30) does not seem to 
exhibit an obvious Tg from the DSC analysis. The Tm of PF10, PF20 and PF30 are 
171.72°C, 172.96°C and 171.40°C respectively (Table 5.2). Tg was not observed in the 
DSC for PEG/PLA filaments and this could be caused by the loss of crystallinity due to 
the presence of PEG, causing the filaments to be in a more amorphous state [528]. This 
can also prove the compatibility of PEG with PLA. The results also showed a slight 
decrease in the Tm of the filaments from the pure PLA filaments. This means the presence 






































the DSC curves in Figure 5.3, we can also see an exothermic peak for all the filaments. 
This could be the cold crystallisation temperature (Tcc) of the filaments. The Tcc of PF10, 
PF20, PF30 and PLA filaments are 79.99°C, 87.25°C, 87.22°C, and 111.81°C 
respectively. The Tcc of the filaments seems to increase as the concentration of PEG 
increases. However, the presence of PEG has lowered the Tcc when comparing to the pure 
PLA filament. Cold crystallisation in the filaments might be caused by the development 
of irregular crystals during the cooling process after extrusion [592].  During the extrusion 
process, the polymers were melted at a temperature close to their melting point and there 
will be a sudden drop in temperature when the materials were being extruded out of the 
extruder die. This uncontrolled and rapid cooling process can create nucleating points that 
does not allow the polymer to crystallise into a more ordered structure, causing the 
development of irregular crystal aggregates [593]. Higher Tcc means PLA crystallised 
later and indicates a slower crystallisation rate. The presence of PEG in PLA has 
promoted the crystallisation rate of the PEG/PLA blends. The new crystalline region is 
reflected as Tcc in the DSC analysis and this is typically above the Tg and below Tm.  
The results confirmed the presence of PEG in the films and the filaments. This because 
the Tg in the films with PEG were lower than the Tg of pure PLA film. However, no 
endothermic events that represent the Tg were recorded from the DSC analysis for the 
PEG/PLA filaments. This could be due to the cooling process after the extrusion. During 
the extrusion process, the filaments were being extruded from the die and allowed to cool 
naturally at room temperature without any cooling assistance. Apart from a decreased in 
Tg, there was an increase in the heat enthalpy value required for melting recorded for all 
PEG/PLA blends. This could be due to the lubricating effect of the PEG in the polymeric 










Table 5.2: Extracted glass transition temperature (Tg) and melting temperature (Tm) and 
calculated heat enthalpy value (∆𝐻) for Tm from DSC curves 
Samples Tg (°C) Tm (°C) Heat enthalpy value (∆𝑯) for Tm 
(J/g) 
Pure PLA film 72.83 175.62 20.2 
P10 61.36 170.54 65.3 
P20 61.69 171.68 72.0 
P30 63.92 172.02 74.1 
Pure PLA 
filament 
61.79 174.53 22.2 
PF10 - 171.72 86.1 
PF20 - 172.96 116.4 
PF30 - 171.40 100.0 
5.4.3 Thermogravimetric analysis (TGA) 
 
Figure 5.4: TGA profiles for a) solvent cast PEG/PLA films and PEG, b) extruded 
PEG/PLA filaments. 
Table 5.3: Temperature at three degradation points (90%, 50%, 10% wt. remaining) for 
all compositions of films and filaments. 
Temperature at weight 
% 
t90 (°C) t50 (°C) t10 (°C) 
Pure PLA 340.43 358.09 367.89 
PEG 6000 338.31 406.72 427.75 
Solvent Cast Films    
P10 309.27 341.4 360.51 
P20 310.19 340.94 364.34 
P30 299.34 337.54 379.24 
Extruded Filaments    
PF10 309.69 338.34 358.13 
PF20 303.06 336.25 369.42 
PF30 291.88 329.57 365.24 
Figure 5.4 shows the TGA profiles for all solvent cast films and extruded filaments. TGA 





at three degradation points was noted from the TGA plots. The temperature when 10% of 
the sample was degraded (t90), 50% of the sample was degraded (t50), and 90% of the 
samples have degraded (t10) were shown in Table 5.3. The TGA study shows that when 
PEG was added to PLA, the PEG/PLA blends starts to degrade at a lower temperature 
than pure PLA. The exact temperatures of degradation for the samples at three different 
points were recorded in Table 5.3. The results show that as the concentration of PEG 
increases, the temperature at which the sample starts to degrade decreases. As the 
temperature when it starts to degrade is still around 300 °C, the blends are still considered 
stable at the temperature required for hot melt extrusion. The maximum temperature used 
for extrusion was only 150 °C, which is well below the degradation temperature. Hence, 
the blends were still stable even when PLA was incorporated with PEG.  
Figure 5.4b shows the TGA profiles for all twin-screw extruded filaments. Similar to the 
solvent cast films in Figure 5.4a, the degradation of the filaments started around 300 °C. 
As the concentration of PEG in the filament increases, the degradation temperature for 
the first 10% wt. (t90) decreases. The study shows that the filaments are still thermally 
stable even after the extrusion process. This means that the filaments can be safely used 
for 3D printing as the melting temperature for 3D printing is around 170 °C. The TGA 
profiles for the PLA and PEG showed a smooth degradation profile. When PEG was 
blended into PLA, there seems to be a second degradation point appearing around 350 
°C. The samples P10, P20, P30 have a second degradation temperature at 364.09 °C, 
360.54 °C, 351.84 °C respectively. Samples PF10, PF20, PF30 have a second degradation 
at around 360.25 °C, 353.68 °C, 346.97 °C respectively. The occurrence of these second 
degradation temperature might have caused by the plasticising effect of PEG, where the 
PEG act as a protective barrier on the surface of the PLA matrix [546]. However, this 
second degradation profiles were not seen in the single-screw extruded PEG/PLA 
filaments as studied in Chapter 4 (Figure 4.9). This could be because due to the more 
effective mixing of PEG with PLA in twin-screw extrusion and single-screw extrusion. 
Hence, the effect of PEG was more evident in twin-screw extruded PEG/PLA filaments. 
In general, PLA when blended with PEG has a lower degradation temperature than pure 
PLA materials. Studies have shown that the incorporation of PEG could reduce the 





5.4.4 Fourier Transform Infrared Analysis (FTIR) 
 
Figure 5.5: FTIR spectra for PEG/PLA, pure PLA solvent cast films and PEG 6000. 
-
 
Figure 5.6: FTIR Spectra for twin-screw extruded PEG/PLA filaments. 
Table 5.4: Wavenumber for the several characteristics peaks extracted from FTIR 
spectra. 
Formulation Wavenumber (cm-1) Vibration 





















































































































FTIR can be used to determine the molecular interaction of PEG and PLA in the 
polymeric matrix. Figure 5.5 and Figure 5.6 display the FTIR spectra for the PEG/PLA 
solvent cast films and their extruded filaments respectively. In all the PEG/PLA blends 
and PLA, the absorption at wavenumbers from 2998 cm-1 to 2944 cm-1 shows the 
characteristic absorption bands corresponding to the band absorption of asymmetric and 
symmetric stretching of C-H. The characteristic peaks at wavenumber around 1080 cm-1 
and 1750 cm-1 were attributed to the C-O and C=O of PLA. The absorption bands at 869 
cm-1 can be attributed to the amorphous phase whereas the band at 755 cm-1 correspond 
to the crystalline phase. These peaks showed a typical characteristic band of a PLA. 
Hence, the chemistry of the PEG/PLA blend was not modified. The wavenumber of the 






The bands at 2873 cm-1 seen in all the PEG/PLA blends were attributed to the stretching 
of PEG. As PEG was added to PLA, the peak intensity at 2988 and 1759 cm-1 were 
reduced. In general, the intensity of the peaks increases as the concentration of the PEG 
increases for the PEG/PLA films and extruder filaments. The increased intensity is due 
to the presence of PEG which has a high absorbance itself. The increase in intensity can 
also be explained by improved bonding in the polymer when PEG is blended with PLA. 
As the PEG is mixed with the PLA polymer matrix, it shows that the PEG has good 
compatibility as it mixed well with the PLA. In the PEG/PLA extruded filaments, there 
are slightly broadened peaks in the region of -OH stretching at approximately 3500 cm-1. 
According to Peng et al., the presence of chemical interaction (hydrogen bonding) 
between the two compatible polymers can be determined as a note by band shift and or 
broadening of the IR spectra of hydroxyl groups. Hence, the broadened peak in the region 
of OH stretching is attributed to the chemical hydrogen bonding interaction between PEG 
and PLA. Comparing the FTIR results of the twin-screw extruded filaments with the 
single-screw extruded filaments in Chapter 4 (Figure 4.6), the broadening of the peaks in 
the twin-screw extruded filaments were more evident. This could be caused by the better 
mixing of PEG and PLA during the twin-screw extrusion process due to shear mixing at 
an elevated temperature. Apart from that, the materials used for twin-screw extrusion 
have better mixing since the two materials were mixed by a common solvent [596]. 
5.4.5 X-Ray Powder Diffraction (XRPD) 
 
Figure 5.7: XRPD spectra for PEG/PLA blends, pure PLA and PEG. 
All three PEG/PLA solvent cast films, pure PLA film and PEG were ground into powder 
form and the crystallinity of the materials was determined using X-Ray power diffraction. 





















The results from the XRPD were shown in Figure 5.7. The study confirms that PLA is a 
semicrystalline material as seen in the spectrum. PLA showed a small crystalline peak at 
around 16° but the spectrum showed amorphicity in PLA as well. On the other hand, PEG 
showed clear crystalline peaks confirming that PEG has high crystallinity in its bulk form. 
The spectra for all three PEG/PLA films showed characteristics of both PLA and PEG 
combined. This confirmed the effective mixing and the presence of PEG in PLA. As 
expected, the spectrum showed more obvious PEG crystalline peaks as the PEG 
concentration increase. The presence of PEG at a higher concentration induced a higher 
crystallinity in the PEG/PLA film. This could mean that a higher concentration of PEG 
may cause brittleness on the polymeric mixture.   
5.4.6 Mechanical analysis  
 
Figure 5.8: Mechanical strength of PEG/PLA filaments compared with pure PLA 
filament and commercial PLA filament measured using tensile testing. 
Tensile testing was carried out to determine the mechanical strength of the filaments. The 
strength of the extruded PEG/PLA filaments and pure PLA filament were being compared 
to a commercially available PLA filament. The results from the tensile testing were 
presented in different strength measurements including yield strength, ultimate tensile 
strength (UTS), Young’s modulus and rupture strain/elongation at break as shown in 
Figure 5.8. Yield strength represents the minimum stress under which the material 
deforms permanently (i.e. the stress at which the material stops behaving elastically is 
called the yield strength). This is the highest point where the strain increases 
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can withstand while being stretched beyond the yield strength before breaking. Young’s 
modulus measures the stiffness of the material. It describes the elastic properties of the 
filament undergoing tension in one direction. This can be obtained by calculating the 
gradient below the point of yield strength, in which the material stretches elastically and 
the distance being stretched increases proportionally to the force applied. The rupture 
strain, which can also be called elongation at break, showed how much the material has 
been extended before it breaks. This can be calculated using the equation:  
Change in length
Original length
×  100 = Strain(%) (Equation 5.1) 
The strength values for the tested filaments were shown in Table 5.5. The results showed 
that tensile strength, elongation/strain and young’s modulus decrease as the concentration 
of PEG increases in the PEG/PLA filaments. This could be because the filaments with a 
higher concentration of PEG has reached the PEG saturation in the polymer matrix. When 
PEG in PLA reaches its saturation point, the PEG/PLA blend may become brittle due to 
phase separation [597]. This finding was consistent with results from XRPD in Figure 
5.7, where the crystallinity of the PEG/PLA blend increased as the concentration of PEG 
increased. Hence, the strength of the filaments decreased. However, the strain values 
showed than the twin-screw extruded PEG/PLA filaments have far more superior 
elongation capabilities than the pure PLA and commercial PLA filament. The superior 
elastic properties of the twin-screw extruded filaments as compared to the commercial 
PLA filaments reflects the plasticising effect of the PEG in the PLA polymer. 
Nevertheless, the plasticising effect of PEG in PLA can be seen and the strength was 
comparable with the commercial PLA filament.  
Table 5.5: Values for the mechanical strength of PEG/PLA filaments, pure PLA 
















PF10 393.2 ± 66.6 396.3 ± 68.1 155.4 ± 37.2 377.6 ± 31.0 
PF20 174.0 ± 24.8 357.5 ± 39.1 47.2 ± 14.2 362.8 ± 63.0 
PF30 50.9 ± 7.5 242.6 ± 26.8 16.5 ± 1.91 342.9 ± 30.5 
Pure PLA 437.3 ± 80.8 498.3 ± 21.6 173.9 ± 71.1 27.9 ± 0.8 
Commercial 
PLA 







Twin-screw extrusion is a very versatile technique and is preferred when different 
polymeric materials are mixed together. In this study, the properties of PLA was enhanced 
by blending it with PEG as a plasticiser using the twin-screw extrusion technique. The 
effect of PEG in PEG/PLA blends was more evident when using twin-screw extrusion as 
compared to single-screw extrusion in Chapter 4. This has suggested that twin-screw 
extrusion provides better mixing as it provides more control over the temperature of the 
extruder and provides more intimate mixing through the shearing that occurs between the 
materials and the twin-screw. As the twin-screw extruder was not able to process PLA 
pellets due to their size, the PEG/PLA blends were required to be pre-processed into films 
through the solvent casting method. The films were then ground into smaller particles so 
that they can be fed into the twin-screw extruder. The presence of PEG has lowered the 
Tg and Tm of the PEG/PLA blends. The plasticising effect of PEG can also be confirmed 
through the FTIR analysis and mechanical testing. Although the yield strength of the 
PEG/PLA filaments were not as strong as the commercially available filament, the 
elongation of the PEG/PLA filaments were at least 5 times better than the pure PLA 
filaments and 50 times better than the commercial filaments. This is because PLA has 
very low ductility and high brittleness at room temperature. The presence of PEG can 
impart elasticity and allows the filaments undergo more plastic deformation. The 
improved mechanical properties can be particularly useful for biomedical applications, 
where such blends can be used as an implantable drug delivery device, sutures, skin 






Chapter 6 : Development and optimisation of novel polymeric 
compositions for sustained-released theophylline tablets 
via HME and FDM 3D printing 
6.1 Introduction 
Since the discovery of additive manufacturing, many industries have been able to adopt 
this technology due to the benefits it could bring. One of the most attractive features of 
3D printing is its ability to produce objects of any shape in a cost-effective way at any 
time [598]. For this reason, 3D printing has a large potential in the use of pharmaceutical 
and biomedical applications. Due to the current rise in the development of personalised 
medicines, there is a need for a cost-effective method to produce these patient-tailored 
medicines in a short time frame after diagnosis [599]. In theory, 3D printing should be 
able to produce these medicines, in particular the solid dosage forms that are adjusted 
according to the patient’s need [600]. The use of 3D printing in producing medicines also 
allows hospital and pharmacies to manufacture the medications to patients immediately 
after the consultation. This is particularly beneficial for hospitals in remote areas so that 
they can supply their own patients with medications.  
Since the U.S. Food and Drug Administration (FDA) approval of the first 3D printed 
drug, Spritram®, there has been plenty of research involves 3D printing for various types 
of drug delivery systems [71,158,601]. The most easily accessible and low-cost 3D 
printing is Fused Deposition Modelling (FDM). There has been much research on the 
polymeric filaments for FDM 3D printers that can be used in biomedical application. This 
is because there is still a lack of pharmaceutical grade filaments currently available in the 
market. Apart from that, there are no commercially available drug-loaded filaments [602]. 
In this study, Active Pharmaceutical Ingredient (API)-loaded pharmaceutical grade 
filament has been produced using HME. HME is a well-established technique that has 
been used for pharmaceutical applications [99,100,104,120]. Many studies have also 
proven that using HME to produce API-loaded filaments that can be used for FDM 3D 
printing is feasible [98,603–605]. However, the main concern of the filaments produce is 
mechanical resilience, which is a main factor that determines its printability. During FDM 
3D printing, the filament is being fed into the heated nozzle head for the melting of the 
filament through a motorised gear. The gear exerts stress and strain onto the filament 





that it does not break during the 3D printing process. It should also have enough plasticity 
so that it can withstand the stress exerted transversely. The mechanical resilience of the 
filament is largely dependent on the type of polymers that are being used as a drug carrier.  
This study was carried out to analyse the feasibility of combining HME and FDM 3D 
printing in order to achieve a cost-effective fabrication platform for a patient-tailored 
drug delivery system. A type of biocompatible filament has been produced by mixing 
several pharmaceutical grade polymers and an active pharmaceutical ingredient (API). 
The polymers are Hydroxypropyl Cellulose (HPC), Eudragit® RL PO and Polyethylene 
Glycol (PEG). The model drug loaded is theophylline. Different ratios of the mixture 
were used for the extrusion for the optimization of filament composition. The properties 
and the printability of the extruded filaments were being studied. The filament produced 
need to have good flexibility and ductility so that it can be fed into the printing head of 
the FDM 3D printer. HPC is a derivative of cellulose and is a type of thermoplastic with 
high amorphous content. As a result, it has high molecular mobility and plasticity [606]. 
Due to its physical properties, HPC has been chosen to be made into FDM printable 
filament. HPC has been widely used in the pharmaceutical industry as a tablet binder, 
thickening agent, viscosity increasing agent and coating agent [606]. A study carried out 
by Sarode et.al shows that HPC can be used to produce chemically stable solid 
dispersions of poorly and highly water soluble drugs [607]. The polymer HPC has been 
used effectively to form amorphous solid dispersions containing crystalline drug, which 
has resulted in improved dissolution and also making the drug sustained release. 
However, HPC is highly hygroscopic and has the tendency to absorb moisture from the 
atmosphere. Eudragit® RL PO is an amorphous polymer and is an ammonio methacrylate 
copolymer type A. It has been used for sustained release products [608]. It is highly 
permeable to water but not water soluble. According to the Heckel analysis by Dave et 
al., the deformation behaviour of Eudragit® RL PO is similar to a typical plastic material 
[609]. A study carried out by (Kotiyan 2001) shows that Eudragit® RL PO can be used to 
prevent crystallisation [610].  PEG is a semi-crystalline polymer that has been used in a 
wide variety of pharmaceutical formulations for controlled release systems. It is 
biodegradable, stable and hydrophilic. Its hydrophilicity can improve aqueous solubility 
and bioavailability of solid dispersion. PEG can also impart plasticity into the polymer 
matrix [606]. By adding Eudragit and PEG into the formulation, the plasticity and the 





from that, the use of higher molecular weight PEG is less hygroscopic, which could bring 
stability to the formulations [531]. The model drug, theophylline, is an odourless white 
crystalline powder with a bitter taste. Theophylline is chosen as it has a high melting 
point of 273°C, which appears as an ideal candidate to withstand thermal processing. Due 
to its thermal stability at high temperature, it is suitable to be used both in HME and FDM 
3D printing. However, theophylline is only slightly soluble in water and alcohol. Due to 
the advantages of HPC and PEG in solid dispersions, these polymers were chosen. HME 
is a technology that can create a solid dispersion effectively [117,133,611]. The shear 
mixing and kneading during the extrusion process allows homogeneous mixing of the 
polymers and the drug as the drug is molecularly dispersed in the polymer matrix. Such 
formulation is known as solid dispersion and the solid dispersion is known to be able to 
improve the solubility of a drug with poor solubility [583]. 
Therefore the aim of this study was to develop and optimise various novel polymeric 
compositions for FDM 3D printing of sustained-release drug delivery systems by means 
twin-screw extruder. The printability of the filaments was assessed thoroughly for 
outlining the scope 3D printing a tablet out of these filaments. The mechano-chemical 
properties as well as In-vitro drug release of the filaments and the 3D printed tablets were 
studied. The release mechanism of the 3D printed tablets was determined using 
mathematical kinetic models such as zero-order, first-order, Higuchi, and Korsmeyer-
Peppas models. Studies have shown that different 3D printing settings can have an effect 
on the release kinetics and mechanisms of a 3D printed tablet [79,612,613]. The 
biocompatibility of the filaments produced was also studied via cell studies.  
6.2 Materials 
Nisso Hydroxy Propyl Cellulose (HPC) (Grade SSL) from Nippon Soda Co., LTD. 
(Tokyo, Japan) was used. Eudragit® RL PO powder used was from Evonik Industries 
(Darmstadt, Germany). Poly (ethylene glycol), average M.W. 6000 was purchased from 
Fisher Scientific (Loughborough, UK). Theophylline 99+% anhydrous purchased from 
Fisher Scientific (Loughborough, UK) was used as a model drug. All materials were used 
as received. 
6.3 Experimental Methods 
HPC powder, Eudragit® RL PO powder, PEG, and model drug theophylline were used 





bottle and further mixing was carried out using a Turbula shaker mixer, Eskens (Alphen 
aan den Rijn, Netherlands) for 15 mins. The ratio of the (HPC : Eudragit : PEG : 
theophylline) used to make into filaments were shown in  Table 6.1. The mixed powder 
was then produced into filaments using a table-top custom-built L/D 10 twin-screw 
extruder by Twin Tech Extrusion Limited (Stoke-on-Trent, UK), assembled by 
Point1Controls/R Controls (Stoke-on-Trent, UK). The extruding temperature for the 4 
zones (Z1 : Z2 : Z3 : Z4) were (70 C : 100 C : 110 C : 110 C) and the die was set to 
110C. The heat soak time of the extruder was set to 5 minutes. The extruding hole on 
the die has a diameter of 2.0 mm and the extrusion speed was set to 60 rpm. A standalone 
filament winder was used to collect the filaments extruded. A Vernier calliper was used 
to measure the diameter of the filaments and only filaments with a diameter of 1.75 mm 
were used for 3D printing as the size of the 3D printing nozzle can only fit filaments with 
diameter below 1.75 mm.  
Table 6.1: The different ratios of (HPC : Eudragit : PEG : Theophylline) used for the 
fabrication of different filaments. 
Formulation No. Ratio of 
(HPC : Eudragit : PEG : Theophylline) 
F1 0 : 8 : 1 : 1 
F2 2 : 6 : 1 : 1 
F3 4 : 4 : 1 : 1 
F4 5 : 3 : 1 : 1 
F5 6 : 2 : 1 : 1 
F6 7 : 1 : 1 : 1 
6.3.1 Design and Fabrication of Tablet 
The extruded filaments were printed into tablets using the Makerbot Replicator 2X 
(Makerbot Inc., NY, USA). The CAD model of the tablet was designed using Solidworks 
(Dassault Systemes, Waltham, MA, USA). Figure 6.1 shows a computer-generated 3D 
model of the tablet used for 3D printing. The 3D model was then saved as an .STL file 
and imported to Makerbot Desktop software (Makerbot Inc., NY, USA) for slicing. The 
tablet has a height of 5 mm, width of 10 mm and length of 20 mm. The layer height for 
printing was set to 0.15mm. A printing temperature of 195°C and bed temperature of 






Figure 6.1: 3D CAD model of tablet for 3D Printing 
6.3.2 Analysis of the Filament and 3D Printed Tablet 
6.3.2.1 Differential Scanning Calorimetry (DSC) 
A DSC 4000 system (Perkin Elmer, Waltham, MA, USA) was used to study the glass 
transition temperature and the melting temperature of all the filaments. The samples used 
were about 5mg. The samples were placed in an aluminium pan, and an empty aluminium 
pan was used as a reference. Nitrogen gas was used as the purged gas at a flow rate of 20 
mL/min in all the DSC experiments. The data were collected and analysed with Pyris 
software (Perkin Elmer, Waltham, MA, USA).  
6.3.2.2 Thermogravimetric analysis (TGA) 
TGA was carried out using a Q40 Thermogravimetric analyser (TA Instruments, New 
Castle, DE, US) to obtain the degradation profile of the PEG/PLA blends. The samples 
used were about 10mg and were placed in an open aluminium pan. The furnace was then 
heated from 30 °C to 550 °C at a rate of 10 °C /min. Nitrogen gas was used as purge gas 
at a flow rate of 20mL/min. Data were collected and analysed using the 
Advantage/Universal Analysis Software (TA Instruments). 
6.3.2.3 X-ray Powder Diffraction  
The crystallinity of the powder mixture, each individual powder, filament and 3D printed 
tablet were assessed using a Siemens D500 X-ray Diffractometer (Siemens, Germany). 
The samples were scanned between 2 Theta ()=5 to 50 using 0.01 step width and 1s 
time count. The divergence slit was 1mm and the scatter slit was 0.6mm. The X-ray 
wavelength was 0.154 nm in Cu source and at a voltage of 40 kV. 
6.3.2.4 Mechanical Testing (Texture Analyser) 
Tensile testing and three-point bending test were carried out on the filaments using 





50 kg was used and a tensile grip probe set was used to measure the tensile strength of 
the filaments. For each filament formulations, five 10 cm filament samples were cut from 
the batch for mechanical testing. The test was set up as a tension test with a maximum 
applied force of 50 kg. The test was stopped as soon as the filament breaks. For the three-
point bending test, a 3D printed custom made three-point bend probe tool was attached 
to the tensile grip. The filaments were securely taped onto a tester platform with a 25-mm 
gap. The data were collected and analysed using the Exponent Software version 7.0.3.0 
(Stable Micro Systems, Godalming, UK). 
6.3.2.5 Scanning Electron Microscope (SEM) 
SEM was carried out using the JEOL JMS 820 (Freising, Munich, Germany) to study the 
morphology of the filaments and the printed samples. The samples were sputter-coated 
with gold under vacuum conditions using the Edwards S-150 sputter coater (Edwards 
High Vacuum Co. International, Albany, NY, US) for electrical conductivity. The 
accelerating voltage was at 3 kV at various magnifications.  
6.3.2.6 Biocompatibility Study 
Cell studies were carried out on the powder mixture and the filaments to ensure their 
biocompatibility. Retinal Pigment Epithelium (RPE) cells were used and the cells were 
seeded at a density of 4 x 104 on the first day. The number of cells was counted again on 
the second day and fifth day after seeding and treated with the powder mixture and 
filaments. 
6.3.2.7 In-vitro Drug Release Study 
In-vitro dissolution test was carried out on three randomly selected tablets from each 
batch for 3D printed tablets for drug release study. The mass of the samples was first 
weighed before dissolution and then weighed again after the dissolution test when the 
samples were dried. The dissolution parameters were chosen according to the US 
Pharmacopeia (USP) 36 monograph ‘Theophylline Extended-Release Capsules Test 6’. 
Determination of the In-Vitro drug release was performed using USP type I dissolution 
apparatus (708-DS Dissolution Apparatus, Agilent Technologies, Santa Clara, CA, USA) 
in 1000mL of 0.05M phosphate buffer solution (pH 6.6) at 37±0.3 °C with a rotation 
speed of 100 rpm. The drug concentration of the dissolution medium was measured using 
a Cary 60 UV-Vis Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA) at 
a wavelength of 271 nm in a 2 mm cell versus a blank solution consisting of a phosphate 





pump (Agilent Technologies, Santa Clara, CA, USA) and sampling was done every 5 
min for the first hour, every 20 min of the following 2 hours and every 60 min for the last 
10 hours. The release profiles were plotted as a percentage of cumulative drug release 
versus time. 
6.3.2.8 Statistical Analysis 
Statistical analysis was carried out on the 3D printed tablets to study the differences in 
the 3D printed tablets due to the difference in formulation composition. The mass of all 
tablets used for dissolution studies were measured before and after the dissolution studies 
in dry conditions. One-way ANOVA test, followed by a post-hoc Tukey HSD test was 
use for the analysis on the change in mass on all tablets for all formulations.  
The dissolution data for all tablet formulations were also compared using model 
independent approaches (difference factor (f1) and similarity factor (f2)) to show whether 
the dissolution patterns of each formulation are different from each other.  
6.4 Results and discussion 
6.4.1 Thermal Analysis 
DSC is a highly sensitive technique to study the thermal transition as a function of heating 
of materials. In the HME process, the powder mixture was thermally stressed. It has been 
proven that the API used, theophylline, has good thermal stability and can be processed 
using HME [153,602,614]. However, DSC measurements have been carried out on the 
pure substances, the powder mixture, the extrudates and the 3D printed products to ensure 







Figure 6.2: DSC measurements for the pure substances used as powder blend for 
producing the filaments. The powders are Hydroxypropyl cellulose (HPC), Eudragit® 
RL PO powder, Polyethylene glycol (PEG) 6000, and anhydrous theophylline 99+%. 
Figure 6.2 shows the DSC measurements for each individual powder before mixing. The 
study shows that HPC and Eudragit® RL PO have high amorphous content as the DSC 
curves for both materials do not show obvious endothermic events. However, amorphous 
materials were expected to show an endothermic slope which represents the glass 
transition temperature (Tg). The Tg is the temperature when the molecules in the material 
starts to transition from a glassy state to a soft, rubbery state [615]. This is the temperature 
when the materials soften. According to the technical data sheet of the HPC Grade SSL 
from the manufacturer, it exhibits two softening temperature, one at 75 C and the second 
at 183 C [616]. From the DSC curve, the Tg of HPC was found to be around 76 C. The 
dip before the slope of the glass transition could be caused by the plasticising effect due 
to the presence of moisture in the HPC polymer. The Tg for Eudragit was around 66 C 
which is similar to the literature [617,618]. PEG is a semi-crystalline polymer and the 
DSC showed a melting peak at around 67°C. The calculated heat enthalpy value (H) of 
PEG is approximately 252.7 J/g. Theophylline is a crystalline drug and has a sharp 
endothermic peak, which is the melting point at around 273 °C. The DSC result of 
theophylline shows that the H value of theophylline is around 68.14 J/g. This shows that 

























theophylline would be a suitable model drug for HME and FDM 3D printing processes 
as these processes require high temperature.  
  
Figure 6.3: DSC Results obtained for Powder Mixture, HME Extruded Filaments and 
FDM 3D Printed Tablet. 
The DSC curve for the powder mixture in Figure 6.3 mimics the temperature cycle of the 
powder mixture went through during the extrusion process and the printing process. This 
is to ensure the thermal stability of the powder mixture as it is required to go through 
processes of high temperature. The powder mixture of HPC, Eudragit, PEG and 
theophylline was placed in the sample pan for heating. However, the results obtained only 
reflect the thermal process experienced by the powder. In the process of extrusion, the 
mixture underwent kneading and shear mixing which is not reflected in the DSC result. 
The extrusion process was carried out at a maximum temperature of 110 °C. The extruded 
filament was then being fed into a hot printing head at a temperature of 195 C. Therefore, 
the heating of the powder mixture in the DSC study was carried out up to 200 °C. The 
DSC curve only showed a small endothermic step at around 60 C for the heating of the 
powder mixture. This could be the Tg of HPC and Eudragit
® RL PO. The DSC curve in 
Figure 6.2, which shows the DSC results of the individual components shows that HPC 
and Eudragit have a very similar Tg. The endothermic peak at around 62 °C, following 
the small step that occurred before, could be the melting point of PEG on the powder 
mixture. As the Tg of HPC and Eudragit are very close to the Tm of PEG, the DSC curve 
showed just on the endothermic peak that coincides with each other when these materials 
are all physically mixed to form a powder mixture.  


























The DSC curves in Figure 6.3 also contain the DSC study for the HME produced 
theophylline-loaded filament. As shown in the DSC results from Figure 6.2, HPC and 
Eudragit have very high amorphous content with a low Tg (around 56 C and 63 °C 
respectively). PEG is a semi-crystalline polymer with a melting point of around 68 °C. 
The model drug, theophylline, is an odourless white crystalline powder with a bitter taste, 
and has a melting point of 273 C. From the DSC results for the filament, we can see that 
the peaks for the PEG and theophylline melting points have been depressed. There were 
no obvious endothermic peaks on the DSC curve due to the lack of crystallinity in the 
filament. This has proven that the theophylline has been molecularly dispersed into the 
polymer matrix, making it amorphous through the process of twin-screw extrusion. It has 
also been reported that HPC can effectively convert the crystalline drug to amorphous 
form, which is also shown in the DSC results obtained. The DSC results for the filament 
showed a very small step change at around 160 °C, which could be the Tg of the new 
amorphous filament. This means that the filament could be softened above this 
temperature. DSC was also carried out on the FDM 3D printed tablet. The results show 
that the tablet contains amorphous content as there was no occurrence of endothermic 
peaks during the heating cycle. There is a small step change at around 170°C which could 
be the Tg of the 3D printed tablet. The high temperature of 3D printing could have slightly 
shifted the Tg of the tablet from the filament. Similar to the filament, the melting point of 
the theophylline could not be seen, which further confirmed that the process of HME has 
converted the crystalline theophylline to amorphous. The DSC study shows that the 
mixture is thermally stable to be used for HME to be extruded into filament at 110 °C, 
and the filaments produced are suitable for FDM 3D printing at a temperature of 195 °C. 







Figure 6.4: DSC analysis for theophylline-loaded filament with 2 heating cycles.  
The DSC results in Figure 6.4 shows the measurement for the extruded theophylline-
loaded filament on 2 heating cycles. The first heating cycle was carried out up to 200 C, 
then a cooling cycle down to 0 C, finally the 2nd heating of up to 300 C. It has been 
recommended that 2 heating cycles can be carried out during a DSC analysis for materials 
consisting a mixture of different materials to remove any possible artefacts and any 
thermal history on the results in order to obtain a better representation of the thermal 
properties of the newly formed material [619]. The first endothermic peak (around 60 C) 
seen on the first heating cycle could be caused by the presence of a volatile substance or 
a plasticiser. This is because, during the second heating cycle, this endothermic peak 
disappears from the curve. This could be explained by the presence of moisture in the 
filament that is absorbed from the environment. The presence of water in the filament 
caused a plasticizing effect on the polymer mixture, causing the polymer to show an 
endothermic event when being heated. The water in the filament has been evaporated 
during the first heating cycle, hence the endothermic does not happen again on the second 
heating cycle. The Tg of the filament is around 160 C in the first heating cycle, and the 
step change is very small. A small endothermic peak occurred after the Tg of the filament. 
This could be an artefact that is caused by the relaxation of the molecules at the glass 
transition. This is because the molecules go from a rigid to a flexible structure and stress 




































there are no endothermic peaks, showing that the filament is amorphous. This can prove 
that the HME is effective in producing amorphous material through the shearing and 
mixing by the co-rotating screws. 
TGA was used to study the degradation profile of each of the individual component used 
in for the formulations, the powder mixture of the formulation, the extruded theophylline-
loaded filament, and the 3D printed tablet (Figure 6.5). The temperature when 10% of the 
sample degraded (t90), 50% of the sample degraded (t50), and 90% of the sample degraded 
(t10) were extracted from the TGA curves and were tabulated in Table 6.2. The TGA 
results confirmed that the individual components and the mixture only start to degrade at 
a temperature of at least above 260 °C. This result suggests that the drug and the polymer 
mixture would not degrade during the HME process and the 3D printing process as the 
operating temperature of both processes were well below the temperature when the 
material starts to degrade. The TGA on the filament and 3D printed tablet also further 
confirmed that the processes did not degrade the materials. Despite the shearing provided 
during the HME process, the extruded theophylline-loaded filaments still maintain great 
thermal stability as the torque applied during the process was relatively low 
(approximately 5 Nm). 
 
Figure 6.5: Thermal degradation profiles for individual materials, powder mixture, 




































Table 6.2: Temperatures at three degradation points (90%, 50%, 10% wt. remaining) for 
each individual component, powder mixture, extruded filament and 3D printed tablet. 
Temperature at weight % t90 (°C) t50 (°C) t10 (°C) 
HPC 269.9 363.3 - 
Eudragit  351.7 386.7 415.8 
PEG 338.3 406.7 427.8 
Theophylline 306.4 343.6 366.7 
Powder Mixture 270.8 357.7 396.9 
Extruded filament 243.2 349.8 388.2 
3D Printed Tablet 291.4 366.0 468.8 
6.4.2 X-Ray Powder Diffraction (XRPD) 
 
Figure 6.6: XRPD results for all individual powders, powder mixture, filament and 3D 
printed tablet. 
XRPD has always been used for qualitative analysis to determine the crystallinity of a 
material. XRPD study has been carried out on all the individual bulk powders, the powder 
mixture, the extruded filament and the 3D printed tablet. The results from the XRPD is 
shown in the figure above (Figure 6.6). The scans from theophylline and PEG show 
obvious crystalline peaks, which means these two materials have high crystallinity in their 
bulk powder forms. The diffractograms for HPC and Eudragit® RL PO confirm that these 
two powders are highly amorphous reflected by no obvious peaks. The powder blend 
shows some crystallinity as expected as the powders were only physically mixed together 
at room temperature. The crystallinity in the powder mixture was due to the presence of 
crystalline theophylline and PEG. As the powders were physically mixed, there is not 
much reaction between the powders which could highly affect the crystallinity of the 
mixture. However, the crystallinity is slightly lower in the powder mixture than the pure 
theophylline and PEG individually. This is expected due to the presence of amorphous 
polymers (Eudragit and HPC) in the formulations. As for the theophylline-loaded 

























filament, the result shows that the filament is highly amorphous with a very small amount 
of crystallinity as the crystallinity peaks are very small. A quite similar phenomenon was 
observed on the 3D printed tablets. The peaks that can be seen on the PEG and 
theophylline are not obvious in the 3D printed tablet. This has proven that the process of 
twin-screw extrusion has successfully converted the crystalline theophylline into 
amorphous form by molecular dispersion of the drug molecules into the polymer matrix. 
These results are in line with the studies from the DSC of filament and 3D printed tablets 
which further confirms that the model drug, theophylline, has been converted to its 
amorphous forms as a function of being molecularly dispersed into the polymer matrix. 
6.4.3 Mechanical properties 
The mechanical strength of the extruded filament is very important as the FDM printing 
process exerts a considerable amount of force onto the filament. The filaments must have 
the right balance between ductility and stiffness for them to the printable. In an FDM 3D 
printing process, a gear is used to feed the filament into the printing head. The gear exerts 
shearing and tensile stresses onto the filament. Therefore, the filament must be ductile 
and strong enough to withstand the transversally applied pressure. Tensile testing and 3-
point bending test were carried out to determine the mechanical resilience of the extruded 
filaments. Using the results obtained from the tensile testing, the strength of the filaments 
can be calculated through the stress-strain curve. The strength of the filaments was 
presented in four aspects: yield strength, ultimate tensile strength, Young’s modulus and 
elongation at break. Yield strength is the minimum stress under which the material 
deforms permanently (i.e. the stress at which the material stops behaving elastically is 
called the yield strength). This is the highest point where the strain increases 
proportionally with stress. Ultimate tensile strength is the maximum stress that a material 
can withstand while being stretched before breaking. Young’s modulus measures the 
stiffness of the material. It describes the elastic properties of the filament undergoing 
tension in one direction. This can be obtained by calculating the gradient of the 
proportional section on a stress-strain curve. The elongation at break is the percentage of 
filament sample that can be stretched without breaking and this value can be calculated 
using the change of length over the original length of the sample. This is also presented 
as a strain values in Figure 6.7. Figure 6.7 shows the results from the tensile testing for 
the filaments, displaying the stress and strain values. The results for the yield strength, 





The study shows that F1 and F2 have two of the highest strain values amongst all the 
filaments.  F1 has the highest strain, which means it can be stretched the most before 
failing. This could be due to the high percentage of Eudragit in the filament as Eudragit 
induces high flexibility and plasticity. As the percentage of HPC increases in the filament, 
formulation, the strain values of the filaments decrease. From the chart in Figure 6.7, F1 
has the highest stress values, which means it can withstand the most force. There seems 
to be no linear pattern on the stress values as the composition of the polymers change. 
The stress values showed are actually the yield strength of the filaments. The stress values 
only mean that was the maximum stress before the plastic deformation of the filaments. 
It seems that both Eudragit and HPC can impart elasticity when only one of itself is at 
high concentration. When both are mixed at a ratio closer to 1, the strength decreases. 
However, the stress that the filament can withstand is already sufficient for FDM 3D 
printing as all filaments have been successfully used for printing. The result from tensile 
testing can only be used as a reference as it only represents the uniaxial force that the 
filaments can withstand. The values of stress for the filaments, although can be used to 
represent the actual stiffness of the filaments, is often the ratio of force to the cross-
sectional area of the filament. The amount of stress applied when the filament breaks was 
considered the maximum ‘load’ and the distance when it breaks was considered as 
‘deformation’. In most cases, the filaments manufactured do not have homogeneous 
diameters due to the processing parameters during the HME process (eg. feeding rate, 
rotating speed of the standalone filament winder). The values obtained in Figure 6.7 and 







Figure 6.7: Stress-strain values from the tensile testing of all theophylline-loaded 
filaments. 












F1 192.2 ± 9.7 216.7 ± 2.6 46.0 ± 5.3 58.7 ± 15.1 
F2 155.7 ± 6.6 188.3 ± 2.5 46.0 ± 6.6 48.4 ± 0.7 
F3  125.7 ± 13.8 139.6 ± 17.5 47.0 ± 5.3 14.6 ± 3.7 
F4  83.0 ± 27.5 105.0 ± 28.9 30.1 ± 6.9 11.0 ± 3.0 
F5 89.1 ± 9.0 109.4 ± 6.7 30.3 ± 2.1 9.3 ± 1.1 
F6 184.1 ± 16.3 200.0 ± 10.9 55.0 ± 2.6 11.0 ± 2.5 
A 3-point bending test was carried out to measure the flexural strength of the filaments. 
The setup of this test means it is suitable to be used to assess the breaking force, breaking 
distance and the rupture strain of the filament. During the printing process, the filament 
is pushed by a rotating gear in which the force exerted can be replicated through a 3-point 
bending test. The stress and rupture strain values were extracted from the 3-point bending 
tests and results were shown in Figure 6.8 and Table 6.4. The test showed that filament 
F1 has the highest stress and strain values. As the percentage of HPC increases in the 
filament, the strength of the filament seems to decrease. This is due to the semi-crystalline 
properties of HPC, causing HPC to be brittle at room temperature. The presence of 
Eudragit improves the flexibility and plasticity of the filament. Despite the decreasing 
strength of the filaments as the concentration of Eudragit decreases, the filaments are still 
suitable to be used to FDM 3D printing as the filaments can still withstand the forces 








































Figure 6.8: Stress and strain values of the extruded filaments obtained from 3-point 
bending test. 
 
Table 6.4: Force, distance, stress and strain values extracted from 3-point bending tests 
for all filaments. 
Formulation No. Force (g) Distance (mm) Stress (MPa) Strain (%) 
F1 5008.80 ± 216.27 10.63 ± 2.5e-15 390.88 ± 16.91 20.42 ± 5e-15 
F2 2867.84 ± 395.07 9.51 ± 3.1e-15 390.042 ± 33.22 15.52 ± 1.39e-14 
F3 1620.33 ± 251.31 8.051 ± 2.43 139.12 ± 8.55 12.34 ± 0.37 
F4 1275.54 ± 124.62 5.43 ± 0.77 147.891 ± 14.31 10.30 ± 1.8e-15 
F5 1170.42 ± 91.55 4.01 ± 0.12 61.39 ± 1.42 8.89 ± 1.3e-15 
F6 1067.90 ± 106.98 3.12 ± 0.44 78.26 ± 24.77 6.96 ± 0.30 
6.4.4 3D Printing  
 
Figure 6.9: 3D printed tablet from the filament F2 a) top view b) side view. 
The theophylline-loaded filaments were used to 3D print into tablets using a Makerbot 
Replicator 2X FDM 3D printer. The temperature of printing was 195°C, which is very 








































filament not being as strong as the commercial filaments available, as proven from the 
tensile testing, the filament can still withstand the shear forces and stress experienced 
through the extruder of the FDM 3D printer. The printing of a tablet took approximately 
10 minutes including the heating up of the printing nozzle and printing bed. Once the 
printer is heated up, the printing time required for one tablet is only 5 minutes. Figure 6.9 
shows an example of a 3D printed tablet produced using the filament of formulation F2. 
All six filaments were printable. All filaments apart from filament F6 can produce good 
quality 3D printed tablets. The quality of tablets F6 was unacceptable (see Figure 6.10). 
The quality was assessed by visual inspection of the shape and the surface finish of the 
printed tablet. The quality of printing was also assessed by the difficulty in removing the 
printed tablet from the printing bed after printing without damaging the tablet. Tablets 
printed from F1-F5 filaments can be removed easily and cleanly from the printing bed. 
They also have a smooth surface finish. F5 tablets were printable and the quality was 
considered acceptable. The surface finish was not as smooth and the tablets were more 
brittle, causing some difficulties in being removed from the printing bed (Figure 6.10). 
However, the F5 tablets can still be removed from the bed cleanly without damaging it 
with extra care and attention. F6 printed tablets also had good adhesion to the printing 
bed, causing it difficult to be removed. When being removed, there were some bits that 
were still adhered to the bed which makes the shape of the tablet to be altered. There was 
no way to remove the tablets cleanly from the printing bed without damaging it. The 
surface finish was not as good as the others. Apart from that, the F4 printed tablets were 
brittle. Some parts of the tablet can be easily damaged when removing because of their 
brittleness. This is not ideal particularly for the fabrication of tablet as the consistency of 
each tablet will be affected. The high content of HPC in F5 and F6 could have contributed 
to its brittleness. To achieve a good quality print, the filament needs to have enough 
plasticity and smoothness which is provided by the presence of Eudragit. The higher the 
content of Eudragit, the higher the plasticity and flexibility of the filament. However, the 
plasticity of the filament cannot be too high as it may lose its ductility which is needed to 
withstand the forces exerted onto the filaments during printing. The filament that has too 
much plasticity could be easily deformed which could be an issue during the feeding 
process of FDM 3D printing. This is because the teeth of the gear may leave an imprint 
on the filament and change the shape of the filament, which is shown in Figure 6.11. 
Filament that has high flexibility is also difficult to keep its shape and remain straight, 





plasticity allows smoother surface finish as the melted filament has a higher viscosity, 
making the extrusion during 3D printing easier. The printability of all four filaments was 
shown in Table 6.5 
 
Figure 6.10:  Quality comparison of good and poor quality 3D printed tablets a) F2 
tablet on the left (good quality), F6 tablet on the right (poor quality) b) zoom in image 
of a, c) remnant of F6 tablet stuck on the printing bed after tablet has been removed. 
Table 6.5: FDM printability and quality of all six theophylline-loaded filaments. 




Printable & Good Quality 
Printable & Good Quality 
Printable & Good Quality 
F4 Printable & Good Quality 
F5 Printable, Acceptable Quality 
F6 Printable, Poor Surface Finish 
Extra attention is required for the storage condition of the filament extruded. This is 
because the filament can absorb moisture from the environment more easily than PLA 
filaments. Although it was reported that the use of higher molecular weight PEG in a 
formulation can be less hygroscopic, HPC typically has high affinity to water molecules 
[531]. If the filament is left in the air for a long period of time, the filament will turn 
brittle due to the absorption of moisture. A brittle filament will fail at the gear during the 
feeding of the filament into the printing nozzle. The brittle filament will be crushed by 
the force exerted by the feeding gear. Therefore, it is recommended that the filament 
should be used immediately for printing after being produced using the twin-screw 
extruder. Otherwise, the filament needs to be stored in a dry environment to preserve and 
prolong the life of the filament. The filaments can be kept in a desiccator or in a sealed 






Figure 6.11: Failed filament during FDM 3D printing a) top view b) side view. 
6.4.5 Scanning Electron Microscopy (SEM) 
 
Figure 6.12: SEM images of the powder mixture use for the extrusion of filaments (a-c) 
and theophylline (d-e) at different magnifications a) 100X b) 500X c) 500X d) 520X e) 
1000X. 
The SEM images shown in Figure 6.12 are the powder form of the materials used for the 
polymeric composition of the filament. Figure 6.12a-c showed the powder mixture at 
different magnifications before it was being extruded into filaments. The mixture 
contained HPC, Eudragit, PEG and theophylline. The SEM images showed that the 
powder mixture contained some crystallinity mixed with amorphicity. This is because 
some of the powder particles exist as solid crystalline and some do not have a definite 
shape. The amorphicity was due to the presence of HPC and Eudragit as both polymers 





6.12d & e showed the SEM images of theophylline powder, where they exist in crystalline 
shapes. The structure of the powder mixture reflects the results obtained from XRD.  
 
Figure 6.13: SEM images of theophylline-loaded filament (a-b) and 3D printed tablet 
(c-f). a) Surface morphology of filament at magnification of 30X (top view), b) cross-
section of filament at magnification of 100X, d) side-view of 3D printed tablet at 
magnification of 100X, e) side-view of 3D printed tablet at magnification of 250X, f) 
side-view of 3D printed tablet taken after dissolution at magnification of 100X. 
SEM images were also taken to study the morphology of the filament and the 3D printed 
tablets. The images of the filament surface and the filament cross-section were shown in 
Figure 6.13a-b. The SEM images showed that the filament has smooth surfaces and a 
very consistent round shape. There was no drug aggregation seen on the images which 
further confirms the twin-screw extrusion has successfully converted the theophylline 
crystals into amorphous form. SEM images of the 3D printed tablet were shown in Figure 
6.13(c-f). The SEM images clearly showed the multiple layers of the tablet that were laid 
down during the FDM 3D printing process. It can be seen from the images that the 
thickness of each layer is quite consistent. The thickness of each layer is 0.15 mm. This 
has proven that FDM 3D printing can achieve high precision and accuracy despite being 
a low-cost 3D printing technique. Due to the layering method of FDM 3D printing, there 
also exist some pores on the tablet as seen in Figure 6.13c. This is unavoidable even with 
the printing of 100% infill being set. Figure 6.13f shows the side-view of the 3D printed 





medium but retained its shape. The layering of materials was still present and 
distinguishable.  
6.4.6 In-vitro Drug Release Study 
 
Figure 6.14: Dissolution profiles for tablets from filament formulations F1-F5. 
After the development of theophylline-loaded filaments and the 3D printing of tablets, 
the drug loading of the filaments and the 3D printed tablets were determined. The samples 
were dissolved in ethanol and the drug concentration was measured using a Biochrom 
WPA Biowave II UV/Visible spectrophotometer (Biochrom Ltd., Cambourne, UK) at a 
wavelength of 271 nm. The percentage of theophylline in the filaments was 93.76%  
2.76 and the drug content in the tablets was 92.46%  5.73. This shows that there was no 
major degradation of the drug caused by thermal processing i.e. HME and the FDM 3D 
printing. Dissolution studies were carried out on the 3D printed tablets. The drug release 
profiles were shown in Figure 6.14. Only F1-F5 tablets were studied as the 3D printed 
tablet of F6 did not show good quality. F1 tablets show the slowest release profile, 
whereas F4 and F5 tablets have similar release profiles. Theophylline is generally a 
poorly water-soluble API. The particles of API were dispersed or dissolved into the 
polymer matrices to form solid dispersion during the HME process, which is also 
confirmed through results from DSC and XRPD. During the dissolution process, a steep 

















































contact with the dissolution medium. The steep concentration gradient allows the 
diffusion of theophylline from the tablet to the medium. There is no burst release at the 
beginning of the dissolution process, seen on the dissolution profiles in Figure 6.14. It is 
suggested that 3D printed tablets often have compact structure and high density which 
may restrict the drug release through diffusion [620]. 
The dissolution results showed that the time taken for theophylline to completely release 
in F1 tablets was around 10 hours. The drug release F4 and F5 tablets plateaued after 4 
hours. The drug release study shows that all formulations are suitable for the purpose of 
controlled release as release continued for over 5 hours. The higher the percentage of 
Eudragit, the slower the release of theophylline. All the tablets showed drug release of 
more than 80% within 14 hours. This confirms that there was no API or excipient 
degradation occurred during the HME and 3D printing process. The 3D printed tablet 
using such polymeric composition seems to be successful in producing a controlled-
release profile.  
 
Figure 6.15: Tablet change in size after drying after dissolution study. 
The tablets for all the formulations did not dissolve completely during the dissolution 
studies and the original shape of the tablet was retained. This is because Eudragit is not 
soluble in the dissolution medium used and it has managed to keep the shape of the tablet 
even after the drug has been completely released. Figure 6.15 above shows that the tablet 
size changed after the tablet was dried after dissolution. The size of the tablet did not 
change when the tablet was removed from the dissolution medium as the dissolution 
medium has been absorbed by the polymer that makes the tablet. The two polymers used 
(HPC and PEG) are soluble in water but only one polymer, Eudragit is not soluble. 
Eudragit is permeable to water, hence it is likely that Eudragit absorbed the dissolution 
medium. During the dissolution process, the HPC and PEG fully dissolved with the drug 
loaded. When the tablet was removed from the dissolution medium, the size and shape of 
the tablet were retained by the Eudragit. Once the medium absorbed by the Eudragit has 





were weighed before and after the dissolution studies for the comparison of the change in 
mass. The changes were shown in Table 6.6. There may some variations in the mass of 
the tablets. This is because 3D printed structures cannot be completely solid even with 
100% infill due to the method of fabrication and the resolution of printing. It will always 
incorporate small internal voids and pores in the printed structures. This causes mass 
deviations. A one-way ANOVA, followed by a post-hoc Tukey HSD test were carried 
out on the change in the mass of the tablets. The results from the statistical tests were 
shown in Table 6.7. The statistical studies showed that the p-value corresponding to the 
F-statistic of one-way ANOVA is much lower than 0.05, suggesting that one or more of 
the 3D printed formulations were significantly different from each other. To identify 
which pair of the formulations are significantly different from each other, the Tukey HSD 
test was then carried out. The results showed that all formulations of 3D printed tablets 
were also significantly different from each other when being compared in pairs. This has 
shown that the different percentage of polymers in the formulation have a significant 
effect in the dissolution of the 3D printed tablets, which causes the change in mass.  
Although all tablets experience a change in mass, they still retained their frame and shape 
after the drug release. This could be useful for the development of a medical implant.  
Figure 6.16 shows the cross-section of the tablet after and before the dissolution. The 
white colour of the tablet was due to the presence of theophylline and HPC. Once the 
drug has been released, the tablet becomes translucent. The image shows that the drug 
has been completely released. This study shows that such polymeric composition could 
be useful for the development of a medical implant. This type of formulation is 
particularly useful to be used as a medical implant for drug delivery or monitoring the 
condition of the body. This is because the insoluble part of the system can still hold the 







Figure 6.16: Cross-section image of tablet after (left) and before (right) dissolution. 





Mass Before Dissolution 
(mg) 












































































Table 6.7: One-way ANOVA results, followed by post-hoc Tukey HSD test results for 
the change in mass of dry tablets before and after dissolution from Table 6.6. 
ONE-WAY ANOVA 
 p-value (α = 0.05) Significant 
Change in mass of tablets after dissolution 2.1e-13 Yes 
POST-HOC TUKEY HSD TEST 
Group compared Q statistic Significant 
F1 vs F2 
F1 vs F3 
F1 vs F4 
F1 vs F5 
F2 vs F3 
F2 vs F4 
F2 vs F5 
F3 vs F4 
F3 vs F5 









































6.4.7 Dissolution efficiency and kinetics 
According to the International Union of Pure and Applied Chemistry (IUPAC), the term 
“dissolution” is defined as the mixing of two phases resulting in a new homogeneous 
phase (i.e. the solution) [621] (see Figure 6.17a). In the case of the dissolution of a solid 
drug particle, the drug will dissolve in the phase of an aqueous liquid as depicted in Figure 
6.17b. 
 
Figure 6.17: Schematic depiction of: a) IUPAC definition of “dissolution”, b) 
dissolution of a solid drug particle in an aqueous liquid (Adapted with permission from 
reference [622]). 
In general, drugs will dissolve upon contact with aqueous body fluids. However, all drugs 
have different dissolution rate and the rate of drug release can be dependent on the water 
penetration into the drug delivery system, polymer swelling and dissolution, as well as 
drug diffusion through polymeric networks [622]. Some drugs with poor solubility do not 
dissolve as easily. As all drugs have different solubility, a better understanding of the 
physico-chemical reactions of the drugs, their solubility and dissolution rates can be 





release mechanism can be achieved using realistic mathematical modelling of the process 
of drug dissolution. The dissolution efficiency and pharmacokinetics are the most popular 
ways for mathematical analysis of drug dissolution. The study of dissolution efficiency 
compares different dissolution profiles using the mathematical analysis of difference 
factor (f1) and similarity factor (f2). The difference factor (f1) measures the percent 








× 100 (Equation 6.1) 
where n is the sampling number, Rj and Tj are the percent dissolved of the reference and 
test products at each time point j. The percent difference is zero when the test and drug 
reference profiles are identical and increase proportionally with the dissimilarity between 
the two dissolution profiles. On the other hand, the similarity factor (f2) is a logarithmic 
transformation of the sum-squared of differences between the test Tj and the reference 
products Rj over all time points: 
𝑓2 = 50 × log{[1 +
1
𝑛
∑ 𝑤𝑗|𝑅𝑗 − 𝑇𝑗|
2𝑛
𝑗=1 ]
−0.5 × 100} (Equation 6.2) 
where wj is an optional weight factor. The result of the similarity factor calculation falls 
between value 0 and 100. It is 100 when the test and the reference profiles are identical 
and tends to 0 as the dissimilarity increase. All dissolution profiles for the 3D printed 
formulations were being compared using the difference factor (f1) and the similarity factor 
(f2). The results for f1 and f2 are tabulated in Table 6.8 and Table 6.9 respectively. In order 
to consider dissolution profiles to be similar, the f1 values should be close to 0 and the f2 
values should be close to 100. In general, f1 values between 0 and 15 and f2 values between 
50 and 100 indicates similarity of the dissolution profiles. Such classification is also 
recognised by the FDA and European Medicines Agency (EMA). This means that when 
hen the values of f1 falls out of the range of 0-15 (i.e. above 15) and f2 falls out of the 
range of 50-100 (i.e. below 50), the two dissolution profiles that are being compared can 
be declared dissimilar. The results in Table 6.8 and Table 6.9 showed that F1 is similar 
to F2 only; F2 is similar to F1 and F3; F3, F4 and F5 are all similar to each other. 
Therefore, it can be said that F3, F4 and F5 have a similar dissolution profile but they are 
different from F1 and F2. This can be explained by a difference in dissolution mechanism 





present. The calculated f1 and f2 values correspond to each other and the similarity of the 
dissolution profiles was also reflected in Figure 6.14. 
Table 6.8: Difference factor (f1) for dissolution of tablets formulation F1-F5. 
Formulation No. 
Compared 
F1 F2 F3 F4 F5 
F1 - 11.83 25.89 35.82 39.01 
F2 13.42 - 14.48 24.34 28.10 
F3 32.54 16.80 - 12.63 11.46 
F4 55.81 32.18 13.33 - 5.26 
F5 63.95 39.08 12.73 5.54 - 
 
Table 6.9: Similarity factor (f2) for dissolution of tablets formulation F1-F5. 
Formulation No. 
Compared 
F1 F2 F3 F4 F5 
F1 - 60.01 42.84 36.47 34.16 
F2 60.01 - 53.60 42.79 40.17 
F3 43.19 53.60 - 55.99 55.18 
F4 36.47 42.79 55.99 - 74.70 
F5 34.16 40.17 55.18 74.70 - 
Comparing the dissolution profiles is a simple method to determine whether the different 
formulations show the same drug release mechanisms and patterns. In addition to 
computing f1 and f2 values of two different dissolution profiles, the different dissolution 
profiles can be further analysed by fitting them to different mathematical models. 
Mathematical models can be used to describe the release mechanism of the 3D printed 
tablet. Several models have been developed over the years. These models are also known 
as pharmacokinetic models and are used to speculate the release mechanism of a drug 
delivery system.  They also play an important role in the process of designing 
pharmaceutical formulations and evaluating the process of drug release. Mathematical 
modelling can help to optimise the design of the new drug delivery systems and improve 
the efficacy of the systems. In this study, the dissolution profiles for each of the 3D printed 
tablets were analysed by fitting the dissolution data into several different kinetic models 
such as zero-order, first-order, Higuchi and Korsmeyer-Peppas models. The kinetic 
models were used to speculate the release mechanisms that the tablet exhibit. The results 
from fitting the dissolution data to the mathematical equations were shown in Table 6.11. 
The model that showed the maximum R2 (RSQ) and minimum mean percentage error 
(MPE) is the best kinetic model fit for that particular dissolution profile. The equations 





Table 6.10: The four dissolution kinetic models used and their respective equations 
Dissolution kinetic models Equation 
Zero-order 𝑀𝑡
𝑀∞









2 + 𝐶 [625] 
Korsmeyar-Peppas (“Power Law”) 𝑀𝑡
𝑀∞




 represents the cumulative drug release percentage at time t, k0, k1, kH, and k 
are the release constant of each model equation and n is the release exponent. The zero-
order release model is often used when the dug release rate is constant over a period of 
time and it represents an ideal situation of a controlled release drug delivery systems. The 
first-order model is used to describe the absorption and/or elimination of drugs [627]. It 
is often used to describe dosage forms containing water soluble drugs in a porous matrix 
[628]. The Higuchi model is the first model that describes the drug release rate from a 
matrix system. It is also one of the preferred models for drug release in different 
geometries and porous model [629–631]. However, it is often not applicable to many 
controlled release systems [625]. The mathematical equation of the Higuchi model is 
related to the API particles dispersed into a homogeneous matrix being submitted to a 








 is the accumulative drug released from time t, C is the initial amount of drug 
contained in dosage form, Cs is the solubility of active agent in the matrix medium and D 
is the diffusion coefficient in the matrix medium. The Higuchi model was derived under 
pseudo-steady states and carried several assumptions [633]: 
1) The initial drug concentration in the matrix is much higher than the solubility of the drug 
2) The diffusion is unidirectional with negligible the edge effects  





4) The swelling or dissolution of the polymer matrix is negligible 
5) The drug diffusion coefficient is constant 
6) The perfect sink conditions during drug release 
The Korsmeyer-Peppas, also known as the “Power law” model, is often used to describe 
the drug release of a polymeric system when the drug release mechanism is not known, 
or drug release mechanism that happen simultaneously such as diffusion, swelling and 
dissolution of the polymer matrix [634]. The constant ‘k’ depends on the structural and 
geometrical characteristic of the system, and the value ‘n’ is the exponent of drug release 
in the function of time t [626]. The power law is a more comprehensive semi-empirical 
equation to describe drug release from polymeric systems. This equation shows an 
exponential relationship between drug release and time. 
The dissolution for each formulation above was fitted to four different mathematical 
models (zero-order, first-order, Higuchi and Korsmeyer-Peppas model) to determine the 
best description of its drug release mechanism. The model fitted to that shows the lowest 
mean percentage error (MPE) and the highest coefficient of determination (R2) is 
typically considered the best model to describe the dissolution. The MPE and R2 for all 
the dissolution of the 5 3D printed formulations were displayed in Table 6.11. The fitting 
data shows that the two best models that could be used to represent the 3D printed 
formulations are Higuchi and Korsmeyer-Peppas models. This is because MPE and R2 
for the formulation were the lowest and highest respectively. The MPE and R2 of these 
two models are very also close to each other. It is shown that the dissolution of 
formulation F1, F2 and F5 can be best described using the Higuchi model, whereas F3 
and F4 can be represented using the Korsmeyer-Peppas model. According to the 
Korsmeyer-Peppas equation, when the value of n falls between 0.45 and 0.89, the drug 
release mechanism can be described as non-Fickian (anomalous). This means that the 
drug release can be caused by diffusion and swelling of the polymer matrix [635]. If the 
n value is small (n < 0.43), this indicates the drug release mechanism is diffusion-
controlled, representing a Fickian diffusion release mechanism [636]. The study indicates 
all formulations may have multidirectional diffusion and polymer swelling during the 
dissolution process as the n values are greater than 0.45. The swelling of the polymer 
matrix happened when the dissolution medium penetrates into the polymer matrix.  This 
could be caused by the presence of Eudragit. Eudragit is permeable to water but not 





analysis showed the dissolution data for all formulation seem to fit both Higuchi and 
Korsmeyer-Peppas models. This could be because these pharmacokinetic models were 
developed for tablets produce in traditional pharmaceutical methods. 3D printing of 
tablets has not been established as a tablet processing technique. This is because 3D 
printed tablets could have variations as shown in Table 6.6 and the 3D printing may 
change some properties of the polymeric matrix due to the thermal stress exerted during 
the 3D printing process. The change on properties could easily affect the release rate and 
release kinetic of the drugs. However, some studies have shown that Higuchi model may 
not be the most suitable model for 3D printed dosage forms as polymeric 3D printed drug 
delivery devices may exhibit multidimensional diffusion and swelling of the polymer 
matrix is often not negligible [155,637]. It is suggested that the Korsmeyer-Peppas model 
may be a better representation of the dissolution profile for 3D printed tablets.  
Table 6.11: The Mean Percentage Error (MPE), Coefficient of determinations 
(R2/RSQ), Diffusion exponent (n) of the calculated by fitting the dissolution profile in 
Table 6.8 to the different mathematical kinetic models. 
Formulation 
No. 
Zero-order First-order Higuchi Korsmeyer-Peppas 
MPE% RSQ MPE% RSQ MPE% RSQ MPE% RSQ n 
F1 (0811) 212.48 0.905 142.49 0.984 25.86 0.992 21.89 0.950 0.911 
F2 (2611) 163.52 0.894 111.82 0.989 30.13 0.994 24.37 0.920 0.810 
F3 (4411) 78.13 0.831 59.82 0.968 28.48 0.972 14.47 0.96 0.710 
F4 (5311) 42.73 0.957 7.14 0.995 12.18 0.996 5.86 0.991 0.727 
F5 (6211) 65.64 0.931 16.01 0.997 2.32 0.999 10.30 0.981 0.802 
6.4.8 Biocompatibility study 
A cell study was carried out to ensure the biocompatibility of the formulation and to 
examine whether the HME process has caused any chemical toxicity to the polymer. The 
results from the cell study in Figure 6.18 shows the number of cells in the well on the first 
day (day 0), second day (day 1) and fifth day (day 4). The study showed that the cells can 
still grow in the wells, showing no signs of toxicity from the foreign materials. This 
confirms that the materials are not cytotoxic and the HME process did not cause any 
degradation or changes in chemical properties to the bulk materials. Hence, such a 






Figure 6.18: Cell count of biocompatibility study on day 0, day 1 and day 4. 
6.5 Conclusions 
This study showed that when HME is combined with a low-cost FDM 3D printing 
technique, it can be used as a continuous fabrication process for a sustained release drug 
delivery device. This is a cost-effective and convenient way to produce drug delivery 
systems, especially for medications that need to be personalised and customised 
according to the patients’ requirements. The success of this approach allows local 
hospitals to manufacture their own medical and pharmaceutical products on-site 
according to their patients’ needs. This will help save time from waiting for suitable 
products to be manufactured off-site or using the traditional manufacturing processes. 
This technique is particularly useful for hospitals in remote areas as it is able to overcome 
some distribution and supply chain challenges. The filaments were produced by 
optimising various compositions of pharmaceutical grade polymers, such as 
hydroxypropyl cellulose (HPC), Eudragit® (RL PO), polyethylene glycol (PEG) whereas 
theophylline was used as a model drug. For the purpose of the study, HME was 
implemented from the view that it would result in the formation of solid dispersion of 
drug onto the polymeric carrier matrices by means of high shear mixing inside the heated 
barrel. HME has been used to produce 3D printable filament that can be loaded with any 
thermally stable API. HME can also effectively convert a crystalline API into amorphous 
form, forming a solid dispersion. In order to produce FDM 3D printable filaments, the 
type of polymeric carrier chosen is essential. It must have suitable flexibility and ductility 
that can withstand the forces experienced during the FDM 3D printing process. The 































filaments suitable for FDM 3D printing of tablets. The 3D printed tablets showed good 
consistency and have an elegant appearance for the majority of the filament formulations. 
Only one formulation (F6) did not produce an acceptable 3D printed tablet as the molten 
filament was too viscous, causing the 3D printed tablet to stick to the printing surface. 
Solid state analyses conducted via DSC and XRD showed the amorphous nature of the 
crystalline drug dispersed onto the polymeric matrices. The surface analysis conducted 
via SEM showed smooth surfaces of the produced filaments as well as tablets, where no 
drug crystals were visible. 
In-vitro dissolution was carried out for the tablets to study the drug release profiles. The 
3D printed tablets showed promising results in controlling the release rate of the drug. 
The in-vitro drug release study showed a sustained release profile over 10 hours, where 
about 80% of the drug was released from the printed dosage forms. This indicates that 
the optimised 3D printed tablets are suitable for the development of sustained-release 
personalised delivery systems. The dissolution efficiencies for the dissolution profiles 
were calculated and the release mechanism of the 3D printed tablets were determined by 
fitting the dissolution data to mathematical kinetic models. As the 3D printed tablet 
formulations consist of different polymeric mixture, the Korsmeyer-Peppas law may be 
the most appropriate model to describe the drug release kinetics of the 3D printed tablets. 
Cell study was carried out the bulk materials and the extruded filaments to ensure the 
biocompatibility of the materials. The study showed that the materials are biocompatible 
and do not have any cytotoxic effect on living cells. Therefore, this polymeric mixture 
can be used for printing not just tablets but also drug-loaded implants. The study also 
confirms that the thermal process of HME also did not induce any toxicity or degradation 





Chapter 7 : Development of metformin-loaded filaments for 
3D printing of sustained release drug delivery system 
7.1 Introduction 
A sustained-release drug delivery system is a purposefully designed system where the 
drug is released at a predetermined rate in order to maintain a constant drug level over a 
period of time [638]. The benefits of sustain release drug delivery system include the 
reduced frequency of medication intake required reduced side effects and improved 
patient compliance [639]. Sustained release drug delivery systems have been designed to 
solve problems that arises from drugs that have short half-lives and are eliminate quickly 
from blood circulation [640]. Such drugs required patients to increase the frequency of 
intake, which could increase the side effect and cause much inconvenience to the patients. 
Much effort has been put into designing sustained-release formulations as such 
formulations are able the most effective treatment using the smallest quantity of a drug at 
the shortest possible time. The primary aim of this system is to improve the efficacy of 
drugs and patient compliance.  
Traditionally, sustained release dosage forms are prepared by applying a coating of 
pharmaceutical excipient that act as a protective membrane on a tablet [641]. The type of 
polymers used also plays an important role in sustaining the release of a formulation. 
Some of the polymers that have been successfully used for sustained release formulations 
include hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), 
polyvinylpyrrolidone (PVP), Eudragit, and polyethylene oxide (PEO) [642–646]. The 
suitability of the polymers used can also depend on the physicochemical properties of the 
drug.  
Metformin hydrochloride (HCl) is a highly soluble active pharmaceutical ingredient 
(API) and is one of the most studied API for prolonged-release formulations [647]. The 
chemical structure of metformin is shown in Figure 7.1. Due to its high water solubility, 
metformin is often available as an immediate release formulation. As a result, it is 






Figure 7.1: Chemical structure of diabetic drug Metformin Hydrochloride (HCl). 
Freely water-soluble Metformin is the most commonly used drug as a first-line treatment 
for newly diagnosed Type II diabetes patients [648]. There are several ways where 
metformin can help lower blood glucose levels in diabetic patients. Metformin can reduce 
hepatic glucose production in the liver, increases insulin sensitivity by improving the 
skeletal muscle uptake and utilisation of glucose, and reduce the intestinal absorption of 
glucose [649]. However, the treatment of metformin is often insufficient and additional 
drug such as gliclazide is often prescribed additional treatment to improve the 
convenience and adherence to the prescribed therapy and to contribute to better glucose 
control [650,651]. It has also been reported that patients with type II diabetes mellitus 
typically achieve better glucose control when received two combined medications [652–
654]. However, metformin will often be used as the first option of treatment particularly 
for newly diagnosed patients as it is still considered the most effective treatment [655].  
Metformin is normally absorbed in the upper gastrointestinal (GI) tract [656]. 
Formulating metformin as a sustained release dosage form can allow metformin to be 
released in the upper GI tract over a longer period of time and can help address issues of 
gastrointestinal intolerability [656,657]. This can help avoid multiple daily dosing and 
improve patient adherence. With an extended-release metformin, the patient could 
experience fewer GI side effects as only one pill is taken per day but the daily dose remain 
the same [658,659]. This will not only benefit the patients by improving glycaemic 
control but will also help reduce the burden on health care usage and overall costs [660]. 
In order to achieve a prolonged release metformin formulation, the polymeric excipients 
used play a crucial role. Studies have shown that polymer such as HPMC and Eudragit 
have successfully been used to prolong the release of metformin release [169,661]. 
Nanjwade et al. also designed a metformin extended-release table using a combination of 
a hydrophobic carrier (stearic acid) and a hydrophilic polymer (PEO) [662]. 
One of the innovative techniques to formulate sustained release drug delivery systems is 





and pharmaceutical applications has received a tremendous amount of interests. This is 
because there has been increasing need to customised products according to the 
requirements of patients and 3D printing seems to be the most cost-effective production 
method for such products. Pharmaceutical products use a lot of polymers and some may 
be suitable for 3D printing processes, in particular fused deposition modelling (FDM) 3D 
printing. Suitable polymers loaded with a desired API can be formed into filaments using 
hot-melt extrusion (HME) and the filaments can be used as a feedstock for FDM 3D 
printing. This technique has been proven feasible and simple in the earlier chapters. 
Studies have also shown that the parameters of the 3D printing process and the shape of 
the printed tablet may have an effect on the release profile of the drug [79,612,613,667].  
The polymeric composition study carried out from Chapter 6 exhibit sustained-release 
properties for the incorporated API. This is particularly true for composition with higher 
Eudragit® RL PO. The results suggested that the formulations with a high concentration 
of Eudragit provides a sustained release profile for the drug theophylline. Hence, an 
attempt to apply the two compositions that showed the slowest drug release profile from 
the HPC and Eudragit compositions in the previous chapter to produce sustained release 
metformin formulations. A study by Gioumouxouzis et al. also showed that metformin 
was loaded onto Eudragit® RL PO  to achieve a prolonged release pattern [169]. In this 
chapter, metformin will also be loaded onto another type of biodegradable polymer, 
polycaprolactone (PCL). PCL is commonly used in biomedical applications and also 
widely available as a 3D printing filament.   
Poly-ε-caprolactone (PCL) is a synthetic, semicrystalline polymer that exhibit very low 
glass transition temperature (Tg) and low melting temperature (Tm). The Tg of PCL is 
typically around -60 °C to -65 °C and the Tm is around 60 °C [668]. PCL is synthesised 
through ring-opening polymerisation of ε-caprolactone as shown in Figure 7.2 [669]. The 
main basic building blocks of PCL are esters and ethe groups and its chemical structure 
is depicted in Figure 7.3. The high mobility of the polymeric chain and the low molecular 







Figure 7.2: Ring opening polymerisation of ε-caprolactone producing poly-ε-
caprolactone (PCL) [671]. 
 
Figure 7.3: Chemical structure of polycaprolactone (PCL) [672]. 
PCL is considered non-toxic and is a biodegradable material by hydrolysis of its ester 
bonds [672,673]. The degradation time of PCL can be over 3-4 years [674]. PCL has been 
used in a wide range of medical applications including tissue engineering [675], drug 
delivery systems [676,677], regenerative medicines [678] and various implants [679–
681]. Apart from medical applications, PCL has also been used in the polymer industries 
as hot-melt adhesives, food packaging, model making and laminating pouches [682–684]. 
PCL is non-hazardous and has received U.S. Food and Drug Administration (FDA) 
approval for use in a large number of drug delivery and medical devices. It has been 
reported in the literature that PCL exhibit a typical modulus of elasticity of ~440 MPa 
and tensile strength of ~16MPa [685]. Some other properties of PCL include resistance 
to water, oil, solvent and chlorine [668]. 
PCL has shown great potential to be used for biomedical applications including implants 
and drug delivery systems due to its biocompatibility and biodegradability [686,687]. 
Some examples of PCL-based implants include implantable contraceptive devices and 
stents [71,677,688]. PCL has been used to produce drug delivery systems that exhibit 
long sustained drug attributed to the properties of the polymer [71,689,690]. This is 
because PCL is a hydrophobic polymer, which could act as a protective layer to freely 
soluble drugs. The excellent mechanical properties of PCL also allowed the material to 
be produced into filaments that are suitable to be used for Fused Deposition Modelling 





In this study, metformin will be loaded onto a polymeric matrix consists of PCL and 
polyethylene glycol (PEG) in addition to the sustained release Eudragit compositions. 
PEG is highly water soluble and has been widely used as a drug carrier [691]. As PCL is 
hydrophobic, PEG will improve its hydrophilicity and drug loading ability. Four different 
polymeric compositions will be processed with HME to form into 3D printing filaments. 
Two formulations are Eudragit-based and two PCL-based. The extruded filaments will 
be used to 3D print metformin loaded tablets and drug release studies will be carried out 
to investigate the sustain release properties of the polymeric compositions.  
Both PCL and PEG has a very low melting point which could prevent thermal degradation 
of thermosensitive drugs. This could be highly beneficial especially when thermal 
processes such as HME and FDM 3D printing are involved. Due to the low melting point 
and low glass transition temperature of PCL, the polymer can be soft and flexible even at 
room temperature.  
7.2 Materials 
Nisso Hydroxy Propyl Cellulose (HPC) (Grade SSL) was purchased from Nippon Soda 
Co., LTD. (Tokyo, Japan). Eudragit® RL PO powder was purchased from Evonik 
Industries (Darmstadt, Germany). Poly (ethylene glycol), average molecular weight 
(M.W.) 6000 g/mol was purchased from Fisher Scientific (Loughborough, UK). 
Polycaprolactone (PCL) in powdered form with average M.W. 50000 g/mol was 
purchased from Polysciences Europe GmbH (Hirschberg an der Bergstrasse, Germany). 
Metformin Hydrochloride purchased from Tokyo Chemical Industry UK Ltd. (Oxford, 
UK) was used as a model drug. All materials were used as received. 
7.3 Experimental Methods 
7.3.1 Preparation of metformin-loaded filaments 
Two types of metformin-loaded filaments were produced. The material compositions 
were shown in Table 7.1. The materials in powder form were first mixed together in a 
pestle and mortar. The mixed powder was then transferred into a bottle and further mixing 
was carried out using a Turbula shaker mixer, Eskens (Alphen aan den Rijn, Netherlands) 
for 15 mins. The mixed powder was then produced into filaments using a table-top 
custom-built L/D 10 twin-screw extruder by Twin Tech Extrusion Limited (Stoke-on-
Trent, UK), assembled by Point1Controls/R Controls (Stoke-on-Trent, UK). The extruder 





controlled independently. The extruding temperatures set were different for each 
formulation. For M1 and M2, the temperatures at the 4 zones (Z1 : Z2 : Z3 : Z4) were 
(70°C : 100°C : 110°C : 110°C) and the die was set to 110°C. For M3 and M4, the 
temperatures were (40°C : 50°C : 65°C : 65°C) and the die was set to 65°C.  The heat 
soak time was set to 5 minutes for all formulations. The extruding hole on the die has a 
diameter of 2.0 mm and the extrusion speed was set to 60 rpm. A standalone filament 
winder was used to collect the filaments extruded. A Vernier calliper was used to measure 
the diameter of the filaments and only filaments with a diameter of 1.75 mm were used 
for 3D printing as the size of the 3D printing nozzle can only fit filaments with diameter 
below 1.75 mm. 
Table 7.1: Percentage of composition in different formulation of metformin-loaded 
filaments. The quantities are in percentage (w/w). 
Compound Formulation Code 
M1 M2 M3 M4 
Metformin HCl 10 10 10 10 
Hydroxy Propyl Cellulose 
(HPC) 
20 - - - 
Eudragit® RL PO 60 80 - - 
PEG 6000 10 10 20 10 
Polycaprolactone (PCL) - - 70 80 
 
7.3.2 3D printing process 
The extruded filaments were used for 3D printing using a Makerbot Replicator 2X 
(Makerbot Inc., NY, USA) FDM 3D printer. The CAD model of a drug delivery device 
(tablet shape) was designed using Solidworks (Dassault Systemes, Waltham, MA, USA). 
Figure 1 shows a computer-generated 3D model of the tablet used for 3D printing. The 
3D model was then saved as an .STL file and imported to Makerbot Desktop software 
(Makerbot Inc., NY, USA) for slicing. The tablet has a height of 5 mm, width of 10 mm 
and length of 20 mm. The layer height for printing was set to 0.15 mm. Tablet infill for 
printing was set to 100%.   
7.3.3 Differential Scanning Calorimetry (DSC) 
A DSC 4000 system (Perkin Elmer, Waltham, MA, USA) was used to study the glass 
transition temperature and the melting temperature of all the filaments. The samples used 
were about 5mg. The samples were placed in an aluminium pan, and an empty aluminium 





mL/min in all the DSC experiments. The data were collected and analysed with Pyris 
software (Perkin Elmer, Waltham, MA, USA). 
7.3.4 Thermogravimetric analysis (TGA) 
TGA was carried out using a Q40 Thermogravimetric analyser (TA Instruments, New 
Castle, DE, US) to obtain the degradation profile of the filaments. The samples used were 
about 10mg and were placed in an open aluminium pan. The furnace was then heated 
from 30C to 550C at a rate of 10C/min. Nitrogen gas was used as purge gas at a flow 
rate of 20mL/min. Data were collected and analysed using the Advantage/Universal 
Analysis Software (TA Instruments). 
7.3.5 X-ray Powder Diffraction  
The crystallinity of the individual compound and the extruded filaments were assessed 
using a Siemens D500 X-ray Diffractometer (Siemens, Germany). The samples were 
scanned between 2 Theta(θ)=5° to 50° using 0.01° step width and 1s time count. The 
divergence slit was 1mm and the scatter slit was 0.6mm. The X-ray wavelength was 0.154 
nm in Cu source and at a voltage of 40 kV. 
7.3.6 In-vitro Drug Release Study 
In-vitro dissolution test was carried out on three randomly selected tablets from each 
formulation for drug release study. The mass of the samples was first weighed before 
dissolution and then weighed again after the dissolution test when the samples were dried. 
Determination of the In-Vitro drug release was performed using USP type I dissolution 
apparatus (708-DS Dissolution Apparatus, Agilent Technologies, Santa Clara, CA, USA) 
in 1000mL of 0.05M phosphate buffer solution (pH 6.8) at 37±0.3◦C with a rotation speed 
of 100 rpm. The drug concentration of the dissolution medium was measured using a 
Cary 60 UV-Vis Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA) at a 
wavelength of 232 nm in a 2 mm cell versus a blank solution consisting of a phosphate 
buffer (pH 6.8). The samples were drawn automatically using an Agilent 810 peristaltic 
pump (Agilent Technologies, Santa Clara, CA, USA) and sampling was done every 5 min 
for the first hour, every 20 min of the following 2 hours and every 60 min for the last 10 






7.4 Results and Discussion 
 
Figure 7.4: DSC thermograms for all four metformin filaments and the bulk material 
used: Polycaprolactone (PCL), Hydroxypropyl cellulose (HPC), Eudragit® RL PO, 
Metformin HCl and PEG 6000. 
DSC analysis was carried out for the extruded metformin filaments and the materials used 
to fabricate the filaments which include PCL, HPC, Eudragit, Metformin and PEG. The 
DSC profiles for all materials analysed were shown in Figure 7.4. The DSC thermograms 
for HPC and Eudragit did not show any thermal events due to their amorphicity in nature. 
Metformin is a highly crystalline drug and showed a large endothermic peak which 
reflects its melting point at around 233.7 °C. Due to the high melting point of metformin, 
it can be used in thermal processes such as HME and 3D printing as it will be able to 
withstand the temperature of the processes. The DSC results confirmed that PEG has a 
melting point of around 66 °C. Similarly, PCL also has a very low melting point at 64.2 
°C. The use of PCL and PEG as drug carrier means that the processing temperature can 
be very low, which could prevent any thermal degradation of the materials. The melting 
temperature and the melting enthalpy of the materials were displayed in Table 7.2. 
The composition of M1 and M2 filaments were made of HPC, Eudragit and PEG, similar 
to the composition being studied in Chapter 6. The two formulations that showed the 
slowest drug release from Chapter 6 were chosen to investigate the effect of such 
composition for a readily soluble drug, metformin. The DSC curves for M1 and M2 
filaments showed small endothermic peaks at 227 °C and 226.2 °C respectively. These 
two endothermic events represent the melting point of metformin in the filament 































formulation. This confirms the presence of metformin in the filaments. The melting 
temperatures were actually lower than the pure metformin. This is because the polymeric 
composition was able to suppress the melting point of metformin when it has been 
processed with the carriers. Apart from that, the energy required to melt metformin in M1 
and M2 were lower as compared to pure metformin. The DSC for M1 and M2 suggest 
that the filaments may have high amorphous content. However, there is still some 
crystallinity due to the presence of metformin. Similar to the formulations in Chapter 6, 
M1 and M2 filaments can be prepared using twin-screw extrusion at a maximum 
temperature of 110 °C. This processing temperature was required to melt/soften HPC and 
Eudragit to a suitable viscosity that can be mixed with other materials and processed into 
3D printable filaments. The filaments, M1 and M2, can be 3D printed at a printing 
temperature of 195 °C.  
M3 and M4 filaments contain PCL, PEG and metformin as a drug. The DSC analysis for 
these two filaments showed two endothermic events. The first endothermic event 
corresponds to the melting of PCL as it happened around 68.2 °C and 66.1 °C for M3 and 
M4 respectively. The second endothermic event corresponds to the melting of metformin. 
The results suggest that both filaments may have high crystallinity due to the nature of 
compositions. PCL, PEG and metformin are materials that contain high crystallinity. Due 
to the low melting point of PCL, the processing temperature of the PCL filaments were 
also low. The maximum temperature required to extrude metformin-loaded PCL 
filaments was 65 °C. The temperature used for the 3D printing of M3 and M4 filaments 
was 70 °C. This printing temperature was much lower than M1 and M2 filaments. Such 
formulation may be suitable for thermosensitive materials and active ingredients as the 
processing temperatures were relatively low. This can be attractive as the formulation can 
offer the benefit of 3D printing of personalised tablets and implants for thermal sensitive 
and low melting point drugs.  
Table 7.2: Melting temperature (Tm) and the measured heat enthalpy value for melting 
extracted from the DSC profiles for all metformin filaments and individual materials. 
Sample  Melting point Tm 
(°C) 
Heat enthalpy value 
(∆𝑯) for Tm (J/g) 
HPC - - 
Eudragit® RL PO - - 
PCL 64.2 102.7 





PEG 66.7 252.7 
M1  227.0 30.9 
M2  226.2 47.3 
M3 68.2 / 235.1 174.1 / 69.8 
M4 66.1 / 236.0 119.1 / 56.4 
 
 
Figure 7.5: TGA profiles for all extruded metformin filaments and individual materials. 
The thermal degradation profiles of the extruded filaments and the individual materials 
were displayed in Figure 7.5. Three different degradation points t90, t50, and t10 were 
extracted from the profiles representing the temperature when 10%, 50% and 90% of the 
sample has degraded respectively. The exact values of the temperatures at these 
degradation points were displayed in Table 7.3. The active ingredient used, metformin, 
degraded at the lowest temperature amongst all the materials used. At around 243 °C, 
10% of the metformin has degraded. However, the drug is still considered thermally 
stable as the maximum temperature of the twin-screw extrusion process was 110 °C and 
the maximum temperature of the FDM 3D printing process was 195 °C. Metformin only 
fully degrades at a temperature above 495 °C. All other materials used also only start to 
degrade at above 270 °C. The four filaments produced also showed good thermal stability. 
The TGA analysis confirmed that the components were suitable for the twin-screw 






































Table 7.3: Temperature at three degradation points (t90 = 90%, t50 = 50%, t10 = 10% wt. 
remaining) for all filaments and the individual materials. 
Samples t90 (°C) t50 (°C) t10 (°C) 
HPC 269.9 363.3 - 
Eudragit 293.4 367.7 - 
PEG 338.3 406.7 427.8 
PCL 369.5 394.7 414.2 
Metformin 243.2 286.2 495.7 
M1 Filament 240.8 347.2 387.5 
M2 Filament 249.5 368.4 - 
M3 Filament 303.5 357.1 388.5 
M4 Filament 309.4 372.2 399.4 
 
 
Figure 7.6: XRD analysis on the 3D printed metformin tablets and their individual 
materials. 
Figure 7.6 shows the XRD analysis for all 3D printed metformin tablets using the twin-
screw extruded filaments, and the individual materials that made up the tablets. The XRD 
spectra for HPC and Eudragit showed that these two materials contain high amorphous 
content. On the other hand. PCL, PEG and metformin are highly crystalline. As for the 
3D printed tablets using the M1 and M2 formulations, the XRD spectra suggest that there 
were some amorphicity and crystallinity in the tablets. The crystallinity was due to the 
presence of metformin as the crystallinity peaks on the spectra corresponds to the peaks 
that can be found on the metformin spectrum. However, the peaks were much smaller as 
the percentage of the drug present in the polymeric composition was just 10 %. Apart 
from that, the polymeric mixture of HPC and Eudragit are mainly amorphous. This 
finding was consistent to the DSC results as the DSC recorded the melting point of 

























metformin in both M1 and M2 filaments. This suggests that the crystalline drug still 
maintained its crystallinity even though it has been processed using twin-screw extrusion. 
Hence, the drug has not been converted to amorphous form. The spectra for M3 and M4 
tablets showed that both tablets contain high crystallinity as well. The crystallinity peaks 
present were mainly attributed to the crystallinity peaks from PCL and PEG. As the 
concentration of metformin in the compositions were low, the peaks may not be obvious. 
This could also be that the crystalline peaks of PCL and PEG were much larger than the 
metformin crystalline peaks, hence the smaller peaks of metformin were not as evident. 
Nevertheless, the presence of Metformin in the M3 and M4 formulations were confirmed 
in the DSC analysis. In general, the results from the XRD analysis and DSC analysis were 
consistent with each other.   
 
Figure 7.7: In-vitro drug release study on the 3D printed metformin tablets. 
The four metformin-loaded filaments were used to 3D print tablets. The drug release 
profiles of the 3D printed tablets were obtained via drug dissolution testing and the results 
were shown in Figure 7.7. Formulation M1 showed the quickest release where more than 
80 % of the drug was released within the first 2 hours, whereas M4 showed the slowest 
release where the drug release only started to plateau after 10 hours. Metformin is a highly 
soluble drug. The results suggest that the formulations made of PCL and PEG were 
capable of sustaining the release of metformin. HPC and Eudragit are highly amorphous 
polymer and were mainly used to improve the solubility of poorly water-soluble drugs. 
Hence, the formulation which contains HPC in its composition, M1, showed the quickest 





































PEG but bot HPC as the polymeric matrix. Eudragit has been used mainly for sustained-
release products. It is permeable to water but not soluble. Therefore, M2 formulation 
exhibit a more prolonged release profile and the drug release reach 80 % after 3 hours.  
Formulations M3 and M4 were made of PCL and PEG, both components exhibit high 
crystallinity. As the drug metformin is also high crystalline, the formulation also showed 
high crystallinity content as suggested in the XRD analysis. A study has reported that 3D 
printed implant with a low degree of crystallinity showed faster drug release profiles 
[179]. These dissolution studies confirmed that PCL is capable of producing a sustained-
release product, and formulation with higher concentration PCL, M4, had the slowest 
drug release profile. PCL is also not soluble in water; hence the drug release mechanism 
was mainly due to diffusion. Nevertheless, PCL showed drug loading capability and can 
be suitable to be used for sustained release applications as it is also a biodegradable 
material.  
Table 7.4: Difference factor (f1) for dissolution of 3D printed metformin tablets 
Formulation No. 
Compared 
M1 M2 M3 M4 
M1 - 48.30 56.17 63.39 
M2 44.48 - 25.36 36.32 
M3 103.93 33.55 - 14.75 
M4 140.03 56.39 14.77 - 
 
Table 7.5: Similarity factor (f2) for dissolution of 3D printed metformin tablets 
Formulation No. 
Compared 
M1 M2 M3 M4 
M1 - 25.95 20.37 17.66 
M2 25.60 - 41.96 34.18 
M3 20.89 41.25 - 61.02 
M4 17.92 34.18 61.02 - 
The dissolution profiles for each of the 3D printed metformin tablets obtained in Figure 
7.7 were compared with each other to determine their similarities. A mathematical 
analysis was carried out on the dissolution data and two common parameters were 
obtained, difference factor (f1) and similarity factor (f2). f1 measures the percentage 
difference between the two compared dissolution curves. f1 value is 0 represents the 
percentage difference between two dissolution profiles is zero. This means the two 
dissolution profiles are identical. In general, f1 values between 0 and 15 indicates that the 





the similarity of two dissolution profiles, hence called the similarity factor. Two profiles 
are considered identical when f2 = 100. However, an f2 value of between 50 to 100 will 
be enough to indicate the similarity between the two dissolution profiles. The is because 
an f2 value of between 50 and 100 indicates that the average difference of the dissolution 
at each sampling point is less than 10%. The obtained values for f1 and f2 were displayed 
in Table 7.4 and  
Table 7.5 respectively. The values shown are comparison of two dissolution profiles at a 
time. The results suggest that the dissolution characteristics of the formulations did not 
show similarities to each other, particularly for M1 and M2. This can also be reflected in 
the dissolution profiles in Figure 7.7. M1 and M2 did not show similarity as the absence 
of HPC in M2 had made a huge difference to the drug release in the formulation. M1 and 
M2, when compared to M3 and M4 are completely different polymeric compositions that 
exhibit different physicochemical properties. Hence, they were not comparable. On the 
other hand, M3 and M4 showed some similarity as the f1 values were below 15 and f2 
values were above 50. These two formulations have the same polymeric mixture at 
different concentrations, hence they showed similarities.  
Table 7.6: The Mean Percentage Error (MPE), Coefficient of determinations (R2/RSQ), 
Diffusion exponent (n) of the dissolution profiles for all 3D printed metformin tablets 
when fitted to the different dissolution kinetic models. 
Formulation 
No. 
Zero order First order Higuchi Korsmeyer-Peppas 
MPE% RSQ MPE% RSQ MPE% RSQ MPE% RSQ n 
M1 91.18 0.493 89.18 0.815 64.33 0.728 23.40 0.921 0.891 
M2 95.87 0.798 56.56 0.983 37.57 0.945 14.12 0.953 0.718 
M3 36.60 0.829 31.40 0.933 15.84 0.958 3.35 0.989 0.449 
M4 36.87 0.757 35.39 0.809 17.44 0.887 4.33 0.989 0.415 
Dissolution theories and kinetic models are often used to describe the drug release 
characteristics of the tablets by using the dissolution data obtained. The dissolution data 
for all four 3D printed tablets were fitted to four mathematical models to determine which 
model is most suitable to describe the release mechanism of the formulations. In general, 
the model that shows the highest coefficient of determinations (RSQ) and the smallest 
mean percentage error (MPE) can be considered as the closest representation of the drug 
release mechanism for the formulation. The results from the kinetic model analysis were 
shown in Table 7.6. The results suggest that all four metformin formulations seem to best 





Korsmayer-Peppas equation, when the value of n falls between 0.45 and 0.89, the drug 
release mechanism can be described as non-Fickian (anomalous). This means that the 
drug release can be caused by diffusion and swelling of polymer matrix [635]. This 
phenomenon can only be seen in M1 and M2 tablets. This could be caused by the presence 
of Eudragit. Eudragit is permeable to water but not dissolvable. Hence, the swelling of 
the polymer occurs. When n value is below 0.45, the drug release mechanism is diffusion-
controlled, representing a Fickian diffusion release mechanism [636]. This means that the 
drug release from M3 and M4 were diffusion. Unlike formulations M1 and M2, there was 
no swelling of polymer in M3 and M4 as PCL is hydrophobic and PEG is highly soluble 
in water. Hence, metformin was released through diffusion. In general, the Korsmeyer-
Peppas model is a more comprehensive and suitable model to describe the drug release 
mechanism for polymeric systems.  
7.5 Conclusion 
Sustained release drug delivery systems can offer several advantages to patients as it can 
reduce the frequency of medication intake, improve the therapeutic efficacy of a 
medication, and reduce the side effects that can be caused by the drug. An attempt to 
sustain the release of metformin using four different polymeric composition was 
investigated. The polymeric compositions were loaded with metformin using HME in the 
form 3D printable filaments. The filaments were then used as feedstock for the 3D 
printing of metformin tablets. The study showed that PCL based filaments were more 
effective in sustaining the release of metformin than the Eudragit based filaments. The 
higher the percentage of PCL, the slower the drug release. This is because PCL is 
hydrophobic and the drug release study suggests that metformin was released through 
diffusion. The advantage of using PCL is that it has a very low melting point at around 
60 °C. Therefore, the HME and 3D printing processes can be operated at a temperature 
as low as 65 °C, which could prevent any possible thermal degradation. This could is 
particularly beneficial for pharmaceutical applications as this offer an opportunity to 
process some excipients and API are thermosensitive. Due to the low processing 
temperatures, thermal degradation can be prevented.  
3D printing was chosen as it offers great flexibility in the type of drug delivery devices 
that can be produced. Apart from that, 3D printing is very effective at producing 





the desired outcome. Although a tablet has been chosen to be 3D printed, other drug 
delivery systems such as transdermal patches and microneedles can also be easily 
produced due to the flexibility of 3D printing. The 3D printing technology also allows the 
incorporation of more than one API into a formulation. This can be easily achieved using 
printers with more than one printing head, where different filaments containing different 
APIs can be printed one after the other. However, the filaments containing different APIs 
can also be changed around to achieve a dosage form containing multiple APIs.  With the 
use of HME, the release pattern and the dose can be tailored according to the patient’s 






Chapter 8 : Fabrication of flexible Resistance Temperature 
Detectors (RTDs) temperature sensors via FDM 3D 
printing and thin-film fabrication technology 
8.1 Introduction 
Continuous health monitoring has received a significant amount of interest from 
consumers to technology development companies. Due to the advancement in 
technology, people are now able to measure and monitor their own health status without 
needing to attend clinics appointment in person. Therefore, healthcare resources can be 
reserved for those when it is absolutely necessary. Being able to monitor vital signs 
ourselves via some healthcare technology can help us to track how our lifestyle is 
affecting our health and allow us to make changes accordingly. These technologies may 
help revolutionise our healthcare systems to make them more accessible and also reduce 
the ever-increasing pressure that is put on healthcare services due to our ageing society. 
Hence, much effort has been put into improving the reliability of these technologies.  
One simple but important parameter that needs to be frequently monitored is our body 
temperature. Our body regulates its temperature so that it could stay constant at around 
37 °C and other organs can function normally. A constant body temperature can be highly 
important and a slight shift for just a couple of degrees can cause serious health problems, 
affecting the normal functions of our body such as enzyme activity, hormones etc [692]. 
Some of the factors that may cause a disruption to our body temperature include abnormal 
metabolic function, elevated glucose levels or even side effect of some medications 
[207,693,694]. 
Heat is often produced through the metabolic reactions that happen in our body. As heat 
is produced, an equal amount of heat needs to be dissipated to ensure our body 
temperature stays constant [695]. Heat dissipation often occurs through our skin as it is a 
superior thermoregulator [696]. However, the glucose level in our body can disrupt the 
heat balance as an increase in glucose level can cause an increase in body temperature 
[697,698]. This is because the active oxidation process of glucose produce heat. This can 
be more evident in diabetic patients as they often have issues with dissipating heat and 
keeping their body temperature in control [694]. For instance, when a diabetic patient 





heat production than heat dissipation [699]. Hence, constant monitoring of body 
temperature can be useful for diabetic patients as it can give an indication of their daily 
glucose level. This method of glucose monitoring has been proven feasible and can be 
highly preferred as it is not invasive, reusable and cost less than using a traditional lancet 
and test strip [700].  
Apart from that, skin temperature can be used as a parameter to early detect any 
underlying health issues. For example it can be used to detect wound or other infections, 
and predict the occurrence of diabetic foot ulcers [701–705]. This can help avoid and act 
as warning signs for any life-threatening conditions. A study has reported that local skin 
temperature assessment can be an effective way for the early detection of diabetes-related 
foot complications. The difference in the mean temperature values of the two feet at any 
spot may be used to determine the urgency of treatment [706]. Besides the skin, some 
other parts of the human body which may be suitable temperature measurement include 
the forearm, wrist and fingertips [700]. 
The purpose of this study is to fabricate a simple and low-cost temperature sensor that 
exhibit flexibility and stability to be used as a skin temperature sensor. The flexible sensor 
fabricated could have the potential of being integrated with the 3D printed drug delivery 
systems as described in the previous chapters, forming a smart drug delivery system. This 
can potentially be in the form of an implant or a smart electronic tattoo that can be 
attached to the skin [341,707–709]. The function of smart medical systems relies heavily 
upon the sensors integrated into the systems. This is because the sensor in the system 
detects signals it is purposed to sense, then feeds the information to the system for it to 
respond as being programmed. The fabrication of flexible sensors has received much 
research interest in particular for biomedical sensing applications. This is because not a 
part of the human body is completely flat and flexible sensors can conform to the 
curvature of the human body whilst retaining its function.  
In this study, the flexible temperature sensors were designed to be Resistance 
Temperature Detectors (RTDs). RTD temperature sensor is a common device used for 
temperature measurement and is usually made of materials that have a positive 
temperature coefficient. A material that exhibit a positive temperature coefficient means 
that the electrical resistance of the material will increase with an increase in temperature. 





RTD is often more accurate and stable as compared to a thermocouple and thermistor 
[212,710]. It is more suitable when high precision and accuracy is required. Platinum is 
often used in RTDs as it has excellent corrosion resistance, excellent long-term stability 
and measures a wide range of temperature (-200 °C to 850 °C) [711].  
Two fabrication methods were used to fabricate the temperature sensors; Fused 
Deposition Modelling (FDM) 3D printing method and a thin-film fabrication technique 
called the lift-off process. The 3D printed sensors were printed using two different 
conductive Polylactic acid (PLA) filaments that are commercially available. The sensors 
were printed on flexible mylar substrate. Both conductive filaments used were 
commercially available, one contained carbon black (CB) and the other contained 
graphene. The exact percentage of compositions for these conductive PLA filaments were 
not available publicly due to intellectual property protections. The product information 
of the CB PLA filament shows that the filaments were made up of Natureworks 4043D 
PLA, a dispersant and conductive CB. It was suggested that the percentage of CB present 
was ~20% via thermal degradation analysis on the filament [712]. The filament showed 
excellent flexibility and its measured resistance is 1.8 kΩ at 10 cm length for a 1.75 mm 
thick filament. Its volume resistivity is 15 Ω-cm. On the other hand, the graphene PLA 
may contain graphene of ~8% in its composition and contain other additives as well [713].  
The resistance of the graphene filament is 4 kΩ at a length of 1 meter and has a volume 
resistivity of 0.6 Ω-cm. The performance of the two 3D printed temperature sensors was 
measured and compare. 
Furthermore, thin-film temperature sensors were fabricated on a flexible polyimide 
substrate using a thin layer of gold. The performance of all fabricated sensors was 
measured. Thin film flexible sensors were preferred as they can be more suitable for 
biomedical applications, in particular for non-invasive monitoring on human skin. Thin 
film sensors are typically smaller and have faster response time, which is desirable in 
many applications, particularly for biomedical applications. Thin-film fabrication is very 
effective for the fabrication of thin and flexible sensors. Some of the advantages of this 
fabrication method includes low cost, large area compatibility and high scalability 
[327,714]. This study will also demonstrate how a flexible resistive temperature sensor 
can be easily fabricated by patterning gold on flexible polyimide thin films. The thin-film 
fabricated sensor may offer better flexibility than the 3D printed sensor as the thin-film 







DuPontTM Kapton® E polyimide film with a thickness of 50 μm was purchased from RS 
Components Ltd. (Corby, UK). ma-N 1420 negative photoresist and ma-D 533 developer 
for photoresist from micro resist technology was purchased from A-GAS (Rugby, UK). 
Isopropanol (IPA) was purchased from VWR chemicals (East Grinstead, UK). Acetone 
was purchase from Sigma Aldrich (Gillingham, UK). Gold (Au) Pellets up to 4 mm with 
99.99% purity suitable for thermal evaporation were purchased from Kurt J. Lesker 
Company® (Hastings, UK). Conductive Polylactide (PLA) Filaments from Protopasta 
were purchased from 3DFilaPrint (Southend on Sea, UK). This conductive filament was 
also referred to as carbon black (CB) PLA. Conductive graphene (G) PLA filaments from 
BlackMagic3D were purchased from graphene supermarket (NY, US). Mylar polyester 
film with a thickness of 0.25 mm was purchased from RS Component (Corby, UK). 
Deionised water was prepared using Merck Millipore Milli-QTM ultrapure water 
purification system from Fisher Scientific (Loughborough, UK). All materials and 
chemicals were used as received. 
8.3 Experimental methods 
8.3.1 3D printing of temperature sensor 
The CAD model of an RTD sensor was created in Solidworks (Dassault Systemes, 
Waltham, MA, US). The 3D model was then saved as an .STL file and imported to Cura 
for Robo 2.5.0 software (Robo3D, San Diego, CA, US) for slicing. The sliced 3D model 
saved as .gcode file and was printed using a Robo R2 FDM 3D printer (Robo3D, San 
Diego, CA, US). The layer height for printing was set to 0.1 mm, the printing temperature 
for both filaments was 225°C and the print bed temperature was set to 70°C. The designed 







Figure 8.1: CAD model designed to be used for 3D printing of RTD sensors 
8.3.2 Thin-film fabrication of flexible resistance temperature detectors (RTDs) 
 
Figure 8.2: Schematic diagram for the fabrication process of a thin-film temperature 
sensor via the lift-off method a) clean polyimide substrate, b) polyimide substrate spin 
coated with a layer of photoresist solution, c) mask with sensor structures aligned with 
polyimide substrate coated with photoresist for UV exposure, d) deposition of gold 
layer, e) removing of unwanted gold layer with uncured photoresist in an acetone bath 
to form sensor structures required on the substrate. 
The fabrication technique for the flexible temperature sensors is called the lift-off 
technique. The simplified steps for the process are shown in Figure 8.2. Firstly, a 
polyimide substrate of 60 mm x 60 mm was first cleaned in an acetone bath with a beaker 
was placed in an ultrasonic cleaner (Cole-Parmer, St. Neots, UK) for 5 mins. The 
substrate was then transferred to an IPA bath and sonicated for another 5 mins. The 
residue solvents were removed from the substrate by rinsing it with deionised water. The 
wet substrate was then blow dry with compressed air. The cleaned substrate was then 
placed on a pre-heated hotplate at 150 °C for 5 mins to completely remove the moisture 
and contaminants on the surface. After heating, the substrate was allowed to cool down 





was dropped onto the substrate surface using a pipette and spin-coated at 3000 rpm for 
30 s. The substate coated with ma-N 1420 was then placed on a hotplate at 100 °C for 2 
mins.  
After the coating of ma-N 1420 negative photoresist on the polyimide substrate, a 
chromium mask with RTDs structures pattern on a glass substrate produced by Masken 
Lithograhie und Consulting GmbH (ML&S, Jena, Germany) (depicted in Figure 8.3) was 
aligned with the coated PI substrate using a manual mask aligner MJB3 (Karl Suss, 
Garching, Germany). Once aligned, the substrate was exposed to Ultraviolet (UV) light 
for 28 s to crosslink the photoresist with the substrate. After crosslinking the photoresist 
with the PI substrate, the substrate was immersed in a ma-D 533 developer bath for 150 
s. After the development, the substrate was then cleaned with deionised water and dried 
with an air gun for gold deposition. The gold deposition was carried out using an Edwards 
Auto 306 Vacuum Thermal Evaporator (Island Scientific Ltd, Isle of Wight, UK). The 
current for gold deposition was set to between 3 A and 4 A, and the thickness of the gold 
deposited was 50 nm. The lift-off process was then carried out after gold deposition. The 
gold deposited PI substrate with developed negative photoresist was placed in an acetone 
bath for 20 mins to remove the gold layer where the photoresist was not crosslinked. This 
process was repeated 3 times to ensure all unwanted gold surfaces had been removed. 







Figure 8.3: Mask used for UV patterning of the RTDs structure for the fabrication of 
thin-film temperature sensor. 
8.3.3 Characterisation of temperature sensors 
The electrical conductivity of the 3D printed and the thin film temperature sensors were 
determined by carrying out a current-voltage characterisation using the Keysight B1500A 
Semiconductor Device Analyzer (California, USA). A voltage of 5 V to -5 V double 
sweep was applied and the current flow of the devices were measured. The data were 
collected and analysed using the Easy EXPERT group+ software (Keysight, California, 
USA). 
8.3.3.1 Response of sensors to temperature change 
The resistance of the 3D printed temperature sensors and the thin film temperature sensor 
were measured at different temperatures (15 °C, 20 °C, 25 °C, 30 °C, 35 °C, 40 °C, 45 
°C, 50 °C, 55 °C, 60 °C, 65 °C, 70 °C, 75 °C, 80 °C). The sensors were placed on an 
Ecotherm digital chilling/heating dry bath (Torrey Pines Scientific, Carlsbad, CA, US), 
also referred to a hot plate, at the temperatures aforementioned and the change in 
resistance was measured using a tabletop digital multimeter Keysight 34465A (Keysight 
Technologies, Wokingham, UK).  
8.3.3.2 Temperature cyclic test 
Furthermore, temperature cyclic tests were then carried out on both the 3D printed sensors 
and thin film temperature sensors. The sensors were attached to a hot plate and the 





kept for 5 mins and the change in resistance of the sensors were captured at a rate of every 
second.  
8.4 Results and discussion 
8.4.1 3D printed temperature sensors 
 
Figure 8.4: 3D printed RTD sensors a) printed using conductive carbon black PLA b) 
printed using conductive graphene PLA. 
Figure 8.4 shows the image of the 3D printed RTD sensors in both conductive filaments. 
The thickness of the sensors was measured at around 0.3 mm. As the 3D printer was set 
to print at a resolution of 0.1 mm, three layers of materials were printed in total for both 
3D printed RTD sensors. The thin meander structures at the centre were designed for 
temperature sensing. These thin oscillating patterns were to ensure the resistance of the 
sensor to be as high as possible. The temperature sensors were designed to have four 
larger square contact pads which were used for measurements. This is known as the 
Kelvin setup and it is aimed to reduce the influence of resistance at the contacts in order 
to get a more accurate measurement. Due to the poor resolution and printing technique of 
Fused Deposition Modelling (FDM) 3D printing, the printed structures may not be 
perfectly straight and some bits were connected to each other as seen in Figure 8.4. The 







Figure 8.5: Voltage of -5V to 5V applied to obtain the obtain the current vs voltage of 
the 3D printed sensors. 
The conductivity of the 3D printed temperature sensors was measured by applying a 
voltage of -5 V to 5V to the sensors through the contact pads. Figure 8.5 shows the 
comparisons of the current vs voltage plots for the 3D printed temperature sensors printed 
with both G and CB PLA. The graph shows the relationship between the electric current 
through the device at the corresponding voltage applied. Both sensors showed linear 
behaviour obeying Ohm’s law, where the current is proportional to the applied voltage. 
Ohm′s Law: V (Voltage)  =  I (Current) x R (Resistance)  (Equation 8.1) 
The G PLA shows better conductivity than the CB PLA. The maximum current that it 
reaches is much higher than CB PLA. The maximum current that G PLA can achieve is 
around 550 μA whereas the CB PLA can only achieve a maximum of around 150 μA. 
The conductivity of the sensors can be further quantified by calculating the conductance 
of the sensors using the resistance measured. The electrical conductance of can be 
calculated using the inverse of the resistance (1 𝑅⁄ ). Electrical conductance is a 
measurement of how easily electricity can flow along an electrically conductive path 
[715]. The calculated conductance of the CB PLA sensor and the G PLA sensor was 
0.0238 mS and 0.1042 mS respectively. This shows that G has superior conductivity than 
CB, making it very suitable to be used for electronics applications. The current vs voltage 
plot showed no hysteresis for both materials, which means the current-voltage 
relationship does not depend on the history but only the present voltage applied. This 
characteristic is highly desirable for the fabrication of a sensor with high sensitivity in 


























Figure 8.6: The change in resistance of the 3D printed temperature sensors as 
temperature increases from 15 °C to 80 °C. 
Figure 8.6 shows the change in resistance of the 3D printed temperature sensors when the 
temperature changes. The results showed here confirmed that the 3D printed temperature 
sensors are working as the resistance increases as the temperature increases. This shows 
that both materials have a positive temperature coefficient, where the resistance increase 
with temperature. The maximum resistance of the G sensor is much lower than the 
maximum resistance of the CB sensor. This finding is coherent with the results in Figure 
8.5, showing G has better conductivity than CB as the overall resistance measured in the 
graphene sensor was lower than the CB sensor. However, the increase in resistance with 
temperature for the sensor printed with CB PLA was more linear than the G PLA. It seems 
that CB was more responsive to the change in temperature than graphene. This may 
suggest that CB may be more suitable for temperature sensing than graphene as it may 
have better sensitivity to temperature change. The sensitivity of the temperature sensors 
can be measured using the temperature coefficient of resistance for the sensors. This can 
be calculated using the following equation: 
Rt = Rref(1 + 𝛼(T − Tref)  (Equation 8.2) 
where Rt is the resistance at temperature T in °C, Rref is the resistance at 20 °C, α is the 
temperature coefficient resistance, and Tref is the temperature at 20 °C [716]. The CB 
PLA sensor has a sensitivity of 0.01416 ± 0.00004 °C-1 whereas the G PLA sensor has a 































has a higher sensitivity than the G PLA sensor. The is as reflected in Figure 8.6, where 
the increase in resistance with temperature of CB PLA sensor was more linear than the G 
PLA. 
 
Figure 8.7: 5 cycles of resistance measurements from 20 °C to 40 °C for both 3D 
printed temperature sensors. 
Temperature cyclic tests were carried out on the 3D printed temperatures that were made 
of two different conductive materials and the results were shown in Figure 8.7. It is 
important for a temperature sensor to be able to produce repeatable measurements. The 
purpose of the cyclic test was to confirm whether the temperature sensors are responsive 
and sensitive enough to the change in temperature. The temperature range of 20 °C to 40 
°C was chosen for the test as this is within the fluctuation of skin temperature range, 
depending on the activities being carried out [717]. The sensors were placed on a hot plate 
and the temperature was set to increase from 20 °C to 40 °C. The change in resistance 
was measured for 5 mins at every second. After 5 mins, the plate was cooled down to 20 
°C. The results showed that the CB PLA printed temperature sensor was more stable and 
repeatable when heated. This is because the changes in resistance of the CB PLA sensor 
were similar throughout the cycles when heated up to 40 °C. When cooled to 20 °C, the 
CB PLA sensor also return to its original resistance value as indicated in Figure 8.7, 
showing the change in resistance was close to zero. On the other hand, the cyclic response 
of the temperature sensor printed using G PLA was not as reliable and repeatable. The 
resistance of the sensor did not return to the value when it was first measured at the end 
of the cycle and there were some small fluctuations during the measurements. This 





change in resistance of G PLA seemed to experience a lag as the temperature change, 
whereas the response of CB was quicker. Although G PLA has better conductivity, CB 
PLA seems to exhibit better sensitivity and reliability as a temperature sensor.  
 
Figure 8.8: Bending test on curved surface with a radius of a) 3.5 cm b) 2.55 cm. 
 
Table 8.1: Resistance measurement for the bending cycles of 3D printed temperature 
sensors at room temperature. 
Resistance of 3D printed temperature sensors (kΩ) 








Flat Bend Flat Bend Flat Bend Flat Bend 
30.18 30.56 4.14 5.05 30.21 30.68 2.91 3.12 
30.26 30.54 4.19 5.18 30.48 30.63 2.92 3.39 
30.28 30.74 4.09 4.52 30.34 30.68 2.98 3.38 
30.24 30.76 4.03 4.55 30.52 30.78 2.95 3.31 






Figure 8.9: Change in resistance for 5 bending cycles of the 3D printed temperature 
sensors. 
A bending test was carried out to investigate the flexibility of the 3D printed sensors. The 
sensors were first peeled from its original mylar substrate and positioned over two curved 
surfaces with radii of 3.5 cm and 2.5 cm at room temperature for the bending test. The 
set-up of the bending for the 3D printed sensors were as shown in Figure 8.8. The strain 




 (Equation 8.3) 
where df is the thickness of the sensor, ds is the thickness of the substrate and R is the 
radius of curvature [718]. The estimated strain on the surface of the sensors when being 
bent over the surfaces with radii 3.5 cm and 2.55 cm were 0.0715 % and 0.0981 % 
respectively. The resistance values of both the 3D printed sensors when they were flat 
and bent throughout 5 cycles were recorded and displayed in Table 8.1. The results 
showed that there were very subtle changes to the resistance as the sensors were bent. 
Generally, the resistance of the sensors increased slightly as it was bent over a curved 
surface. This could be due to the thickness of the 3D printed sensors. The sensors were 
relatively thick which means they could be more resistant to bending. Hence, the change 
in resistance was small. However, the increase in resistance when bent was more obvious 
in the G PLA sensors than the CB PLA sensors. The average values of the change in 
resistance during the bending cycles were shown in Figure 8.9. The results showed that 
CB PLA sensors were more stable in the bending test than G PLA sensors. This indicates 
that CB PLA may have better flexibility and more suitable to be used for flexible sensing 





curvature. On the other hand, the resistance G PLA sensor had a larger increase when the 
radius of curvature increase. Nevertheless, the sensors showed good stability and 
flexibility which make the sensors suitable to be used on curved surfaces. This could be 
particularly beneficial for biomedical applications such as measuring skin temperature as 
the sensor may be able to conform to the skin surface.  
As the sensors were peeled off from their substrate and attached to a curved surface, this 
shows that the sensors offer the advantage of being transferrable to other substrate after 
being fabricated. The resistance of the sensors still remained consistent and stable even 
after being transferred. Hence, the 3D printed sensors also exhibit good stability and 
modularity for use in biomedical applications. To demonstrate further the ability of the 
3D printed sensors to perform as temperature sensors on different substrate surface, the 
printed sensors were attached to wood and plastic surfaces at room temperature (Figure 
8.10). The resistance of the sensors was then measured and the results were shown in 
Table 8.2. The resistance values shown were an average value of resistance over 1 minute. 
The results showed the stability of both 3D printed sensors when being used to measure 
the temperature at different surfaces. Both the wood and plastic surface were at room 
temperature of around 20 °C. The resistance values for both CB and graphene PLA 
sensors were considered consistent as both the sensors measured similar resistance values 
for different surfaces at the same temperature.  
 
Figure 8.10: Temperature sensing of different substrate surface at room temperature a) 
wood surface b) plastic surface. 
Table 8.2: The resistance of the 3D printed temperature sensors when attached to wood 
and plastic as new substrate. 
Substrate Resistance (kΩ) 
Carbon Black PLA Graphene PLA 
Wood 30.52 ± 0.07 3.52 ± 0.04 






Figure 8.11: 3D printed temperature sensors attached on the outer surface of glass vial 
filled with water at 3 temperature points for temperature sensing. 
To measure the response of both 3D printed temperature sensors at different temperatures, 
the sensors were attached to the outer surface of a glass vial (Figure 8.11). The glass vial 
was then filled with water at 3 different temperature: room temperature water (~ 25 °C), 
warm water (~ 40 °C), and boiling water (~ 100 °C). The resistance of the 3D printed 
temperature sensors was then measured for a duration of 1 min. The results in Table 8.3 
show the average resistance of the sensors when the vial was filled with water at 3 
temperature points. The temperature sensors were responsive to the temperature of the 
water. However, the resistance measured does not reflect the temperature of the water but 
of the outer surface of the glass vial. This is because heat energy was lost through 
conduction when heating up the glass. Hence, the temperature of the glass could a lower 
than the water itself.  
The measurements here may not be directly comparable to the measurements shown in 
Figure 8.6. This is because the measurements from Figure 8.6 were only taken up to a 
maximum temperature of 80 °C. Apart from that, the sensors were placed on a flat surface 
for the measurements in Figure 8.6. However, the measurements tabulated in Table 8.3 
were recorded when the sensors were attached to a curved surface. This means that the 
sensors were bent on the surface and the bending of the sensors can cause the resistance 
to increase due to the strain exerted on the sensors. The resistance values in Table 8.3 
have accounted for the bending of the sensors and the higher temperature detected by the 
sensors. A more accurate comparison for the performance of the sensors may be 
calculating the temperature coefficient resistance, α. The calculated α for the CB PLA 





1, which corresponds to the measurement using the data as in Figure 8.6 above. This 
shows the stability of the temperature sensors even under bent conditions.  
Table 8.3: The resistance of 3D printed sensors when attached to the outer surface of a 
glass vial filled with water at 3 different temperatures. 
Water Temperature Carbon Black PLA Graphene PLA 
Room temperature (~ 25 °C) 31.2 ± 0.2 3.19 ± 0.08 
Warm (~ 45 °C) 51.9 ± 0.9 3.42 ± 0.09 
Boiling (~ 100 °C) 64.7 ± 0.5 4.16 ± 0.08 
8.4.2 Thin-film temperature sensors 
 
Figure 8.12: Images of the fabricated thin-film RTDs a) image of the whole film pattern 





structure on the left, d) enlarged image of the resistor structure in the centre, e) enlarged 
image of the resistor structure on the right. 
Figure 8.12 shows the images of the flexible temperature sensors fabricated on the 
polyimide substrate. Figure 8.12a shows the arrays of temperature sensors, where the 
substrate consists of many rows of the single temperature sensor. The temperature sensors 
are made of gold layers at a thickness of 50 nm. A single sensor strip has a width of 500 
μm and a length of 67.5 mm. Each sensor strips are separated with a gap of 200 μm. 
Similar to the 3D printed temperature sensors, the structure of the sensors consists of 
resistors that have very thin oscillating lines. There are three resistors in a single strip 
which is shown in Figure 8.12b-e. The very thin structures of the temperature sensor can 
enhance the response time and resolution for temperature sensing. The thin-film 
structures were fabricated via the lift-off technique, which is a simple, easy and efficient 
technique to pattern metals without the use of any strong chemicals. As the method can 
eliminate the use of strong and hazardous chemicals, this method could be highly 
desirable particularly for the fabrication of biomedical sensors. This is because most 
biomedical sensors will have close contact with the human body and must not pose any 
health hazards to the human body. Apart from that, sensors fabricated using this technique 
can be compatible with pharmaceutics fabrication as some pharmaceutical materials can 
be chemically sensitive and can degrade in the presence of hazardous chemicals.  
 
Figure 8.13: The average current vs voltage sweep and average resistance for a bunch of 
10 thin film RTD strips 
The curent-voltage characteristics of the flexible temperature sensors were measured and 























tested is shown in Figure 8.13. The measurements were taken only from the resistors at 
the centre (Figure 8.12d) using the larger long contact pads on the left and right. The 
fabricated gold thin-film temperature sensors showed excellent conductivity reaching a 
maximum current of around 5.5 mA at 5 V and around -6 mA at -5 V. The maximum 
average resistance measured was around 900 Ω. The temperature sensors also showed no 
hysteresis in the double I-V sweep as the current flow follows the same straight line when 
the voltage of -5 V to 5 V was applied twice.  
 
Figure 8.14: The I-V sweeps for a single thin film RTD strip at two different 
temperatures (room temperature and 45 °C). 
The current-voltage characteristic at two different temperatures for the same single 
flexible temperature sensor strip was then measured. Measurements were taken when the 
sensor was place on the plate of the probe station at room temperature (~ 20 °C) and at ~ 
45 °C. To obtain a temperature of 45 °C, a heating element with a temperature sensor was 
attached to the plate to heat up the plate. The current-voltage measurement was taken 
when the temperature of the plate was stabilised. Figure 8.14 shows the I-V sweeps for 
the thin-film temperature sensor at both temperatures. The maximum current flow in the 
sensor was higher at room temperature than at 45 °C. At room temperature, the current 
flow was around 6.5 mA at 5 V and -7 mA at -5 V. On the other hand, the current flow 
temperature at 45 °C reached only around 5.5 mA at 5 V and -6 mA at 5V. This also 
means that the resistance at 45 °C is higher than at room temperature, showing that the 
resistance of the sensor is higher at higher temperature. The resistance at room 



























the thin-film temperature sensor were then further confirmed with a temperature response 
experiment by increasing the temperature it was measuring more systematically.  
 
Figure 8.15: The change in resistance of thin film RTDs as temperature increases from 
15 °C to 80 °C. 
To verify the positive temperature coefficient response of the thin-film RTDs, the 
resistance of a bunch of 20 RTDs were measured at the same time as temperature increase 
from 15 °C to 80 °C. The result is shown in Figure 8.15 as a resistance vs temperature 
plot. The resistance of the RTDs increase linearly as the temperature increase. This 
showed that gold is very responsive to change in temperature and is very suitable to be 
used as a temperature sensor. The sensitivity of the thin film temperature sensor was 
calculated using Rt = Rref(1 + 𝛼(T − Tref)  (Equation 8.2). The calculate sensitivity was 



















Figure 8.16: change in resistance for thin-film RTDs for cyclic test from 20 °C to 40 °C. 
The temperature cyclic test result for the thin-film RTDs was shown in Figure 8.16. The 
test showed that these thin-film RTDs made of gold were responsive and sensitive to the 
change in temperature. These sensors had good repeatability as the resistance at 20 °C 
and 40 °C were consistent throughout the cycle. The thin-film RTDs also had excellent 
sensitivity as the temperature increased from 20 °C to 40 °C, the change in resistance was 
instant and showed minimum lag time. These RTDs will be suitable to be used for skin 
temperature sensing as they were fabricated on a flexible substrate that is conformable to 
human skin. Pasindu et al. showed the effectiveness of a similar flexible temperature 
sensor which was integrated into a textile yarn [719]. The temperature sensing yarns have 
a very fast response time, even faster than the rate of change in skin temperature. This 
shows that such temperature sensors can accurately acquire temperature data and can be 



















Figure 8.17: Optical image taken after measurements. 
During the characterisation of the thin-film RTDs, the sensor strips that were made up of 
thin gold layer were exposed to friction with metal contacts for measuring the 
conductivity and resistance. Figure 8.17 shows the image of the RTDs after measurements 
were carried out. It can be seen metal contacts were scratched but gold layers were still 
intact on the polyimide substrate. Unlike platinum sensors from Kinkeldei et al., platinum 
lines will crack after deformation [711]. It was then suggested that more ductile metals 
such as gold, copper and aluminium can be used to overcome the issue of cracking on the 
sensors [711]. Therefore, the thin-film sensors made of gold may be more durable and 
were still working even after the surface was slightly scratched.  
As mentioned, these thin-film RTDs were very small and it was possible to fabricate up 
to 100 strip of sensors on a piece of polyimide film of approximately 60 mm x 60 mm. 
Although 100 sensors were fabricated on a single film, it was also possible to cut the 
sensors into single strips and function independently. This shows the modularity of the 
sensors. Similar to the 3D printed sensors, the thin-film sensors can also easily be 
transferrable to other surfaces but with the polyimide substrate. These thin-film sensors 
are highly integrable with many other applications, particularly for the smart textile and 
wearable devices applications [720–723]. The thin-film sensors exhibit better 
conductivity and temperature sensing response than the 3D printed sensors. This is mainly 
due to the excellent electrical properties of gold. The thin-film sensors were also more 
flexible due to the thinner structure.  
8.5 Conclusion 
Temperature is one of the most simple but important signals to be measured for health 





detection of diabetic foot problems. RTD temperature sensors were fabricated here using 
two different fabrication methods. Both 3D printing and thin-film deposition are simple 
and low-cost fabrication method. The 3D printed temperature sensors were printed using 
conductive PLA filaments. CB PLA filaments and G PLA filaments were used for the 3D 
printing of sensors and the temperature sensing performance were compared. The 3D 
printed G PLA showed better electrical conductivity than the CB PLA. However, the CB 
PLA temperature sensor showed better linearity and sensitivity than the G PLA sensor. 
The cyclic response test also confirms that the CB PLA temperature sensor was more 
stable responsive than the G PLA sensor. The CB PLA sensor showed better flexibility 
and stability after a few bending cycles. A batch of thin-film RTD sensors was also 
fabricated using a thin-film fabrication technique that involves the lift-off process. This 
thin-film RTD is made of a thin layer of gold, which was only 50 nm thick. The gold is 
deposited onto a flexible film that is 50 µm thick. Hence, the sensors showed high 
flexibility. As the thin-film sensors were much thinner than the 3D printed sensors, they 
offer better flexibility than the 3D printed sensors. The thin-film temperature sensors were 
also more conductive than the 3D printed sensors as they were made of gold. They also 
exhibit excellent linearity and cyclic response.  
The benefit of the 3D printed sensor is that it can be produced in one automated process 
through 3D printing. As in previous chapters, 3D printing has been used to produce drug 
delivery systems. This 3D printed sensor added to the drug delivery system to form a 
sensor integrated drug delivery device. The benefit of a temperature sensor can be used 
to detect and inflammation or infection on the site of drug delivery when being integrated 
with a drug delivery device such as a transdermal patch. Both 3D printed temperature 
sensors and thin-film temperature sensors showed great modularity. They can be easily 
attached to another substrate or system for temperature sensing. Hence, the fabricated 






Chapter 9 : Fabrication of a MoS2-based thin-film glucose 
sensing device 
9.1 Introduction  
Diabetes is one of the top ten chronic diseases in the world and is caused by the 
uncontrolled elevation of blood glucose levels. According to the World Health 
Organization (WHO), there are around 422 million people suffering from diabetes 
mellitus around the world and this number is still steadily increasing [293]. Diabetes can 
cause serious health consequences and can cause damage to the heart, blood vessels, eyes, 
kidneys and nerves. Therefore, diabetic patients are required to monitor their blood 
glucose levels regularly as the glucose level needs to be corrected immediately in order 
to prevent any diabetes-related complications. By regularly testing blood glucose levels, 
diabetic patients can monitor how their diets, medications and activities affect their 
diabetes. It is also important for doctors to manage the treatment plan according to the 
patient’s condition. 
The most commonly used technology for blood glucose monitoring is by using a 
glucometer. The glucometers analyse a small amount of blood on a paper strip drawn 
from the diabetic patient. This method involves regular finger pricking, in which a small 
drop of blood is drawn using a lancet and the blood is then dropped onto an enzymatic 
strip to generate a reading on a glucometer. This method has been very convenient and 
has improved over the years, but it is still not very patient compliance as diabetes is a 
lifetime chronic disease. Not only does finger pricking may cause pain, but it also creates 
a wound on the skin which may increase the risk of infection when proper hygiene is not 
kept. Besides that, the sensitivity of the fingertip may be impaired and the patient may 
often forget to measure their glucose level as this needs to be done regularly throughout 
the day. Continuous glucose monitoring has therefore received growing interest as it 
provides a continuous profile of a patients glucose level, allowing patients to identify 
glycaemic spikes and administer the right amount of insulin at the right time [724].  
Currently, continuous glucose monitors are implanted under the skin and can send 
glucose levels information to a display device via a transmitter. This information can also 
be accessed by the healthcare team remotely so that the diabetic patient is closely 





under the skin, the glucose levels being measured are actually from the interstitial fluids 
rather than the blood. The advantage of continuous glucose monitoring is that it shows 
the trend of glucose levels in diabetic patients so that the patients can take action early. 
As a result, it can help to reduce the possibility of hypo or hyperglycaemic events. 
However, current continuous glucose monitoring systems require implantation and is a 
very expensive technology. Some are also not patient-friendly as it requires frequent 
calibration. Most of the transmitter in the glucose monitoring devices are operated by 
batteries and the batteries life often last for only a few weeks or months [725,726]. The 
batteries will need to be replaced or recharge. The glucose sensors in these devices often 
have a short lifetime of a few days or weeks which also requires frequent replacing [727].  
Therefore, a minimally or non-invasive glucose measurement has attracted much 
attention from researchers to health technology companies. The work to improve the 
sensitivity and reliability of the sensor has been ongoing. Many have shown improved 
performance but has been their usability has been limited due to the high cost. Not only 
does the development of a glucose biosensor need to be highly sensitive and have a quick 
response time, but much focus has also been put on low-cost fabrication as well. To 
achieve non-invasive glucose monitoring, an alternative to blood glucose measurements 
is required. Some has suggested that tear fluid is an attractive option due to easy 
accessibility of the samples and evidence that have shown a correlation between tear 
glucose and blood glucose [728]. Other biofluids that have shown potential include sweat, 
saliva and interstitial fluid [729–732].  
In general, the glucose-sensing ability of the glucose sensors can be simplified into two 
categories: enzyme-based and non-enzyme-based glucose sensors [733,734]. Enzyme-
based glucose sensors are the gold standard as enzymes are sensitive to glucose and can 
create a rapid electrochemical response accurately in the presence of glucose 
[733,735,736]. One of the most widely used enzymes in the glucose biosensor industry is 
glucose oxidase (GOx), which is a glucose-sensing protein [303,737]. GOx is a typical 
flavin enzyme with flavin adenine dinucleotide (FAD) and it’s normally isolated from 
fungi such as Aspergillus niger and Penicillium [738,739]. It has also been reported that 
GOx exhibits antibacterial activity in the presence of oxygen and glucose [740]. For 
glucose sensing, GOx oxidises glucose to gluconic acid and hydrogen peroxide [741]. 






glucose + GOx → gluconic acid + hydrogen peroxide (Equation 9.1) 
hydrogen peroxide → 2e− + O2 + 2H
+ (Equation 9.2) 
Typically, enzymatic glucose sensors detect the presence of glucose by measuring the 
rate of glucose oxidation. The reactions describe from the equations above transfer 
electrons to a sensing electrode.  The electronic current produced on the electrode will be 
measured and will correspond to the glucose concentration detected [742]. Such glucose 
biosensors are called amperometric biosensor as it is based on the direct electron transfer 
between an electrode and immobilised GOx. This has been a promising method for 
glucose sensing and GOx is widely used because it is inexpensive, stable and its catalytic 
ability to glucose [743,744]. 
One of the widely known issues with enzyme-based glucose biosensors is the low 
electron-transfer rate causing low electrochemical signal in glucose biosensors [745]. 
Improving the electron transfer on the biosensor can enhance the sensitivity and accuracy 
of the sensors. Hence, much effort has been focused on improving the surface to improve 
electron transfer efficiency between the enzyme and the electrode. One innovative 
method that has been discovered is utilising the excellent chemical properties of advanced 
nanostructures and their nanocomposites. Some examples of the nanomaterials that have 
been used include metal nanoparticles, carbon nanotubes, graphene and many more [746–
750]. Nanomaterials have received much attention as it has become an attractive material 
in bioelectrochemistry, and also for the direct electrochemistry of GOx. This is because 
nanomaterials could provide an environment similar to the redox proteins in the native 
systems and give the protein molecules more freedom in orientation, which could reduce 
the insulating property of the protein, resulting in a better electron transfer [751,752]. In 
recent years, one class of nanomaterials, known as two-dimensional (2D) materials, has 
been of great interest particularly in many electronic applications [753]. 2D materials can 
include graphene and 2D transition metal dichalcogenides (TMDs) materials.  
Molybdenum Disulphide (MoS2) is one of the most popular TMDs being studied [754]. 
These materials are usually in layered positions where the Mo atoms and S atoms are 
covalently bound, and each layer is separated by van der Waals interactions [755]. MoS2 
exhibit unique electronic properties and high electron mobility, making it an interesting 
2D materials to be studied for use in wide range of applications [756]. Some of the most 





photo-active materials [761]. Apart from the high electron transfer abilities, the 
biocompatibility and high electrochemical catalytic activities of MoS2 makes it suitable 
for biosensor device applications [762].  
There have been several interests in using MoS2 for glucose biosensor. Su et al. has 
developed an electrochemical glucose biosensor by using a glass carbon electrode that 
was modified with MoS2 and decorated with gold nanoparticles [763]. Shan et al. 
developed a back-gated FET-based MoS2 glucose biosensor that is capable of detecting 
glucose at very low concentration [430]. A systematic study to investigate the effect of 
different MoS2 morphologies on its glucose-sensing ability was carried out by Tuan et al. 
[764]. The study showed that MoS2 nanoplatelets-based glucose biosensor had a higher 
sensitivity than MoS2 nanoparticles and MoS2 nanoflowers-based glucose biosensors. 
The layered structure of MoS2 allowed it to exhibit excellent mechanical properties and 
flexibility. Studies have shown that modification of MoS2 nanosheets with gold 
nanoparticles has increased the effective surface area and improve the conductivity of the 
material as it promotes electron transfer reactions [765–768]. The presence of MoS2 is 
able to improve the electron transfer rate and the electrochemical signal, hence improving 
the sensitivity and accuracy of the sensors.  
Due to the layered structure of MoS2, the material also exhibits high flexibility. The 
flexibility of such materials offers the opportunity to develop more reliable flexible 
sensors. This is because the increasing interest in wearable and point-of-care diagnostics 
devices have contributed to the need for flexible biosensors [769,770]. Flexible sensors 
are highly desirable especially for biomedical applications as they are more conformable 
to the human body.   
In this study, a flexible electrochemical glucose biosensor was developed via a simple 
thin-film fabrication method using easily accessible Kapton® polyimide film. Flexible 
electrodes have the potential to be used in wearable and flexible biosensing systems for 
biomedical applications [771]. Typically, flexibility can be achieved by using bendable 
polymers as the sensing electrode. However, most polymers are electrically insulators 
instead of conductors. Hence, the flexible polymer used was coated with materials that 
exhibit excellent electrical property to provide a flexible biosensor platform [772]. The 
electrode of the thin-film glucose biosensor was made of thin layers of gold and MoS2 
nanosheets. A synergistic effect can be achieved when using gold and MoS2 as the sensing 





enhance electron transfer on the electrode surface [773]. GOx was then immobilised onto 
the surface of the electrode for glucose sensing. MoS2 has also attracted much attention 
and has been promising for the fabrication of flexible electronics. The MoS2 layer was 
prepared using a simple liquid-based exfoliation method, forming a MoS2 dispersion 
which can be utilised easily.  
MoS2 dispersion which was prepared was characterised using the Atomic Force 
Microscopy (AFM) and Transmission Electron Microscopy (TEM). Studies have shown 
that MoS2 has been the potential for biosensing applications for the detection of 
biomolecules [426]. The bandgap in TMDs allows it to be sensitive in detecting 
biomolecular targets. The hydrophobic nature of MoS2 also allows better adsorption of 
biomolecule [774]. A study by Parlak et al. showed that MoS2 is an ideal semiconductor 
interface, and when assembled with gold nanoparticles can enhance electrocatalytic 
reactions as well as providing excellent electrochemical properties [775]. The MoS2 
prepared here is in the form of liquid and can be easily deposited onto the electrode via 
spin coating to achieve a homogenous layer as the electrode. As MoS2 is in the form of 
ink/dispersion, it also offers the potential to be used for printing electronics in the future. 
The advancement of 3D printing technologies has opened up the possibility of printing 
electronics material. The fabrication of functional electronics through printing can be a 
more low-cost fabrication method as the process is fully automated and can be completed 
in a single step without any post-processing steps [776]. 
The glucose-sensing ability of the fabricated thin-film glucose biosensors was 
investigated via cyclic voltammetry (CV) measurements. CV is a type of potentiometry 
electrochemical measurement that applies low to high voltages and vice versa on an 
electrode to obtain analytical, thermodynamic, kinetic and mechanistic information about 
chemical systems involving redox reactions [777]. The constant voltage sweep is applied 
to a working electrode that is connected to a reference electrode to produce a resulting 
current. The oxidation and reduction reactions that occurred on the electrode produces a 
current which could be used to indicate the concentration of an analyte. The current is 






9.2 Materials  
Molybdenum (IV) sulphide (MoS2) powder, Phosphate Buffer Saline (PBS) tablets pH 
7.4, Glucose Oxidase (GOx) from Aspergillus niger powder with 100,000-250,000 
units/g, 6-Mercaptohexanoic acid (6-MHA), NafionTM perfluorinated resin solution, 
acetone and glucose solution with 20% concentration in water were purchased from 
Sigma Aldrich (Gillingham, UK). Ethylcellulose, ethoxyl content 48%, 22 cps and 
microscope glass slides were purchased from Fisher Scientific, (Loughborough, UK). 
Isopropanol (IPA) was purchased from VWR chemicals (East Grinstead, UK). Gold (Au) 
Pellets up to 4mm with 99.99% purity suitable for thermal evaporation were purchased 
from Kurt J. Lesker Company® (Hastings, UK). DuPontTM Kapton® E polyimide film 
with a thickness of 50 μm and copper tape were purchased from RS Components Ltd. 
(Corby, UK). Deionised water was prepared using Merck Millipore Milli-QTM ultrapure 
water purification system from Fisher Scientific (Loughborough, UK).  All materials and 
chemicals were used as received. 
9.3 Experimental methods 
9.3.1 Preparation of MoS2 ink/dispersion 
Ethyl cellulose (EC) was mixed with Isopropanol (IPA). The IPA with EC was placed on 
a hot plate of 60C and was stirred using a magnetic stirrer at 600 rpm until the EC is 
fully dissolved. The MoS2 powder was then added to the IPA with dissolved EC.  The 
concentration of EC in IPA is 4 wt% and the initial concentration of MoS2/IPA was 
10mg/ml. The MoS2 was then dispersed into the solvent through 24 hours of sonication 
using a Fisherbrand® FB15051 bath sonicator (Fisher Scientific, Loughborough, UK). 
The dispersion was then centrifuged at 1000 rpm for 10 minutes to remove larger MoS2 
flakes that are not properly exfoliated using a Thermo Fisher Scientific SorvallTM ST8 
benchtop centrifuge (Fisher Scientific, Loughborough, UK). After centrifugation, around 
45 ml of the supernatant was transferred to a fresh bottle and the sediments obtained 
through centrifugation were discarded. Fresh 5 ml of 5 mg/ml MoS2 solution was 
prepared and added to the 45 ml of the MoS2 solution remained. The bottle of MoS2 
solution was then sonicated for another 24 hours. After the sonication process, the MoS2 
ink was left at a standstill for 24 hours to allow the sedimentation of larger MoS2 flakes 
which have not been properly dispersed before being used. Only the supernatant of the 





9.3.2 Deposition MoS2 dispersion onto a glass slide 
Two small pieces of copper tape, roughly 0.5 cm x 0.5 cm, were cut and stuck onto a 
microscope glass slide parallel to each other, leaving a gap of approximately 0.5 cm 
between the two copper tapes. A 1ml micropipette (Gilson Scientific, Dunstable, UK) 
was used to take the prepared MoS2 dispersion and dropped onto the glass substrate to 
fill the gap between the two copper tapes. The glass slide with MoS2 dispersion between 
two copper tapes was placed in an oven at a temperature of 330C for 3h for the annealing 
of MoS2. This sample was then used to measure the conductivity of the deposited MoS2. 
9.3.3 Fabrication of thin-film glucose sensor 
 
 
Figure 9.1: Schematic diagram of the fabrication of thin-film flexible electrochemical 
glucose biosensor made of gold/MoS2/gold layer functionalised with glucose oxidase. 
A piece of polyimide (PI) substrate was first cleaned in an acetone bath using ultrasound 
for 5 mins. The substrate is then transferred to an Isopropanol (IPA) bath and sonicated 
for another 5 mins. The residue solvents were removed from the substrate by rinsing it 
with deionised water. The wet substrate was then blow dry with compressed air. The 
cleaned substrate was then placed on pre-heated hotplate at 150 °C for 5 mins to 
completely remove the moisture and contaminants on the surface. After heating, the 
substrate is allowed to cool down on a clean metal cooling plate for 1 min. Once cooled, 
the substrate is deposited with the first layer of gold in an Edwards Auto 306 Vacuum 
Thermal Evaporator (Island Scientific Ltd, Isle of Wight, UK). The current for gold 
deposition was set to between 3 and 4 amps and the thickness of the gold deposited was 





for 30 s. The substrate was then placed in an oven at a temperature of 330 °C for 3h for 
the annealing of MoS2. A final layer of gold was then coated on top of the MoS2 layer.  
9.3.4 Functionalisation of glucose sensing device  
For the functionalisation of the glucose biosensor, the surface of the fabricated thin-film 
device was cleaned using ethanol and deionised water. 6-MHA was dissolved in ethanol 
at a concentration of 4 mM. The device was then immersed into the 6-MHA solution for 
3h at 4 °C. The enzyme glucose oxidase was dissolved in PBS pH 7.4 at a concentration 
of 5 mg/ml. Once the surface of the sensor was immobilised with 6-MHA as a chemical 
linker, 50 μl of dissolved GOx was dropped onto the surface and left for another for 3h 
at 4 °C. Finally, 5 μl of 0.05% Nafion was dropped onto functionalised surface to form a 
protective layer. The complete process of fabricating a flexible glucose biosensor is 
depicted in Figure 9.1. 
9.3.5 Characterisation studies 
9.3.5.1 Viscosity testing of MoS2 dipsersion 
A Brookfield DV2T Touch Screen Viscometer (Brookfield Ametek Inc., Middleborough, 
MA, USA) attached with an LV Spindle 61 was used to measure the viscosity of the MoS2 
ink with a speed of 100 rpm for 30 seconds at room temperature. The accuracy of the 
viscometer is ±0.60 cP. The viscosity of the MoS2 ink straight after the sonication process 
and after 24 hours of sedimentation were measured.  
9.3.5.2 Conductivity measurement 
The electrical property of MoS2 and the glucose biosensors fabricated were measured 
using the Keysight B1500A Semiconductor Device Analyzer (California, USA). A 3V to 
-3V of potential difference was applied. The data were collected and analysed using the 
Easy EXPERT group+ software (Keysight, California, USA). 
9.3.5.3 Atomic Force Microscopy (AFM) 
AFM was carried out to study the surface morphology of the thin-film devices using the 
Bruker Dimension Icon XR AFM (Bruker, MA, USA). The surface characterisation was 
carried out using the non-contact Kelvin Probe Force Microscopy (KPFM) technique. 
AFM data were collected using the software Nanoscope Bruker (Bruker, MA, USA) and 





9.3.5.4 Transmission Electron Microscopy (TEM) 
TEM was carried out on a 120 kV JEOL JEM1400-Plus (JEOL, Peabody, MA, USA) 
equipped with a Gatan OneView 4K camera (Gatan Inc., Pleasanton, CA, USA) for the 
MoS2 samples. Samples were prepared by pipetting 3-5 µL of MoS2 ink onto carbon 
square mesh (CF300CUUL) and ultrathin carbon grids by Electron Microscopy Sciences 
(CN Technical Services, Ltd., Wisbech, UK). The samples were allowed to dry before 
characterisation. The TEM data were collected and analysed using the Gatan Microscopy 
Suite Software (Gatan Inc, CA, USA).  
9.3.5.5 Electrochemical measurement of flexible glucose sensor 
The electrochemical investigation was done using a conventional three-electrode system 
with a PBS pH7.4 solution used as the electrolyte. The flexible glucose sensor was used 
as the working electrode, a silver/silver chloride (Ag/AgCl) double-juction reference 
electrode was used as the reference electrode and a platinum (Pt) wire electrode was used 
as the counter electrode. Cyclic voltammetry (CV) measurement and the amperometric 
response of the glucose sensor were measured at room temperature. The parameters for 
sampling interval was set to 2 mV/s, and a scan rate of 10 mV/s was used for the CV 
measurements. The applied voltage range was 600 mV to -800 mV. Three samples shown 
in Table 9.1 were used in the CV measurement for comparisons. 
For the amperometric response, the same three samples were first measured in the 
electrolyte without the presence of glucose. After the first measurement, 1 mM of glucose 
was added to the electrolyte and the change in current on the working electrode was 
measured. An initial potential of -0.8 V, and a sampling interval of 0.2 s were set as the 
parameter for the amperometric response measurements. All data were collected and 
analysed using the Gamry Data Acquisition and EChem Analyst software (Gamry 
Instruments, Warminster, PA, USA). 
Table 9.1: Three different glucose biosensors prepared for comparisons. 
Sample Glucose sensing surface 
A Gold surface functionalised with GoX protected with Nafion layer 
B Gold/MoS2/Gold surface functionalised with GoX protected with Nafion layer 





9.4 Results and Discussion 
9.4.1 Viscosity testing of MoS2 dispersion 
Table 9.2: Viscosity of MoS2 Ink after the sonication process 
Test run Viscosity (cP) 
Test 1 15.36 
Test 2 15.39 
Test 3 15.48 
Average 15.41 ± 0.06 
After 24 hours sedimentation 
Test 1 11.16 
Test 2 11.88 
Test 3 11.88 
Average 11.64 ± 0.42 
The viscosity of the MoS2 ink prepared was measured at room temperature on the results 
were shown in Table 9.2. The viscosity of the MoS2 ink was first measured after it was 
freshly prepared. The ink was then left to settle for 24 hours before a second viscosity 
measurement was taken. The results showed that the viscosity of the ink was slightly 
higher when it was freshly prepared than after being left to settle for a day. This shows 
that the MoS2 ink contains some larger MoS2 particles. The exfoliation process through 
sonication was to separate the layers of MoS2 to thinner layers by breaking the interactive 
forces between the layers. After 24 hours of leaving the ink to settle, some heavier MoS2 
layers sediment. Hence, the viscosity was slight lower. However, the difference in 
viscosity was not large, showing that the liquid exfoliation method was a simple and 
effective method preparing MoS2 dispersion which could stay relatively stable over time. 
The presence of EC as a surfactant in the ink also contributed to the stability of the ink. 
The MoS2 ink prepared was shown in Figure 9.2. 
The results from viscosity testing also suggested the suitability of MoS2 ink for use in 
printing applications. Ink viscosity plays a vital role in the reliability and repeatability of 
the printing of functional electronics as the viscosity affects the form and volume of the 
ink droplet [778,779]. A high viscosity ink can cause clogging of the printer nozzle. 
Surfactant and dispersing agents can reduce aggregation and sedimentation. Inkjet 
printing typically requires ink at a viscosity of around 10 cP [780]. Another attractive 
printing method which may be suitable is the aerosol-jet printing technique. This printing 
technology is a more versatile non-contact printing method as it is capable of printing on 





ultrasonic atomiser and a pneumatic atomiser. The ultrasonic atomiser is typically 
suitable for ink viscosity with 1-10 cP and the pneumatic atomiser can print ink with 
viscosity ranging from 1 to 1000 cP [781].  
 
Figure 9.2: MoS2 ink/dispersion. 
 
Figure 9.3: Optical images of MoS2 dispersion a) 4X magnification b) 10X 
magnification. 
A microscopic image of a drop of MoS2 dispersion on a glass slide was shown in Figure 
9.3. The images showed the formation of the MoS2 flakes in the dispersion after 
exfoliation. It can be seen that some particles are larger. In general, the liquid exfoliation 
has been effective in separating the MoS2 particles into thin sheets. The MoS2 were 
originally in the form of powder with average an particle size of below 2 µm. The 
exfoliation method uses ultrasound forces to break the particles that have agglomerated 
and the solvent keeps the thin sheets of MoS2, forming a percolation of MoS2 network. 






Figure 9.4: Set up for conductivity measurement of prepared MoS2 dispersion. 
The conductivity of the MoS2 dispersion was tested by depositing the ink onto a glass 
slide between two copper tapes. The copper tapes act as contact pads for the measuring 
probes to be placed to achieve a more reliable measurement of the conductivity. The 
MoS2 was required to be annealed at 330 °C for 3 hours to ensure its electrical 
conductivity and remove any excess solvents. After annealing the conductivity 
measurement was carried out the results were shown in Figure 9.3. The measurements 
were carried out in a bright and dark environment for comparisons. In the conductivity 
measurements, a 3V to -3V of potential difference was applied and the current (I) values 
were recorded. It showed that in a dark environment, the current is lower and the current 
increases in the presence of light. This shows the reaction of MoS2 to the presence of light 
and can be used as a light sensor. MoS2 is known to have photoluminescence properties 
and have been successfully used in retinal implant application [782]. Therefore, the 
measurement here was consistent with the findings in the literature. This study has shown 
that the liquid exfoliation method can be a low-cost and effective method to prepare MoS2 







Figure 9.5: I-V Sweep for the conductivity measurement of annealed MoS2 in the 
presence of light and in dark environment. 
 
Figure 9.6: SEM images of MoS2 after annealing a) magnification of 500X b) 2000X c) 
10,000X. 
The surface morphology of the deposited MoS2 dispersion on the glass slide was then 
studied using SEM. The SEM images at several magnifications were shown in Figure 9.6. 
The SEM images in Figure 9.6 b and c clearly showed the shape of the MoS2, which are 
in the form of thin layers of sheets. This further confirms that the exfoliation method of 
separating the layers was efficient and simple. The MoS2 layers formed a network, 
allowing the annealed patch of MoS2 to be conductive.  
AFM was carried out to further study the morphology of MoS2. The sample used for AFM 
was prepared using the spin coating method. This was to achieve the thinnest layer of 
MoS2 on a smooth surface. A pipette was used to drop 100 µl of MoS2 ink onto a flexible 
polyimide film with a thickness of 50 µm. The film was then spun at 2000 rpm for 10 s 


























characterising using the AFM. The AFM image of the MoS2 film was shown in Figure 
9.7. The image showed the MoS2 flakes on the film, which was consistent with the study 
using SEM. The AFM image in Figure 9.7 showed that there was a layer of gold on the 
polyimide film. This is because the polyimide film used had a layer of gold coated onto 
some parts of the film before the film was spin-coated with MoS2. However, the purpose 
of the AFM study here is not to measure the gold surface but only the coated MoS2 flakes. 
The AFM measurement showed that the maximum thickness of the spin-coated MoS2 
layer was up to 70 nm. It has been reported that a single layer MoS2 has a thickness of 
around 0.7 nm [379]. Therefore, the liquid exfoliated MoS2 solution here contains 
multiple layers of MoS2, where up to 100 layers can be found. Nevertheless, the spin 







Figure 9.7: a) AFM image of spin coated MoS2 layer on flexible substrate, b) Average 
height profile of the MoS2 layer deposited in the rectangular region marked in (a). 
 
Figure 9.8: TEM images of exfoliated MoS2 flakes a) magnification: 3000X b) 
30,000X, c) 80,000X. 
TEM was carried out to investigate the lateral thickness of the exfoliated MoS2 dispersion. 
The MoS2 dispersion were dropped onto carbon grids specifically for TEM imaging. The 
TEM images of the exfoliated MoS2 at different magnification were shown in Figure 9.8. 
The lateral size of the MoS2 flake in Figure 9.8b is around 690 nm. The TEM shows the 
exfoliation method can effectively produce several thin layers of MoS2. The structure of 
MoS2 is very similar to graphene, shown in Figure 9.9. Several studies have shown that 
the structure MoS2 has advantages of being used to fabricate flexible biosensors with high 
selectivity and sensitivity [426,430,783]. As such, MoS2 is a promising material that can 







Figure 9.9: TEM of exfoliated graphene layer at a magnification of 10,000X. 
9.4.2 Fabrication of glucose biosensor 
An enzymatic glucose biosensor was prepared using a simple thin-film fabrication 
method by first depositing a thin layer of gold (~50 nm) on a flexible polyimide substrate, 
then spin coating a layer of MoS2 dispersion, and finally another layer of gold (~50 nm) 
on top of the MoS2. The surface was immobilised with glucose oxidase so that it could 
perform as a glucose-sensing device. As a comparison, another glucose sensor was 
prepared by just depositing a layer of gold onto the polyimide substrate. The microscopic 
images of these two glucose sensors were shown in Figure 9.10. The image in Figure 
9.10a shows the sensor made up of just a gold layer on a flexible polyimide substrate, and 
the sensor Figure 9.10b consisted of a gold layer, MoS2 layer, and another gold layer. 
Both the sensor surfaces were functionalised with GOx for glucose sensing. The surface 






Figure 9.10: Microscopic images of the surface of glucose biosensors at 5X 
magnification. a) gold only (sample A), b) gold/MoS2/gold glucose sensor (sample B). 
 
 
Figure 9.11: AFM study on the surface of glucose biosensors for a) sample A, b) sample 
B. 
The surface morphology of the two glucose biosensors (sample A and B) was obtained 
using AFM. The results were displayed in Figure 9.11. AFM is a common technique for 
nanoscale surface characterisation of a sample by making probe scans over a surface in a 
surface plane x-y while the distance between the surface and the probe is being controlled 
[784,785]. It is also capable of taking topographic images and can be used to measure the 
surface roughness of the thin-film glucose biosensors fabrication. Surface roughness is 
often referred to as the variation in the height of the surface relative to a reference plane 
[786]. It can usually be calculated and presented as an arithmetical mean deviation of the 
mean (Ra) or a root mean square deviation for the mean (Rq). For an image where the area 
















𝑖=1  (Equation 9.4) 
where y is the height at a given pixel (i) in the image. The AFM surface topography 
measurement uses a tapping mode, which is a gentler mode where the measuring tip is 
oscillated at a resonance frequency as the top gently interacts with the surface at a 
constant amplitude of oscillation. The method of measuring used here is non-destructive 
to the surface of the sample. The results for the surface roughness measurements were 
displayed in Table 9.3. The surface roughness for both glucose biosensors were also 
compared with the surface of the flexible polyimide film without any materials deposited 
on its surface. The results showed that the clean polyimide film that was 50 μm thick has 
a very smooth surface which was excellent for the deposition of nanoparticles. The 
glucose sensor with the gold surface was smoother than the glucose sensor containing 
gold/MoS2/gold layers. This was as expected as the gold surface was smoother than MoS2 
flakes. However, the results showed that both sensors have rather smooth surfaces with 
could help maintain their function whilst being bent.  
Table 9.3: Surface roughness parameters of the glucose biosensors from AFM 
measurements Ra represents the arithmetic average of the absolute values of the surface 
height deviations measured from the mean plane, Rq represents the root mean square 
average of height deviation from the mean image data plane. 
Sample no. Ra (nm) Rq (nm) 
Clean polyimide film 2.25 3.32 
Sample A (Au only) 18.16 19.86 







Figure 9.12: Conductivity measurement of the glucose biosensors. 
The conductivity of two glucose biosensors was measured and the current vs voltage (I-
V) plot was displayed in Figure 9.12. Both biosensors have good conductivity between 
the applied voltage of -1.4 V to 1.4 V. The maximum current flow for both sensors were 
around 100 mA. The resistance of the biosensors can be calculated using the gradient of 
the I-V curve, where resistance R = 
𝑉
𝐼
. The calculated resistance for sample A is 13.6 Ω 
whereas for sample B is 14.6 Ω. The slightly higher resistance in sample B could be due 
to the presence of a MoS2 layer sandwiched in between two gold layers. Gold has very 
high conductivity as it is a metal in nature. The results showed that even with the presence 
of MoS2, the biosensor still showed excellent conductivity, which is vital for electron 
transport during glucose sensing.  
9.4.3 Glucose sensing 
The flexible glucose biosensor contains gold/MoS2/gold layers as the electrode. The 
surface of the electrode was functionalised with the enzyme GOx through gold-thiol 
interaction. The flexible electrode was first deposited with a thin layer of 6-MHA, which 
provides a bonding to bind the enzyme GOx onto the electrode surface through 
electrostatic interactions. The electrochemical reaction of the electrode was measured 
using the cyclic voltammetry (CV) method. CV is a widely used electroanalytical 
technique for a systematic study on the electrochemical behaviour of a system through 
the study of the current-voltage measurements [787]. This technique is relatively simple 



























electrochemical reaction, where each peak corresponds to a particular electrochemical 
process [788].  
The set-up for a CV measurement typically requires a working electrode, reference 
electrode and a counter electrode immersed in an electrolyte. In this study, the flexible 
glucose biosensor is the working electrode, an Ag/AgCl electrode is the reference 
electrode, a platinum wire used as a counter electrode, and PBS pH 7.4 used as the 
electrolyte. During the CV measurement, the potential/voltage at the working electrode 
is controlled against the reference electrode. A controlling potential is also applied across 
the working electrode and the counter electrodes, producing an excitation signal. The 
excitation signal is varied linearly with time, carrying a forward scan and a backward 
scan from a range of potential to complete a cycle. The completed cycle can be used to 
form a plot called the cyclic voltammogram, which represents the current at the working 
electrode against the applied excitation potential [789].  
 
Figure 9.13: Cyclic voltammograms of the glucose biosensors. 
The presence of glucose oxidase (GOx) on the surfaces of the sensors can be verified 
through the detection of the redox peak via cyclic voltammetry. Figure 9.13 shows the 
cyclic voltammograms of three glucose biosensors samples which were immobilised with 
GOx. As the glucose biosensor acts as the working electrode, it is an oxidant and an 





voltammograms and is called the anodic process. The scan direction is then switched to 
a reverse direction, producing a cathodic process as reduction occurs. Sample A was made 
of only a gold layer immobilised with GOx plus an additional Nafion layer for protection. 
There wasn’t much of an anodic current peak recorded. Sample B was made of 
gold/MoS2/gold layers immobilised with GOx and protected with a Nafion layer. Sample 
C was the same composition as sample B but without the Nafion layer. This was to 
compare the effectiveness of Nafion as a protective layer for enzyme-based sensors. 
Sample C has a higher oxidation peak than sample B at the anodic process. The anodic 
currents start to decrease as the scanning potential was reversed. The peak reduction 
current of the sensors was around -600 mV as shown in Figure 9.13. The values of peak 
reduction currents for all samples were displayed in Table 9.4. Both sample B and C 
showed an increase in the reduction peak current compared to sample A. This showed the 
presence of MoS2 improved the redox peak current, which would improve the 
performance of the electrochemical reaction of the sensors. This also showed that the 
presence of MoS2 can improve the electrocatalytic activity towards the oxidation of 
glucose as the immobilised GOx could electrocatalyse the reduction of the dissolved 
oxygen, causing an increase in the reduction peak current.  
The presence of Nafion can act as a perm-selective outer membrane and it can be used to 
improve the performance of glucose sensing [790]. Nafion can also reduce the 
interference from other physiological chemicals. GOx can leach off the sensor without 
Nafion, which can reduce the sensitivity of the sensor [791]. Upon addition of 1mM 
glucose, the reduction peak current decreased, which showed the sensors can effectively 
detect the presence of glucose. This is because the addition of glucose restrained the 
electrocatalytic reaction and led to the decrease of the reduction current.  
The presence of O2 can be a natural mediator for the catalytic reaction between GOx and 
glucose. GOx glucose biosensor can catalyse the electron transfer from glucose to 
oxygen, which is accompanied by the production of gluconolactone and hydrogen 
peroxide. The biosensors immobilised with GOx detects H2O2 concentration which is 
obtained from the GOx enzymatic reaction with glucose. The enzymatic and 






GOx(FAD) +  glucose →  GOx(FADH2)  +  gluconolactone (enzymatic) (Equation 
9.5) 
GOx(FADH2)  +  O2  →  GOx(FAD)  + H2O2 (enzymatic) (Equation 9.6) 
 
 GOx(FADH2) →  GOx(FAD) +  2e + 2H
+ (electrochemical) (Equation 9.7) 
GOx(FAD) +  2e + 2H+ →  GOx(FADH2) (electrochemical) (Equation 9.8) 
where FAD represents flavine adenine dinucleotide (FAD) cofactors, which are found in 
GOx, GOx(FAD) represents the oxidised form of GOx and GOx(FADH2) represents the 
reduced form of GOx [793]. GOx(FAD) accepts an electron and is reduced to 
GOx(FADH2). GOx(FADH2) is oxidised by oxygen in which oxygen is then reduced to 
hydrogen peroxide (H2O2).  
Table 9.4: Reduction peak currents of glucose oxidase on the glucose biosensors during 
cyclic voltammetry. 
Sample no. Peak current at reduction (µA) 
No glucose With glucose 
Sample A 10.03 6.53 
Sample B 13.00 8.94 
Sample C 12.32 11.82 
 
 
Figure 9.14: Amperometeric response of glucose biosensors upon addition of 1mM 
glucose solution to the electrolyte. 
Amperometry electrochemical measurement measures the electric current of the glucose 
biosensor over time at a constant electric potential and can be used to detect the glucose 

















Chronoamperometric response for glucose sensors 
Sample A no glucose
Sample A with glucose
Sample B no glucose
Sample B with glucose
Sample C no glucose





presented as current vs time of the biosensors. The amperometry measurements were 
obtained for the glucose biosensors without glucose and with the addition of 1mM 
glucose. The chronoamperometric response curves were shown in Figure 9.14. The 
results can confirm the glucose-sensing abilities of all three samples as the current in all 
three biosensors increased upon addition of glucose. The magnitude of current increased 
in sample B is the largest among the three, which could indicate that the sensors are the 
most sensitive. This could be attributed to the additional MoS2 layer when compared to 
sample A. However, the increase in current in sample C was very small upon the addition 
of glucose. Sample C is without Nafion and this showed the effectiveness of Nafion as a 
protective layer. As sample C was immersed into the electrolyte for testing, it is possible 
that some of the enzyme GOx might have leached during the redox reactions. 
Nevertheless. The fabricated glucose biosensors have shown stability and glucose sensing 
abilities.  
9.5 Conclusion  
A simple enzymatic flexile glucose biosensor has been fabricated using a simple thin-
film fabrication technique. The surface of the glucose biosensor is made of three thin 
layers of materials, gold, MoS2, and gold. The thin layers of sensing materials ensured 
the flexibility of the sensor. The biosensor was functionalised with enzyme GOx for 
glucose sensing due to the stability and availability of GOx. The glucose sensors utilised 
the concept of electrochemistry where glucose is oxidised by the enzyme GOx for glucose 
measurement. Therefore, the electrons produced on the biosensors were measured by 
utilising techniques of voltammetry and amperometry. The deposition technique of gold 
and MoS2 layers to form the sensing electrode is an easy and practical approach. The 
glucose biosensor can benefit from the synergistic combination of gold and MoS2 as the 
glucose sensor with MoS2 showed an improved performance of when compared to a pure 
gold glucose sensor. This is because the excellent electrical properties of 2D MoS2 
produce faster direct electron transfer on the surface of the biosensor. The effect of a 
Nafion protective layer was also investigated and the results showed that the biosensors 
with Nafion showed better performance. This is because Nafion can act as a permselective 
membrane that could prevent any potential interferences from other compounds in the 
solution [795,796]. Although enzymatic glucose sensors are highly sensitive, the lifetime 
of these sensors is limited by decreasing enzymatic activity with time. This lifespan is 





hence the performance is highly dependent on the amount of immobilised enzymes on 
the surface of the sensors. The sensitivity is often directly proportional to the enzyme 
surface density, hence an increase in enzyme could possibly improve the sensitivity of 
the biosensor [797]. Apart from that, the magnitude of the measured current of the 
biosensors can change at different glucose concentrations. However, this has not been 
investigated here and could be useful to determine the sensitivity of the sensor in detecting 
different glucose levels. Other parameters such as pH and temperature may affect the 
biosensor response. This is because enzymatic biosensors can be highly sensitive to the 
surrounding environmental factors which may limit their sensing performance. Although 
enzymatic glucose sensors are highly sensitive but the lifetime of these sensors is limited 
by decreasing enzymatic activity with time, this lifespan is typically one to two weeks. 
The flexibility of the sensors allows it to be used as a wearable device that can conform 





Chapter 10 : Conclusions and future work  
10.1 Summary of key findings 
The research work in this thesis can be split into two different aspects. The first part 
focused on the development of biocompatible polymeric compositions which are suitable 
to be made into 3D printable filaments. The developed polymeric compositions were 
developed using biocompatible and pharmaceutical grade materials. The different 
polymeric materials were mixed together using the hot-melt extruder technique to achieve 
enhanced physicochemical properties as well as to produce 3D printable filaments. These 
polymeric compositions can also be used for drug loading and can be modified to achieve 
different drug release patterns for patients.  
Firstly, a study on improving the physicochemical properties of a widely recognised 
biocompatible polymer, polylactic acid (PLA), was carried out. PLA is a hydrophobic 
thermoplastic polymer which has been widely used in food packaging and also as 
filaments for 3D printing. However, it exhibits poor flexibility and ductility due to its 
semicrystalline nature. The properties of PLA are required to be enhanced to improve its 
usability for a wide range of biomedical applications. In this study, polyethylene glycol 
(PEG) was mixed with PLA to enhance the properties of pure PLA. PEG is often found 
in pharmaceutical products as an excipient and can act as a plasticiser when mixed with 
other polymers. The role of a plasticiser can be to increase flexibility and reduce the 
hardness of a polymeric material. The effect of different PEG grades on PLA was 
investigated by mixing PEG with PLA using the solvent casting method. The study 
showed that PEG showed excellent compatibility with PLA as the PEG/PLA mixture did 
not show any changes in the chemical interactions between the two polymers. The 
presence of PEG has caused a reduction in the glass transition temperature and the melting 
temperature of the PEG/PLA mixture. The lower molecular weights PEGs seem to have 
a more evidence plasticising effect in the blend. This could be due to the smaller 
molecular chains of PEG which allows an easier interaction within the intermolecular 
spaces of PLA. Nevertheless, PEG is an effective plasticiser when blended with PLA.  
A study to produce biocompatible PEG/PLA filaments then follow. A benchtop FilaFab 
filament extruder was used to produce the filaments that can be used for 3D printing. PEG 





form and PLA exists as solid pellets at room temperature. Due to the difficulty in griding 
the PLA pellets into powder form, the large difference in size between the PLA and PEG 
can prevent a homogeneous mixing when being fed into a single-screw filament extruder. 
This is because the large pitch on the screw can cause segregation between the materials 
instead of mixing them together. Therefore, a simple coating process was carried out by 
first dissolving PEG in water, then coating the PEG solution onto the surface of PLA 
pellets. The coated PLA pellets were allowed to dry and to solidify the PEG on the surface 
of the pellets before processing. Three different concentrations of PEG/PLA blends (10%, 
20%, 30% w/w PEG/PLA) were produced into filaments. The characterisation studies 
showed that the higher the concentration of PEG, the more evident the plasticising effect. 
The filament with 30% PEG showed the highest thermal degradation temperature and 
highest elongation strain. The filaments were also tested for their printability by printing 
a cylindrical-shaped object. The printing temperature of the PEG/PLA filaments were 
slightly lower than the pure PLA and commercial PLA filaments. The print quality was 
also comparable to the commercial filaments. Although the single-screw extrusion can 
produce filaments that can be used for 3D printing, the mixing efficiency may not be the 
best. This is because the single-screw extrusion often does not produce homogeneous 
mixing when the mixing of material is involved in the extrusion process as the single-
screw was not capable to provide intimate shear mixing between materials.  
To improve the mixing efficiency of the polymeric mixture when producing filament 
compositions, the use of a twin-screw extruder was investigated. The twin-screw extruder 
provides a more intimate mixing between different materials due to the twin-screw 
configuration. It also allows more control of the temperature and speed of the extrusion 
by the user. The same PEG/PLA blends were extruded into filaments using the twin-
screw extruder. However, the preparation work for the PEG/PLA mixture was slightly 
different due to the difference in the screw size and feeding zone of the extruder. The 
twin-screw extruder used was designed to process powder materials. Therefore, the 
feeding zone is very close to the screws which did not allow enough space for the PLA 
pellets to be conveyed down the extruder. The PEG/PLA blends were first processed into 
films using the solvent casting method. The solvent cast films were then mechanically 
ground into finer particles that can be fed into the twin-screw extruder. The 
characterisation studies on the twin-screw extruded PEG/PLA filaments showed that the 





PEG/PLA filaments. As expected, the presence of PEG has lowered the glass transition 
temperature and melting temperature of the PEG/PLA blends. The mechanical test carried 
out showed that the elongation ability of the PEG/PLA filaments were at least 5 times 
better than the pure PLA filaments and 50 times better than a commercially available 
filament. However, it was noticed that as the concentration of PEG increases, the 
plasticising effect did not increase. There seemed to be a slight decrease in the plasticising 
effect as the PEG concentration increase which could be caused by a saturation of PEG 
in the polymer matrix. When PEG in PLA reaches its saturation point, the PEG/PLA 
blend may become brittle. This is shown by the increase in crystallinity of the PEG/PLA 
blend and the slight decrease in strength of the filaments. However, the strength of the 
twin-screw extruded filaments was still more superior to the single-screw extruded 
filaments, pure PLA filaments and the commercially available filament.  
Due to the excellent mixing efficiency of twin-screw extrusion, it was used to develop 
some drug-loaded filaments that can be used to 3D print drug delivery devices with 
adjustable release systems. The materials used to produce the drug-loaded filaments were 
common pharmaceutical grade polymers but were not conventional materials used to 
produce commercially available filaments. The filaments were composed of HPC, 
Eudragit® RL PO, and PEG. The drug loaded onto the filament was theophylline, which 
is a poorly soluble drug. The effect of changing the percentage of HPC and Eudragit on 
theophylline release was being investigated. The drug release profiles were obtained by 
carried out in-vitro dissolution studies on the 3D printed tablets. The results showed that 
the higher the percentage of Eudragit, the more sustained the release of theophylline. The 
Korsmeyer-Peppas model may be the most appropriate model to describe the drug release 
kinetics of the 3D printed tablets. The cell studies carried out on the materials and tablets 
also confirmed that the 3D printed tablets did not induce any toxicity to living cells.  
Furthermore, an attempt to sustain the release of readily soluble metformin in the 
composition with high Eudragit concentration was investigated. A completely different 
composition which contained only PCL and PEG was also loaded with metformin for 
comparison. The PCL-based filaments were more successful at sustaining the release of 
PCL. PCL filaments also offer the advantage of being able to be printed at a temperature 
of around 68 °C. This would be ideal for pharmaceutical applications when dealing with 





The second part focused on the fabrication of flexible sensors for biomedical applications. 
Two types of sensors were fabricated: temperature sensor and glucose biosensor. The aim 
was to utilise simple and cost-effective fabrication technique to produce flexible sensors 
with good stability and reliability. Two fabrication techniques were used to produce RTD 
temperature sensors. The two techniques were FDM 3D printing and a thin-film 
fabrication technique called the lift-off process. FDM 3D printing is now an established 
simple and low-cost fabrication technique. The recent developments of conductive 
thermoplastic filaments open up the possibility of using FDM 3D printing for electronic 
applications. The lift-off technique involves several simple steps such as deposition of 
gold on a substrate, patterning of sensors using UV light, and removing the unwanted 
structures using acetone. Both techniques were simple and cost-effective for the 
fabrication of flexible temperature sensors. The 3D printed sensors were printed with two 
different conductive PLA filaments: carbon black PLA and graphene PLA. The 3D 
printed graphene PLA showed better electrical conductivity than the carbon black PLA. 
However, the carbon black PLA temperature sensors showed better linearity and 
sensitivity for temperature sensing. The carbon black PLA temperature sensors also 
exhibit better flexibility and stability as shown in the bending test and temperature cyclic 
test. On the other hand, the thin-film temperature sensors were much smaller in size and 
more delicate due to the different fabrication technique. The thin-film sensors also 
showed excellent stability, linearity and flexibility. Both the 3D printed sensors and thin-
film temperature sensors are easily transferable to other substrates. The only disadvantage 
of the 3D printed sensors was its size is limited due to the resolution of FDM 3D printing 
at 0.1 mm. This means that the 3D printed sensors cannot have a thickness of below 0.1 
mm and is difficult to miniaturise.  
A similar thin-film fabrication technique was used to produce a glucose biosensor. 
However, the glucose biosensor was produced only via deposition of materials without 
the need for the solvent removal of material. The glucose biosensor contained gold and 
MoS2 as the conductive electrode. The performance of the glucose sensing containing 
MoS2 and without MoS2 was compared. The results showed that the presence of MoS2 
can enhance electron transfer during glucose oxidation. The enhancement of electron 
transfer help improves the sensitivity of the sensor. 
In summary, regarding the aim and objectives set out in Chapter 2, the following have 





• Physicochemical properties of pure PLA can be enhanced by blending it with 
plasticisers such as PEG 
• Twin-screw extrusion is much preferred than single-screw extrusion especially 
when mixing of materials is required 
• Coupling twin-screw extrusion and FDM 3D printing is an effective method to 
produce personalised drug delivery systems 
• PCL blended with PEG can be used for drug loading and the composition can 
achieve sustained-release systems. The printing temperature of PCL-based 
filaments was much lower. 
• FDM 3D printing can be used to produce flexible and transferable RTD 
temperature sensors 
• Thin-film fabrication technique is a cost-effective technique to produce high 
quality RTD temperature sensors and glucose biosensors 
• The use of MoS2 can improve electron transfer of the sensor, which could improve 
sensitivity  
• Findings and results obtained have been reported in peer-reviewed literature and 
at scientific conferences 
10.2 Suggestions for future work 
The development of smart and personalised medical devices is highly beneficial to our 
society as this can improve treatment efficacy and reduce on-going pressure on our 
healthcare systems. As we now live in a world with a wide range of smart technologies 
around us, having reliable smart medical devices for continuous health monitoring and 
diagnostic can greatly improve our healthcare systems and quality of life. With the help 
of advanced healthcare technology, healthcare resources can be better utilised and the 
ever-increasing pressure on healthcare services can be relieved. This is particularly 
beneficial in the long term when the life expectancy of our society is constantly 
increasing. However, one of the main issues that have prevented the wide usage of such 
medical technology is that most of these advanced technologies are not affordable to the 
members of the public. These technologies are often too expensive and are only 
affordable for rich patients. This phenomenon is not encouraged as it can cause further 
division and inequality in our society. Everyone should have equal opportunity to access 





As proposed, the personalisation of drug delivery systems can be easily achievable when 
integrating the HME with the FDM 3D printing technology. This could be the most cost-
effective method as it allows the fabrication of personalised medicines in-house. As 3D 
printing is not suitable for mass production, it is also ideal for personalised medicines as 
the personalised medicines are typically required in a small amount for specific patients 
only. Apart from the fabrication of personalised tablets with customised drug release, 3D 
printing can also be used to produce different drug delivery devices such as transdermal 
patches [452,798], microneedles [799,800], orodispersible films [176] and various 
implants [178,179,801]. Therefore, 3D printing has proven to have a great potential for a 
wide range of biomedical applications. More studies are still required to prove the 
reliability and feasibility of 3D printing in producing various drug delivery systems that 
are safe in order to promote the translation of laboratory research to clinical applications.   
The developed glucose biosensor in this work is enzyme based. Enzymatic glucose 
biosensors have been well established and have the advantages of simplicity, efficiency, 
high sensitivity and selectivity. However, enzymatic glucose biosensors often suffer from 
high cost and instability [783]. Enzymes are often sensitive to temperature, humidity, and 
pH. Hence, storing and transporting enzymes can add to the cost. Enzymes also degrade 
over time and hence the sensors also have a limited lifetime. Therefore, the study of 
developing non-enzymatic glucose biosensor can be highly desirable. One approach to 
produce enzyme-free sensors involves the use of nanostructured material modified 
electrodes as electrochemical sensors for direct oxidation of glucose. For example, a non-
enzymatic glucose biosensor was developed by Anderson et al. by nucleating colloidal 
silver nanoparticles on MoS2 [802]. Another study by Huang et al. showed copper 
nanoparticles can be decorated onto MoS2 nanosheets and has showen electrocatalytic 
activity towards glucose oxidation [803]. An alternative for the fabrication of an enzyme-
free glucose biosensor involves the use of synthetic receptors [804]. For examples, a 
synthetic peptide can be designed as a glucose receptor to mimic the glucose binding sites 
for glucose sensing [805]. The sensors fabricated using peptides offer significant 
advantages over proteins as peptides can be immobilized at high density but still preserve 
their stability and specificity of binding [806–809]. 
A minimally or non-invasive monitoring approach can also be explored for ease of use 
and patient comfort. Examples of body fluids that can be measured non-invasively are 





alcohol), electrolytes, trace elements and some large molecules (such as proteins or 
cytokines) which could provide useful information for physiological health status and 
disease diagnosis and management. Interstitial fluid is particularly attractive as the 
concentration of the analytes in the interstitial fluid correlates well with the blood. This 
is because the components in the interstitial fluid diffuse directly from the capillary 
endothelium. On the other hand, sweat can be easily obtained as it is produced naturally 
on the skin. Even when there is limited sweat produced due to inactivity, an iontophoresis 
technique can be used to extract sweat through the surface of the skin in a non-invasive 
manner (Figure 10.1). The iontophoresis process applies a mild current across the skin to 
induce ion migration between the two electrodes on the wearable biosensor and can be 
accomplished at rest. It transports the molecules without harming the skin surface or 
contacting the blood.  
 
Figure 10.1: Schematic diagram of an iontophoretic-based biosensor. The working 
electrode will be made of functionalised MoS2 for biosensing application (adapted with 
permission from reference  [346]). 
Similarly, reverse iontophoresis can be used to extract interstitial fluids, where the 
application of a low current induces a flux of positively charged ions towards the 
negatively charged skin surface, and also causes an electro-osmotic flow from anode to 
cathode. The flow results in the movement of neutral molecules, such as glucose, toward 
the cathode.  
Another interesting exploration is related to the study of MoS2 as a material for biosensor. 
MoS2 is expected to possess similar advantages as graphene and graphene derivatives as 
it shares the materials properties of graphene. Many research and work have proven that 





generation low-cost biosensors with high biosensing capabilities. Studies have shown that 
MoS2-based biosensors can be used for sensing several important parameters such as pH 
[810], temperature [811], oxygen level [812], antigen level [432] and many more [813]. 
Due to the mechanical properties of MoS2, it is also highly suitable to be used a material 
for the flexible sensor. As MoS2 can be effectively processed into solution, the MoS2 
solution can be adjusted to exhibit the properties of functional inks that can be used for 
printing applications. For example, inkjet printing or aerosol-jet printing can print in very 
high resolution which could be ideal for the fabrication of miniaturised sensors.  
The development of smart pills for better drug delivery can also be explored. This can 
possibly be achieved by integrating the 3D printed personalised drug delivery systems 
with the fabricated flexible. The integration can potentially be achieved in a single 
fabrication process by utilising the FDM 3D printing technique. Some 3D printers can 
have more than one printing nozzle, which means the printer can print using at least two 
different materials in a single print without being disrupted. Some studies have proven 
that printers with multiple print heads can be used for the printing of novel drug delivery 
devices such as polypills [814–816]. The work here showed that it is possible to print 
reliable temperature sensors using conductive filaments. Hence, the desired object can be 
creatively designed to print the drug delivery device and integrate the sensor onto the 
printed drug delivery device in a single print. Such smart drug delivery systems can be 
highly beneficial to detect the effects of the drug. 
A smart drug delivery system will be suitable for a wide range of applications and enable 
therapies not possible with conventional means. As an example, a smart drug delivery 
system for diabetic care can be achieved by integrating the wearable glucose biosensor 
with a transdermal drug delivery system. The biosensor can measure the fluctuation of 
the glucose of the patient, as well as the pH and temperature non-invasively. When the 
glucose level is too high, insulin or other anti-diabetic drugs will be released through a 
polymeric microneedle to regulate the glucose level. The rate of drug release and the dose 
will be controlled through a micropump in the smart system. However, the design of such 
systems is highly complex as it involves the use of microelectronics and the selection of 
suitable biomaterials. Computer modelling and testing will be required to simulate the 
environment, response and drug release of the smart pill. Computer simulation will help 
decide several important parameters when designing the smart pill such as the pressure 





method for this multifunctional wearable device such as using piezoelectric could also be 
explored. A self-powering device will obviate the need for power supply or battery which 
could miniaturise the device for better patient comfort. There is also a need for wireless 
communication of the device to send its recorded data to be displayed on a user device. 
This novel smart device would also require unique and state-of-the-art fabrication 
techniques.  
The development of a state-of-the-art smart medical device is a highly complex task. This 
is considered cutting-edge research that requires experts from different fields to ensure 
the success of the project. To this day, there is still no such smart integrated medical 
device that can act as a continuous health monitoring system as well as a smart drug 
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